

**Committee for Risk Assessment  
RAC**

Annex 1  
**Background document**  
to the Opinion proposing harmonised classification  
and labelling at EU level of

**(RS)-1-{1-ethyl-4-[4-mesyloxy-3-(2-methoxyethoxy)-o-toluoyl]pyrazol-5-yloxy}ethyl  
methyl carbonate; tolpyralate**

**EC Number: -  
CAS Number: 1101132-67-5**

**CLH-O-0000001412-86-268/F**

The background document is a compilation of information considered relevant by the dossier submitter or by RAC for the proposed classification. It includes the proposal of the dossier submitter and the conclusion of RAC. It is based on the official CLH report submitted to public consultation. RAC has not changed the text of this CLH report but inserted text which is specifically marked as 'RAC evaluation'. Only the RAC text reflects the view of RAC.

**Adopted  
15 March 2019**



## **CLH report**

### **Proposal for Harmonised Classification and Labelling**

**Based on Regulation (EC) No 1272/2008 (CLP Regulation),  
Annex VI, Part 2**

#### **International Chemical Identification:**

(RS)-1-{1-ethyl-4-[4-mesyl-3-(2-methoxyethoxy)-o-toluoyl]pyrazol-5-yloxy}ethyl methyl carbonate;

#### **TOLPYRALATE**

**EC Number:** Not assigned

**CAS Number:** 1101132-67-5

**Index Number:** Not listed

**Contact details for dossier submitter:** UK Competent Authority  
Chemicals Regulation Directorate  
Health and Safety Executive  
United Kingdom

**Version number:** 2

**Date:** March 2018

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

## CONTENTS

<b>1</b>	<b>IDENTITY OF THE SUBSTANCE</b> .....	<b>1</b>
1.1	NAME AND OTHER IDENTIFIERS OF THE SUBSTANCE.....	1
1.2	COMPOSITION OF THE SUBSTANCE .....	2
<b>2</b>	<b>PROPOSED HARMONISED CLASSIFICATION AND LABELLING</b> .....	<b>3</b>
2.1	PROPOSED HARMONISED CLASSIFICATION AND LABELLING ACCORDING TO THE CLP CRITERIA .....	3
<b>3</b>	<b>HISTORY OF THE PREVIOUS CLASSIFICATION AND LABELLING</b> .....	<b>5</b>
<b>4</b>	<b>JUSTIFICATION THAT ACTION IS NEEDED AT COMMUNITY LEVEL</b> .....	<b>5</b>
<b>5</b>	<b>IDENTIFIED USES</b> .....	<b>5</b>
<b>6</b>	<b>DATA SOURCES</b> .....	<b>5</b>
<b>7</b>	<b>PHYSICOCHEMICAL PROPERTIES</b> .....	<b>5</b>
<b>8</b>	<b>EVALUATION OF PHYSICAL HAZARDS</b> .....	<b>7</b>
8.1	EXPLOSIVES .....	7
8.1.1	<i>Short summary and overall relevance of the information provided on explosive properties</i> .....	7
8.1.2	<i>Comparison with the CLP criteria</i> .....	7
8.1.3	<i>Conclusion on classification and labelling for explosive properties</i> .....	7
8.2	FLAMMABLE GASES (INCLUDING CHEMICALLY UNSTABLE GASES).....	7
8.3	OXIDISING GASES .....	7
8.4	GASES UNDER PRESSURE.....	7
8.5	FLAMMABLE LIQUIDS .....	7
8.6	FLAMMABLE SOLIDS .....	7
8.6.1	<i>Short summary and overall relevance of the provided information on flammable solids</i> .....	8
8.6.2	<i>Comparison with the CLP criteria</i> .....	8
8.6.3	<i>Conclusion on classification and labelling for flammable solids</i> .....	8
8.7	SELF-REACTIVE SUBSTANCES.....	8
8.7.1	<i>Short summary and overall relevance of the provided information on self-reactive substances</i> .....	8
8.7.2	<i>Comparison with the CLP criteria</i> .....	8
8.7.3	<i>Conclusion on classification and labelling for self-reactive substances</i> .....	8
8.8	PYROPHORIC LIQUIDS.....	8
8.9	PYROPHORIC SOLIDS .....	8
8.9.1	<i>Short summary and overall relevance of the provided information on pyrophoric solids</i> .....	8
8.9.2	<i>Comparison with the CLP criteria</i> .....	8
8.9.3	<i>Conclusion on classification and labelling for pyrophoric solids</i> .....	9
8.10	SELF-HEATING SUBSTANCES.....	9
8.10.1	<i>Short summary and overall relevance of the provided information on self-heating substances</i> .....	9
8.10.2	<i>Comparison with the CLP criteria</i> .....	9
8.10.3	<i>Conclusion on classification and labelling for self-heating substances</i> .....	9
8.11	SUBSTANCES WHICH IN CONTACT WITH WATER EMIT FLAMMABLE GASES.....	9
8.11.1	<i>Short summary and overall relevance of the provided information on substances which in contact with water emit flammable gases</i> .....	9
8.11.2	<i>Comparison with the CLP criteria</i> .....	9
8.11.3	<i>Conclusion on classification and labelling for substances which in contact with water emit flammable gases</i> .....	9
8.12	OXIDISING LIQUIDS.....	9

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE**

8.13	OXIDISING SOLIDS .....	10
8.13.1	<i>Short summary and overall relevance of the provided information on oxidising solids</i> .....	10
8.13.2	<i>Comparison with the CLP criteria</i> .....	10
8.13.3	<i>Conclusion on classification and labelling for oxidising solids</i> .....	10
8.14	ORGANIC PEROXIDES .....	10
8.15	CORROSIVE TO METALS .....	10
<b>9</b>	<b>TOXICOKINETICS (ABSORPTION, METABOLISM, DISTRIBUTION AND ELIMINATION) .....</b>	<b>12</b>
9.1	SHORT SUMMARY AND OVERALL RELEVANCE OF THE PROVIDED TOXICOKINETIC INFORMATION ON THE PROPOSED CLASSIFICATION(S) .....	12
<b>10</b>	<b>EVALUATION OF HEALTH HAZARDS.....</b>	<b>13</b>
10.1	ACUTE TOXICITY - ORAL ROUTE .....	14
10.1.1	<i>Short summary and overall relevance of the provided information on acute oral toxicity</i> .....	15
10.1.2	<i>Comparison with the CLP criteria</i> .....	15
10.1.3	<i>Conclusion on classification and labelling for acute oral toxicity</i> .....	15
10.2	ACUTE TOXICITY - DERMAL ROUTE .....	15
10.2.1	<i>Short summary and overall relevance of the provided information on acute dermal toxicity</i> .....	15
10.2.2	<i>Comparison with the CLP criteria</i> .....	16
10.2.3	<i>Conclusion on classification and labelling for acute dermal toxicity</i> .....	16
10.3	ACUTE TOXICITY - INHALATION ROUTE .....	16
10.3.1	<i>Short summary and overall relevance of the provided information on acute inhalation toxicity</i> .....	16
10.3.2	<i>Comparison with the CLP criteria</i> .....	16
10.3.3	<i>Conclusion on classification and labelling for acute inhalation toxicity</i> .....	17
10.4	SKIN CORROSION/IRRITATION .....	17
10.4.1	<i>Short summary and overall relevance of the provided information on skin corrosion/irritation</i> .....	18
10.4.2	<i>Comparison with the CLP criteria</i> .....	18
10.4.3	<i>Conclusion on classification and labelling for skin corrosion/irritation</i> .....	18
10.5	SERIOUS EYE DAMAGE/EYE IRRITATION .....	19
10.5.1	<i>Short summary and overall relevance of the provided information on serious eye damage/eye irritation</i> .....	19
10.5.2	<i>Comparison with the CLP criteria</i> .....	19
10.5.3	<i>Conclusion on classification and labelling for serious eye damage/eye irritation</i> .....	19
10.6	RESPIRATORY SENSITISATION .....	19
10.6.1	<i>Conclusion on classification and labelling for respiratory sensitisation</i> .....	20
10.7	SKIN SENSITISATION .....	20
10.7.1	<i>Short summary and overall relevance of the provided information on skin sensitisation</i> .....	21
10.7.2	<i>Comparison with the CLP criteria</i> .....	22
10.7.3	<i>Conclusion on classification and labelling for skin sensitisation</i> .....	22
10.8	GERM CELL MUTAGENICITY .....	22
10.8.1	<i>Short summary and overall relevance of the provided information on germ cell mutagenicity</i> .....	27
10.8.2	<i>Comparison with the CLP criteria</i> .....	27
10.8.3	<i>Conclusion on classification and labelling for germ cell mutagenicity</i> .....	27
10.9	CARCINOGENICITY .....	27
10.9.1	<i>Chronic / carcinogenicity study in rats</i> .....	30
10.9.2	<i>Chronic / carcinogenicity study in mice</i> .....	31
10.9.3	<i>Short summary and overall relevance of the provided information on carcinogenicity</i> .....	31
10.9.4	<i>Comparison with the CLP criteria</i> .....	33
10.9.5	<i>Conclusion on classification and labelling for carcinogenicity</i> .....	34
10.10	REPRODUCTIVE TOXICITY .....	41
10.10.1	<i>Adverse effects on sexual function and fertility</i> .....	41
10.10.2	<i>Additional studies relevant to reproductive toxicity</i> .....	50
10.10.3	<i>Short summary and overall relevance of the provided information on sexual function and fertility</i> .....	51
10.10.4	<i>Comparison with the CLP criteria</i> .....	51
10.10.5	<i>Adverse effects on development</i> .....	51
10.10.5.1	<i>Supplementary studies relevant to effects on development</i> .....	57
10.10.6	<i>Short summary and overall relevance of the provided information on adverse effects on development</i> .....	58
10.10.7	<i>Comparison with the CLP criteria</i> .....	59

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE**

10.10.8	<i>Adverse effects on or via lactation</i> .....	59
10.10.9	<i>Comparison with the CLP criteria</i> .....	59
10.10.10	<i>Conclusion on classification and labelling for reproductive toxicity</i> .....	60
10.11	<b>SPECIFIC TARGET ORGAN TOXICITY-SINGLE EXPOSURE</b> .....	71
10.11.1	<i>Short summary and overall relevance of the provided information on specific target organ toxicity – single exposure</i> .....	73
10.11.2	<i>Comparison with the CLP criteria</i> .....	73
10.11.3	<i>Conclusion on classification and labelling for STOT SE</i> .....	73
10.12	<b>SPECIFIC TARGET ORGAN TOXICITY-REPEATED EXPOSURE</b> .....	74
	<i>Short summary and overall relevance of the provided information on specific target organ toxicity – repeated exposure</i> .....	86
10.12.1	<i>Comparison with the CLP criteria</i> .....	88
10.12.2	<i>Conclusion on classification and labelling for STOT RE</i> .....	96
10.13	<b>ASPIRATION HAZARD</b> .....	97
<b>11</b>	<b>EVALUATION OF ENVIRONMENTAL HAZARDS</b> .....	<b>104</b>
11.1	<b>RAPID DEGRADABILITY OF ORGANIC SUBSTANCES</b> .....	104
11.1.1	<i>Ready biodegradability</i> .....	105
11.1.2	<i>BOD<sub>5</sub>/COD</i> .....	106
11.1.3	<i>Hydrolysis</i> .....	106
11.1.4	<i>Other convincing scientific evidence</i> .....	107
11.1.4.1	<i>Field investigations and monitoring data (if relevant for C&amp;L)</i> .....	108
11.1.4.2	<i>Inherent and enhanced ready biodegradability tests</i> .....	108
11.1.4.3	<i>Water, water-sediment and soil degradation data (including simulation studies)</i> .....	108
11.1.4.4	<i>Photochemical degradation</i> .....	111
11.1.5	<i>Overall summary on environmental hazard</i> .....	111
11.2	<b>ENVIRONMENTAL TRANSFORMATION OF METALS OR INORGANIC METALS COMPOUNDS</b> .....	112
11.2.1	<i>Summary of data/information on environmental transformation</i> .....	112
11.3	<b>ENVIRONMENTAL FATE AND OTHER RELEVANT INFORMATION</b> .....	112
11.4	<b>BIOACCUMULATION</b> .....	114
11.4.1	<i>Estimated bioaccumulation</i> .....	114
11.4.1.1	<i>Bioaccumulation estimation</i> .....	114
11.4.1.2	<i>Measured bioaccumulation data</i> .....	114
11.4.2	<i>Summary and discussion of aquatic bioaccumulation</i> .....	114
11.5	<b>AQUATIC HAZARD</b> .....	114
	<i>Bold words indicate which type of data the endpoints were calculated from for where there multiple endpoints calculated in a study</i> .....	116
11.5.1	<i>Acute (short-term) toxicity to fish</i> .....	116
11.5.1.1	<i>Short-term toxicity to fish</i> .....	116
11.5.2	<i>Acute (short-term) toxicity to aquatic invertebrates</i> .....	117
11.5.3	<i>Acute (short-term) toxicity to algae or other aquatic plants</i> .....	118
11.5.4	<i>Acute (short-term) toxicity to other aquatic organisms</i> .....	121
11.6	<b>LONG-TERM AQUATIC HAZARD</b> .....	121
11.6.1	<i>Chronic toxicity to fish</i> .....	121
11.6.2	<i>Chronic toxicity to aquatic invertebrates</i> .....	122
11.6.3	<i>Chronic toxicity to algae or other aquatic plants</i> .....	122
11.6.4	<i>Chronic toxicity to other aquatic organisms</i> .....	122
11.7	<b>COMPARISON WITH THE CLP CRITERIA</b> .....	122
11.7.1	<i>Acute aquatic hazard</i> .....	123
11.7.2	<i>Long-term aquatic hazard (including bioaccumulation potential and degradation)</i> .....	123
11.8	<b>CONCLUSION ON CLASSIFICATION AND LABELLING FOR ENVIRONMENTAL HAZARDS</b> ....	124
<b>12</b>	<b>EVALUATION OF ADDITIONAL HAZARDS</b> .....	<b>124</b>
12.1	<b>HAZARDOUS TO THE OZONE LAYER</b> .....	133
<b>13</b>	<b>ADDITIONAL LABELLING</b> .....	<b>134</b>
<b>14</b>	<b>REFERENCES</b> .....	<b>135</b>
<b>15</b>	<b>ANNEXES</b> .....	<b>140</b>


ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

## 1 IDENTITY OF THE SUBSTANCE

### 1.1 Name and other identifiers of the substance

**Table 1: Substance identity and information related to molecular and structural formula of the substance**

<b>Name(s) in the IUPAC nomenclature or other international chemical name(s)</b>	(RS)-1-{1-ethyl-4-[4-mesyl-3-(2-methoxyethoxy)-o-toluoyl]pyrazol-5-yloxy}ethyl methyl carbonate; tolpyralate
<b>Other names (usual name, trade name, abbreviation)</b>	tolpyralate, SL-573
<b>ISO common name (if available and appropriate)</b>	Not available
<b>EC number (if available and appropriate)</b>	Not available
<b>EC name (if available and appropriate)</b>	Not available
<b>CAS number (if available)</b>	1101132-67-5
<b>Other identity code (if available)</b>	Not available
<b>Molecular formula</b>	C <sub>21</sub> H <sub>28</sub> N <sub>2</sub> O <sub>9</sub> S
<b>Structural formula</b>	
<b>SMILES notation (if available)</b>	Not available
<b>Molecular weight or molecular weight range</b>	484.52
<b>Information on optical activity and typical ratio of (stereo) isomers (if applicable and appropriate)</b>	<p>The ratio of enantiomers (R and S isomers) is 50:50 (the active substance is a racemic mixture).</p> <p>The two isomers can be considered equally biologically active with regard to herbicidal activity. In addition <i>in vivo</i> mammalian toxicity testing indicates it is stable to chiral conversion. The ratio of stereoisomers (1:1) was unchanged during hydrolysis, indicating that the rate of hydrolysis of the two stereoisomers is the same in the aquatic environment.</p>
<b>Description of the manufacturing process and identity of the source (for UVCB substances only)</b>	n/a – tolpyralate is not a UVCB substance
<b>Degree of purity (%) (if relevant for the entry in Annex VI)</b>	Minimum 95%



ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

**1.2 Composition of the substance**

**Table 2: Constituents (non-confidential information)**

Constituent (Name and numerical identifier)	Concentration range (% w/w minimum and maximum in multi-constituent substances)	Current Annex VI (CLP)	CLH in Table 3.1	Current self-classification and labelling (CLP)
Tolpyralate, CAS 1101132-67-5	Minimum 95%, 950 g/kg	Not listed		-

**Table 3: Impurities (non-confidential information) if relevant for the classification of the substance**

Impurity (Name and numerical identifier)	Concentration range (% w/w minimum and maximum)	Current Annex VI (CLP)	CLH in Table 3.1	Current self-classification and labelling (CLP)	The impurity contributes to the classification and labelling
Not relevant					

There are a number of process impurities in the substance. These have been taken into consideration and are not considered to impact on the classification proposed in this dossier.

**Table 4: Additives (non-confidential information) if relevant for the classification of the substance**

Additive (Name and numerical identifier)	Function	Concentration range (% w/w minimum and maximum)	Current Annex VI (CLP)	CLH in Table 3.1	Current self-classification and labelling (CLP)	The additive contributes to the classification and labelling
Not relevant						

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

**2 PROPOSED HARMONISED CLASSIFICATION AND LABELLING**

**2.1 Proposed harmonised classification and labelling according to the CLP criteria**

**Table 5:**

	Index No	International Chemical Identification	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors	Notes
					Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)		
Current Annex VI entry	Substance not listed on Annex VI										
Dossier submitters proposal	n/a	(RS)-1-{1-ethyl-4-[4-mesyl-3-(2-methoxyethoxy)-o-toluoyl]pyrazol-5-yloxy}ethyl methyl carbonate; tolpyralate	n/a	1101132-67-5	Carc 2 STOT RE 2 (eyes, kidney) Aquatic Acute 1 Aquatic Chronic 1	H351 H373 H400 H410	GHS08  GHS09 Wng	H351 H373 H410	n/a	M = 10 M = 100	n/a
Resulting Annex VI entry if agreed by RAC and COM	n/a	(RS)-1-{1-ethyl-4-[4-mesyl-3-(2-methoxyethoxy)-o-toluoyl]pyrazol-5-yloxy}ethyl methyl carbonate; tolpyralate	n/a	1101132-67-5	Carc 2 STOT RE 2 (eyes, kidney) Aquatic Acute 1 Aquatic Chronic 1	H351 H373 H400 H410	GHS08  GHS09 Wng	H351 H373 H410	n/a	M = 10 M = 100	n/a

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

**Table 6: Reason for not proposing harmonised classification and status under public consultation**

Hazard class	Reason for no classification	Within the scope of public consultation
Explosives	data conclusive but not sufficient for classification	Yes
Flammable gases (including chemically unstable gases)	hazard class not applicable	No
Oxidising gases	hazard class not applicable	No
Gases under pressure	hazard class not applicable	No
Flammable liquids	hazard class not applicable	No
Flammable solids	data conclusive but not sufficient for classification	Yes
Self-reactive substances	hazard class not applicable	No
Pyrophoric liquids	hazard class not applicable	No
Pyrophoric solids	hazard class not applicable	No
Self-heating substances	data lacking	Yes
Substances which in contact with water emit flammable gases	hazard class not applicable	No
Oxidising liquids	hazard class not applicable	No
Oxidising solids	data lacking	Yes
Organic peroxides	hazard class not applicable	No
Corrosive to metals	data lacking	Yes
Acute toxicity via oral route	data conclusive but not sufficient for classification	Yes
Acute toxicity via dermal route	data conclusive but not sufficient for classification	Yes
Acute toxicity via inhalation route	data conclusive but not sufficient for classification	Yes
Skin corrosion/irritation	data conclusive but not sufficient for classification	Yes
Serious eye damage/eye irritation	data conclusive but not sufficient for classification	Yes
Respiratory sensitisation	data lacking	Yes
Skin sensitisation	data conclusive but not sufficient for classification	Yes
Germ cell mutagenicity	data conclusive but not sufficient for classification	Yes
Carcinogenicity	<b>harmonised classification proposed</b>	Yes
Reproductive toxicity	data conclusive but not sufficient for classification	Yes
Specific target organ toxicity-single exposure	data conclusive but not sufficient for classification	Yes
Specific target organ toxicity-repeated exposure	<b>harmonised classification proposed</b>	Yes
Aspiration hazard	hazard class not applicable	No
Hazardous to the aquatic environment	<b>harmonised classification proposed</b>	Yes
Hazardous to the ozone layer	hazard class not applicable	No

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

### 3 HISTORY OF THE PREVIOUS CLASSIFICATION AND LABELLING

Tolpyralate is a new active substance in Plant Protection Products (in the meaning of Regulation (EC) No. 1107/2009). Tolpyralate does not have an existing entry in Annex VI of CLP and has not been considered for harmonised classification and labelling previously in the EU.

At the time of submitting this CLH report, tolpyralate was not registered under REACH.

#### RAC general comment

Tolpyralate is a new pesticide-active substance (4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitor) proposed for use as a broad spectrum herbicide, effective against broad leaf weeds in maize crops. There is no existing entry in Annex VI to CLP.

### 4 JUSTIFICATION THAT ACTION IS NEEDED AT COMMUNITY LEVEL

Tolpyralate is a pesticide active substance and CLH is required in accordance with Article 36(2) of CLP.

### 5 IDENTIFIED USES

Tolpyralate is a new pesticide active substance with a proposed use as a broad spectrum herbicide, effective against broad leaf weeds in maize crops.

### 6 DATA SOURCES

This classification and labelling proposal has been prepared based on data in the Draft Assessment Report (DAR).

### 7 PHYSICOCHEMICAL PROPERTIES

Table 7: Summary of physicochemical properties

Property	Value	Reference	Comment (e.g. measured or estimated)
Physical state at 20°C and 101,3 kPa	Off-white powder. No discernible odour.	Turner B (2013a) DAR: B.2.3/01	
Melting/freezing point	Melting range of 127 – 129°C	Turner B (2013b) DAR : B.2.1/01	EEC Method A1, OECD Method 102 – metal block method
Boiling point	Not determined	Turner B (2013b) DAR: B.2.1/02	EEC Method A2, OECD Method 103 – Siwolodoff method  The boiling temperature was not determinable as the test substance started to decompose after melting.  The pale yellow liquid darkened in colour as the temperature rose, becoming a dark yellow liquid at approximately 225°C and a brown liquid at approximately 255°C, until the sample formed a thick black

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Property	Value	Reference	Comment (e.g. measured or estimated)
			solid at approximately 305°C.
<b>Relative density</b>	1.32 at 20°C	Turner (2013b) DAR: B.2.14	
<b>Vapour pressure</b>	5.9 x 10 <sup>-4</sup> Pa at 25°C	Turner B (2013c) DAR: B.2.2/01	EEC Method A4, OECD Method 104
<b>Surface tension</b>	68.0 mN/m (90% saturated solution at 20°C)	Turner B (2013b) DAR: B.2.12/01	EEC Method A5, OECD Method 115 Harkins-Jordan corrected value = 67.0 mN/m The substance is not considered surface active.
<b>Water solubility</b>	26.5 mg/L at 20°C Moderately soluble	Comb (2012) DAR: B.2.5/01	EEC Method A6, OECD Method 106 – flask method and content determined by HPLC
<b>Partition coefficient n-octanol/water</b>	Log P <sub>ow</sub> = 1.9 at 25°C (eluent: methanol/ultra pure water pH 6.4)	Furatani (2014) DAR: B.2.7/01	OECD Method 117
<b>Flash point</b>	Not relevant since the melting point is >40°C	DAR: B.2.10/01	
<b>Flammability</b>	Not highly flammable	Turner B (2013a) DAR: B.2.9/01	EEC Method A10
<b>Explosive properties</b>	Not explosive	Turner B (2013a) DAR: B.2.11/01	EEC Method A14
<b>Self-ignition temperature</b>	The sample did not self-ignite up to 400°C.	Turner B (2013a) DAR: B.2.9/02	EEC Method A16
<b>Oxidising properties</b>	Not oxidising	Turner B (2013a) DAR: B.2.13/01	EEC Method A17
<b>Granulometry</b>	No data		
<b>Stability in organic solvents and identity of relevant degradation products</b>	No data		
<b>Dissociation constant</b>	Tolpyralate does not have a dissociation constant in the environmental pH range (pH 4-10)	Turner B (2013d) DAR: B.2.8/01	OECD Method 112 – Spectrophotometric method
<b>Viscosity</b>	Not relevant since the substance is a solid with a melting point >40 °C		

## 8 EVALUATION OF PHYSICAL HAZARDS

### 8.1 Explosives

**Table 8: Summary table of studies on explosive properties**

Method	Results	Remarks	Reference
EEC Method A14	Not explosive	In the mechanical sensitivity test there were no signs of ignition or explosion observed in any of the six tests but decomposition, indicated by a dark mark on the porcelain plate, was observed.	Turner B (2013a) DAR: B.2.11/01

#### 8.1.1 Short summary and overall relevance of the information provided on explosive properties

In a standard explosivity study (EEC, A14) there was no evidence of shock, friction or thermal sensitivity.

#### 8.1.2 Comparison with the CLP criteria

A substance is considered for classification as explosive where a positive result is obtained in the test series indicated in figure 2.1.2 of Annex I of the CLP regulation. There was no evidence of shock, friction or thermal sensitivity when tolpyralate was tested in a standard explosivity study.

#### 8.1.3 Conclusion on classification and labelling for explosive properties

Not classified – data conclusive but not sufficient for classification

### 8.2 Flammable gases (including chemically unstable gases)

Hazard class not applicable (tolpyralate is not a gas)

### 8.3 Oxidising gases

Hazard class not applicable (tolpyralate is not a gas)

### 8.4 Gases under pressure

Hazard class not applicable (tolpyralate is not a gas)

### 8.5 Flammable liquids

Hazard class not applicable (tolpyralate is not a liquid)

### 8.6 Flammable solids

**Table 9: Summary table of studies on flammable solids**

Method	Results	Remarks	Reference
EEC Method A10	Not highly flammable		Turner B (2013a) DAR: B.2.9/01

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

**8.6.1 Short summary and overall relevance of the provided information on flammable solids**

In a standard flammability study, tolpyralate was found to be not highly flammable.

**8.6.2 Comparison with the CLP criteria**

The criteria for classification as a flammable solid (Table 2.7.1 of Annex 1 of CLP) are not met.

**8.6.3 Conclusion on classification and labelling for flammable solids**

Not classified – data conclusive but not sufficient for classification.
---

**8.7 Self-reactive substances**

No studies are available for this end point.

**8.7.1 Short summary and overall relevance of the provided information on self-reactive substances**

No studies are available. However, the structure of tolpyralate does not contain any functional groups known to confer self-reactive properties (as indicated in Tables A6.1 and A6.2 in Appendix 6 of the UN RTDG, Manual of Tests and Criteria).

**8.7.2 Comparison with the CLP criteria**

According to Section 2.8.4.2 of Annex 1 of CLP, if a substance does not contain any chemical groups associated with explosive or self-reactive properties, then the classification procedure need not be applied.

**8.7.3 Conclusion on classification and labelling for self-reactive substances**

Hazard class not assessed in this dossier; hazard class not applicable.
---

**8.8 Pyrophoric liquids**

Hazard class not applicable (tolpyralate is not a liquid).

**8.9 Pyrophoric solids**

No studies are available for this end point.

**8.9.1 Short summary and overall relevance of the provided information on pyrophoric solids**

No studies are available. However, tolpyralate has been handled in air in the available studies and no incidences of self-ignition have been reported.

**8.9.2 Comparison with the CLP criteria**

According to Section 2.10.4.1 of Annex 1 of CLP, the classification procedure for pyrophoric solids need not be applied when experience in manufacture and handling shows that the substance does not spontaneously ignite upon coming into contact with air at normal temperatures. There are no reports in the available studies of tolpyralate spontaneously igniting when in contact with air.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

### 8.9.3 Conclusion on classification and labelling for pyrophoric solids

Hazard class not assessed in this dossier; hazard class not applicable.

### 8.10 Self-heating substances

Table 10: Summary table of studies on self-heating substances

Method	Results	Remarks	Reference
EEC Method A16	The sample did not self-ignite up to 400°C		Turner B (2013a) DAR: B.2.9/02

#### 8.10.1 Short summary and overall relevance of the provided information on self-heating substances

A study conducted in accordance with EEC A16 is available. In this study, tolpyralate did not self-ignite up to a temperature of 400°C.

#### 8.10.2 Comparison with the CLP criteria

Studies conducted according to EEC Method A16 are not sufficient for classification under CLP.

#### 8.10.3 Conclusion on classification and labelling for self-heating substances

Not classified - data lacking

### 8.11 Substances which in contact with water emit flammable gases

No studies are available.

#### 8.11.1 Short summary and overall relevance of the provided information on substances which in contact with water emit flammable gases

No data derived in accordance with the recommended test method in CLP have been provided. However, tolpyralate has been handled in water within many of the studies available in the draft assessment report, and there are no reports of violent reaction and emission of gas.

#### 8.11.2 Comparison with the CLP criteria

According to Section 2.12.4.1 of Annex 1 of CLP, the classification procedure for this hazard class need not be applied if experience in production or handling shows that the substance does not react with water. Therefore, classification for this class is not applicable for tolpyralate.

#### 8.11.3 Conclusion on classification and labelling for substances which in contact with water emit flammable gases

Hazard class not assessed in this dossier; hazard class not applicable.

### 8.12 Oxidising liquids

Hazard class not applicable (tolpyralate is not a liquid).



ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

### 8.13 Oxidising solids

**Table 11: Summary table of studies on oxidising solids**

Method	Results	Remarks	Reference
EEC Method A17	The test substance was not found to possess oxidising properties.		Turner B (2013a) DAR: B.2.13/01

#### 8.13.1 Short summary and overall relevance of the provided information on oxidising solids

A study conducted according to EEC Method A17 indicated that the substance is not oxidising. However, results generated using this study method are not suitable for classification using the CLP criteria.

The waiving criteria specified in Section 2.13.4.1 of Annex 1 of CLP are not met, since the substance contains an oxygen chemically bonded to something other than carbon or hydrogen (i.e., sulphur).

#### 8.13.2 Comparison with the CLP criteria

Data lacking.

#### 8.13.3 Conclusion on classification and labelling for oxidising solids

Not classified - data lacking

### 8.14 Organic peroxides

Hazard class not applicable (tolpyralate is not an organic peroxide).

### 8.15 Corrosive to metals

No data are available.

#### 8.15.1 Short summary and overall relevance of the provided information on corrosive to metals

No data are available.

#### 8.15.2 Comparison with the CLP criteria

No data are available.

#### 8.15.3 Conclusion on classification and labelling for corrosive to metals

Not classified – data lacking

## **RAC evaluation of physical hazards**

### **Summary of the Dossier Submitter's proposal**

Five physical hazards have been assessed by the dossier submitter (DS) and these were open for public consultation. For self-heating substances, oxidising solids and corrosive to metals the DS proposed no classification due to lack of data. For explosives and flammable solids the DS proposed no classification based the following data:

- Explosives: A negative test conducted according to A.14 (Turner, 2013a)
- Flammable solids: A test conducted according to A.10 (Turner, 2013a) giving a result "not highly flammable"

### **Comments received during public consultation**

No comments were received.

### **Assessment and comparison with the classification criteria**

RAC agrees with the DS on no classification due to lack of data (or lack of data generated in line with CLP) for the following hazards: self-heating substances, oxidising solids and corrosive to metals. RAC also agrees on no classification on the basis of conclusive data for flammable solids.

As to the explosive properties, RAC agrees with no classification based on the negative A.14 test but highlights the lack of the time/pressure test prescribed by the CLP regulation and not included in the A.14 testing method.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

## 9 TOXICOKINETICS (ABSORPTION, METABOLISM, DISTRIBUTION AND ELIMINATION)

The toxicokinetics of tolpyralate has been investigated in a range of studies conducted in the rat, as described in Table 12. Note that “SL-573” is the development code for tolpyralate.

**Table 12: Summary table of toxicokinetic studies**

Study	Reference
[ <sup>14</sup> C]SL-573 – Absorption, distribution, metabolism and excretion in the rat	Anonymous (2013a) DAR: B.6.1
[ <sup>14</sup> C]SL-573 - Absorption, distribution, metabolism and excretion in the rat following repeated oral administration	Anonymous (2014a) DAR: B.6.1
[ <sup>14</sup> C]SL-573 - Investigation of the chiral conversion of tolpyralate in the rat	Anonymous (2014e) DAR: B.6.1
[ <sup>14</sup> C]SL-573: Mouse, rat and human liver microsomal metabolism	Foster, J.R. (2015) DAR: B.6.1
[ <sup>14</sup> C]SL-573 – Investigation of metabolite MMTA following oral administration of [Phenyl- <sup>14</sup> C]-tolpyralate to the rat and laying hen	Anonymous (2014b) DAR: B.6.1

### 9.1 Short summary and overall relevance of the provided toxicokinetic information on the proposed classification(s)

The absorption, distribution, excretion and metabolism of tolpyralate have been investigated in a range of studies conducted using two different radiolabelled forms of the technical material, with radiolabels located at either the phenyl or pyrazole moieties.

Data informing on the plasma kinetics of tolpyralate indicate rapid absorption following oral administration. Oral absorption is estimated to be in the region of 60%. Tolpyralate was found to be widely distributed with the highest levels of radioactivity being associated with the liver and kidney. There was some indication of saturation of absorption at high dose levels. There was no evidence of a potential for tolpyralate to accumulate in fat.

Data from a single dose ADME study in the rat indicates that at the early time point the blood and the bone marrow are well exposed following oral exposure in the rodent. From the available data, the  $t_{max}$  of tolpyralate can be estimated to be in the range of 0.5 – 2 hours.


Tolpyralate was found to be extensively metabolised, the primary route of metabolism appears to be by dealkylation and subsequent conjugation with glucuronic acid. Comparative metabolism data from an *in vitro* study did not indicate any significant differences in metabolism between rats, mice and humans. Tolpyralate is eliminated in both the urine and faeces in approximately equal proportions; some radioactivity was also associated with the bile, indicated by studies in bile duct cannulated animals.

Dermal penetration of pure tolpyralate technical material has not been specifically investigated. An *in vitro* study investigated the dermal penetration of tolpyralate from a formulated pesticide product in both its concentrated and in use forms in human skin. Dermal penetration values of 0.1% and 9% were calculated, respectively.

## 10 EVALUATION OF HEALTH HAZARDS

Tolpyralate is a pyrazole herbicide which is reported to inhibit the enzyme 4-Hydroxyphenylpyruvate dioxygenase (HPPD) (see Section 10.12). In mammals, HPPD is the second enzyme in the catabolic pathway of tyrosine (figure 1):

Figure 1: Catabolic pathway of tyrosine



Inhibition of HPPD leads to a build-up of its substrate 4-hydroxyphenylpyruvic acid (4-HPPA), which is excreted in urine or converted back to tyrosine. In common with other important amino acids, tyrosine is not

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

excreted by the kidney (Buist *et al.*, 1974; Goldsmith, 1983) and hence only small amounts of free tyrosine may be readily cleared from the body. The clinical consequence of HPPD inhibition is an increase in circulating levels of plasma tyrosine and increased urinary excretion of the substrate 4-HPPA and related substances, collectively known as phenolic acids (e.g., 4-hydroxyphenylacetate (4-HPLA)).

When HPPD is inhibited, studies have shown that the extent of the elevated tyrosine levels is species-specific with a particularly severe effect induced in male rats (reviewed in Lock *et al.*, 2006). The basis for the species difference is the relative efficiencies of urinary excretion of phenolic acids between rats and mice due to differences in their inherent activity of Tyrosine Aminotransferase (TAT) (see Table 13).

**Table 13: Comparison of innate hepatic TAT (nmol/ HPPA/min/mg protein) activity – rats, mice and humans**

	Rat	Mouse	Humans*
Male	1.7 ± 0.2	7.8 ± 1.5	7.17 ± 1.17
Female	3.3 ± 0.5	10.5 ± 1.9	

From Henderson *et al.*, 1981

Innate hepatic TAT activity is higher in the mouse and, in the rat, a sex difference in TAT activity results in the male having particularly low HPPD activity. This difference in TAT activity results in a species and sex difference in tyrosine accumulation. Due to a high innate TAT activity, humans are expected to be less sensitive to the effects of HPPD inhibition than rats.

In the Mode of Action (MoA) proposed by the Applicant, a number of the effects seen with tolpyralate are said to be linked to significantly elevated plasma tyrosine levels, rather than a direct result of dosing with tolpyralate. This is discussed further in the relevant sections.

**Acute toxicity**

The acute toxicity of tolpyralate has been investigated in specific studies conducted *via* the oral, dermal and inhalation routes.

**10.1 Acute toxicity - oral route**

The acute oral toxicity of tolpyralate was investigated in a GLP compliant study in the rat, conducted in accordance with OECD TG 423.

**Table 14: Summary table of animal studies on acute oral toxicity**

Method, guideline, deviations if any	Species, strain, sex, no/group	Test Item	Result	Remarks
Acute toxic class OECD 423 GLP Anonymous (2012a) DAR: B.6.2.1	Rat, SD (Sprague Dawley) 6 females	2000 mg/kg bw Vehicle: 1% methylcellulose Batch: 20111222-1 Purity: 97.27%	LD50 > 2000 mg/kg bw	No overt clinical signs of toxicity. No unscheduled deaths.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

**10.1.1 Short summary and overall relevance of the provided information on acute oral toxicity**

In a study performed in accordance with the acute toxic class method (OECD 423), a group of 6 female rats was administered tolpyralate by gavage, formulated in 1% methylcellulose, at a single dose level of 2000 mg/kg bw. Animals were observed for mortality and clinical signs of toxicity for a period of 14 days following dose administration. No unscheduled deaths were recorded. There were no overt clinical signs of toxicity. The acute oral LD<sub>50</sub> of tolpyralate can be concluded to be > 2000 mg/kg bw in the rat.

**10.1.2 Comparison with the CLP criteria**

In accordance with the CLP criteria, substances should be classified for acute oral toxicity when the LD<sub>50</sub> has been reliably determined to be ≤ 2000 mg/kg bw. The acute oral LD<sub>50</sub> of tolpyralate was found to be >2000 mg/kg bw, therefore the criteria for classification are not met.

**10.1.3 Conclusion on classification and labelling for acute oral toxicity**

No classification (conclusive but not sufficient for classification).

**10.2 Acute toxicity - dermal route**

The acute toxicity of tolpyralate *via* the dermal route was investigated in a study in the rat conducted in accordance with OECD TG 402 and in compliance with GLP.

**Table 15: Summary table of animal studies on acute dermal toxicity**

Method, guideline, deviations if any	Species, strain, sex, no/group	Test Item	Result	Remarks
Acute dermal toxicity OECD 402 GLP Anonymous (2012b) DAR: B.6.2.2	Rat, SD (Sprague-Dawley) 5 males/5 females	2000 mg/kg bw Vehicle: 1% methylcellulose Batch: 20111222-1 Purity: 97.27%	LD50 > 2000 mg/kg bw	No overt clinical signs of toxicity. No unscheduled deaths.

**10.2.1 Short summary and overall relevance of the provided information on acute dermal toxicity**

The acute dermal toxicity of tolpyralate was investigated in a study conducted in accordance with OECD TG 402. Groups of 5 male and 5 female Sprague-Dawley rats of each sex were exposed to tolpyralate, formulated in 1% methylcellulose, applied topically at a single dose level of 2000 mg/kg bw, for a period of 24 hours. Animals were monitored for mortality and clinical signs of toxicity for a period of 14 days following administration of the test item. There were no recorded mortalities or overt clinical signs of toxicity. The acute dermal LD<sub>50</sub> of tolpyralate was found to be > 2000 mg/kg bw.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

### 10.2.2 Comparison with the CLP criteria

In accordance with the CLP criteria, substances should be classified for acute dermal toxicity where the LD<sub>50</sub> has been reliably determined to be ≤ 2000 mg/kg bw. The acute dermal LD<sub>50</sub> of tolpyralate was shown to be > 2000 mg/kg bw, therefore the criteria for classification are not met.

### 10.2.3 Conclusion on classification and labelling for acute dermal toxicity

No classification (conclusive but not sufficient for classification).

### 10.3 Acute toxicity - inhalation route

The acute toxicity of tolpyralate *via* the inhalation route was investigated in a study in the rat conducted in accordance with OECD test guideline 436 and in compliance with GLP.

**Table 16: Summary table of animal studies on acute inhalation toxicity**

Method, guideline, deviations if any	Species, strain, sex, no/group	Test conditions	Result	Remarks
Acute inhalation toxicity Nose only OECD 436 GLP Anonymous (2012c) DAR: B.6.2.3	Rat, SD 3 males/3 females	4-hour exposure Batch: 20111222-1 Purity: 97.27%  Single concentration of 2.01 mg/L (aerosol)  MMAD 4.0 µm GSD 2.60	LC50 > 2.01 mg/L	2.01 mg/L was the maximum achieved concentration that was found to produce an acceptable test atmosphere.

#### 10.3.1 Short summary and overall relevance of the provided information on acute inhalation toxicity

The acute toxicity of tolpyralate *via* the inhalation route was investigated in a study conducted in accordance with OECD test guideline 436. Three male and three female Sprague-Dawley rats were exposed to tolpyralate, generated as an atmosphere (aerosol) with a concentration of 2.01 mg/L. Animals were exposed to the test atmosphere (nose only) for a period of 4 hours. There were no overt signs of clinical toxicity or unscheduled deaths. The LC<sub>50</sub> of tolpyralate was concluded to be >2.01 mg/L.

#### 10.3.2 Comparison with the CLP criteria

In accordance with the criteria on CLP, classification for acute inhalation toxicity is appropriate where the 4-hour LC<sub>50</sub> is ≤ 5 mg/L (dust/mist). In the case of tolpyralate, the LC<sub>50</sub> was determined to be > 2.01 mg/L, which was the maximum achieved concentration. No mortalities were observed at the maximum achieved concentration, consequently classification is not appropriate.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

**10.3.3 Conclusion on classification and labelling for acute inhalation toxicity**

No classification (conclusive but not sufficient for classification).

**RAC evaluation of acute toxicity**

**Summary of the Dossier Submitter’s proposal**

The DS proposed no classification for acute toxicity based on the results of the following GLP compliant studies:

- Acute oral toxicity study in the rat conducted according to OECD TG 423 (Anonymous, 2012a): No mortality and no clinical signs of toxicity at 2000 mg/kg bw/d.
- Acute dermal toxicity study in the rat conducted according to OECD TG 402 (Anonymous, 2012b): No mortality or overt clinical signs of toxicity at 2000 mg/kg bw/d.
- Acute inhalation toxicity study in the rat conducted according to OECD TG 436, nose-only (Anonymous, 2012c): No mortality or overt clinical signs of toxicity at 2.0 mg/L (aerosol) with a MMAD of 4.0 µm (GSD 2.6). The DS explained that it was not possible to achieve a test atmosphere with appropriate characteristics at the higher concentration of 5.0 mg/L.

**Comments received during public consultation**

No comments were received on this hazard class.

**Assessment and comparison with the classification criteria**

As no mortalities occurred in the oral and dermal acute toxicity studies at the limit dose of 2000 mg/kg bw and no mortalities occurred in the acute inhalation toxicity study at the highest achievable concentration to produce an acceptable test atmosphere (2.0 mg/L), RAC agrees that **no classification** for acute toxicity is appropriate.

**10.4 Skin corrosion/irritation**

The skin irritation potential of tolpyralate was investigated in a study conducted in the rabbit in accordance with OECD TG 404 and in compliance with GLP.

**Table 17: Summary table of animal studies on skin corrosion/irritation**

Method, guideline, deviations if any	Species, strain, sex, no/group	Test conditions	Result	Remarks
Dermal irritation	Rabbit New Zealand	0.5g tolpyralate	All scores (24,48,72h) = 0	There were no recorded signs of dermal



ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Method, guideline, deviations if any	Species, strain, sex, no/group	Test conditions	Result	Remarks
OECD 404 GLP Anonymous (2012d) DAR: B.6.2.4	White 3 females	4-hour exposure Batch: 20111222-1 Purity: 97.27%		irritation.

#### 10.4.1 Short summary and overall relevance of the provided information on skin corrosion/irritation

The skin irritation potential of tolpyralate was investigated in a study conducted in the rabbit in accordance with OECD TG 404 and in compliance with GLP. 0.5g of tolpyralate was applied to a prepared area of skin on the dorso-lateral area of three New Zealand white rabbits for a period of 4 hours. The animals were observed for clinical signs of toxicity and signs of dermal irritation for 3 days following exposure. There were no mortalities, signs of clinical toxicity or signs of dermal irritation in any of the animals.

#### 10.4.2 Comparison with the CLP criteria

In the study conducted with tolpyralate there were no signs of dermal irritation at any point. Consequently none of the criteria for classification were met.

#### 10.4.3 Conclusion on classification and labelling for skin corrosion/irritation

No classification (conclusive but not sufficient for classification).

### RAC evaluation of skin corrosion/irritation

#### Summary of the Dossier Submitter's proposal

The DS proposed no classification for skin corrosion/irritation based on a negative *in vivo* study in the rabbit conducted according to OECD TG 404 (GLP compliant; Anonymous, 2012d).

#### Comments received during public consultation

No comments were received on this hazard class.

#### Assessment and comparison with the classification criteria

Tolpyralate did not elicit any signs of dermal irritation in the available *in vivo* dermal irritation study (Anonymous, 2015d). As the criteria for classification are not met, RAC agrees with the DS that **no classification** for skin irritation/corrosion is appropriate.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

**10.5 Serious eye damage/eye irritation**

The eye irritation potential of tolpyralate was investigated in a study conducted in the rabbit in accordance with OECD TG 405 and in compliance with GLP.

**Table 18: Summary table of animal studies on serious eye damage/eye irritation**

Method, guideline, deviations if any	Species, strain, sex, no/group	Test conditions	Result	Remarks
Eye irritation OECD 405; GLP Anonymous (2012e) DAR: B.6.2.5	Rabbit, New Zealand White 3 females	0.1g tolpyralate Batch: 20111222-1 Purity: 97.27%	All scores (24,48,72h) = 0	Signs of slight eye irritation were observed in the first hour following administration. All reactions had reversed by 24 hours.

**10.5.1 Short summary and overall relevance of the provided information on serious eye damage/eye irritation**

The eye irritation potential of tolpyralate was investigated in a study conducted in the rabbit in accordance with OECD TG 405 and in compliance with GLP. 0.1g of the test item was instilled into a single eye of three New Zealand White rabbits. Ocular reactions to the test item were recorded at 1, 24, 48 and 72 hours following administration. Conjunctival redness (grade 1), chemosis (grade 1 or 2) and discharge (grade 2 or 3) were observed in 2 or more animals at the 1 hour observation. However, all ocular reactions to the test item were resolved by the 24 hour observation and no further signs of eye irritation were recorded for the remainder of the study. Mean scores for all measured parameters, calculated per animal and as the mean of scores at 24, 48 and 72 hours were 0 in all instances.

**10.5.2 Comparison with the CLP criteria**

The mean scores for all parameters were 0 for all animals at 24, 48 and 72 hours. Therefore tolpyralate does not meet the criteria for classification for eye damage/ irritation.

**10.5.3 Conclusion on classification and labelling for serious eye damage/eye irritation**

**No classification (conclusive but not sufficient for classification).**

**RAC evaluation of serious eye damage/irritation**

**Summary of the Dossier Submitter’s proposal**

The DS proposed no classification for serious eye damage/irritation based on a negative *in vivo* study in the rabbit according to OECD TG 405 (GLP compliant; Anonymous, 2012e).

### **Comments received during public consultation**

No comments were received on this hazard class.

### **Assessment and comparison with the classification criteria**

In the available *in vivo* eye irritation study (Anonymous, 2012e), signs of slight eye irritation were observed in the first hour following administration. All reactions had reversed by 24 hours and all scores at 24 h, 48 h and 72 h were zero. As the criteria for classification are not met, RAC agrees with the DS that **no classification** for serious eye damage/irritation is appropriate.

## **10.6 Respiratory sensitisation**

There are no specific data available relating to the respiratory sensitisation potential of tolpyralate.

### **10.6.1 Conclusion on classification and labelling for respiratory sensitisation**

Because of the lack of data, a definitive conclusion on respiratory sensitisation cannot be made.

### **RAC evaluation of respiratory sensitisation**

#### **Summary of the Dossier Submitter's proposal**

There were no specific data available relating to the respiratory sensitisation potential of tolpyralate. The DS proposed no classification because of lack of data.

#### **Comments received during public consultation**

No comments were received on this hazard class.

#### **Assessment and comparison with the classification criteria**

In the absence of information on respiratory sensitisation, RAC agrees with the DS's proposal of **no classification due to lack of data**.

## **10.7 Skin sensitisation**

The skin sensitisation potential of tolpyralate was investigated in both a local lymph node assay (LLNA) and a Guinea pig maximisation test (GPMT), both conducted to appropriate test guidelines and in compliance with GLP.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

**Table 19: Summary table of animal studies on skin sensitisation**

Method, guideline	Species, strain, sex, no/group	Test conditions	Results
Local lymph node assay (LLNA) OECD 429 GLP Anonymous (2013b) DAR: B.2.6.2	Mouse, CBA/J, 5 females/group	0, 10, 25, 50% w/v tolpyralate in <i>N,N</i> -dimethylformamide Batch: 20111222-1 Purity: 97.27% Positive control : 25% $\alpha$ -hexylcinnamaldehyde (HCA)	There was no evidence of a potential for tolpyralate to initiate skin sensitisation. Stimulation indices; Vehicle control = 0 10% tolpyralate = 0.5 25% tolpyralate = 1.1 50% tolpyralate = 1.0 25% HCA = 9.2
Guinea pig maximisation assay OECD 406 GLP Anonymous (2012) DAR: B.2.6.2	Guinea pig, Hartley 5 females/ control group & 10 females/test group	<u>Intra-dermal induction</u> : 10% in liquid paraffin <u>Topical induction</u> : 50% in acetone <u>Challenge</u> : 50% in acetone Batch: 20111222-1 Purity: 97.27%	No evidence of skin sensitisation potential

### 10.7.1 Short summary and overall relevance of the provided information on skin sensitisation

The skin sensitisation potential of tolpyralate has been investigated in both a local lymph node assay (LLNA) and a Guinea pig maximisation test, both were conducted to appropriate test guidelines and in compliance with GLP.

#### Local Lymph Node Assay (LLNA)

In the LLNA, female CBA/J Mice (five per group) were each given three consecutive daily topical applications to the dorsal surface of both ears of 0, 10, 25 or 50% w/v tolpyralate in *N,N*-dimethylformamide. The proliferative response of the lymph node cells from the draining auricular lymph nodes was assessed five days after the first application by measuring the incorporation of <sup>3</sup>H-methyl thymidine in suspensions of the lymph node cells. The ratio of <sup>3</sup>H-methyl thymidine incorporation into the nodes from treated mice to that from controls was calculated (the Stimulation Index).

There were no significant differences in mean lymph node weights between the tolpyralate treatment groups and the vehicle control group. In the positive control group, there was a significant increase in mean lymph node weight compared to the vehicle control group.

Stimulation indices (SIs) were 0.5, 1.1 and 1.0 in the 10, 25 and 50% w/v tolpyralate treatment groups, respectively. There were no significant differences in mean cellular proliferation activities between the tolpyralate treatment groups and the vehicle control group. There was a significant increase in mean cellular proliferation activity in the positive control group with an SI value of 9.2.

#### Guinea Pig Maximisation Test (GPMT)

In the GPMT, groups of 10 test and 5 control animals were used. Intradermal induction was performed at a concentration of 10% w/v in paraffin, topical induction and challenge were performed with 50% w/v in

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

acetone. As the test item was found to be not-irritating at 50%, dermal irritation was induced with application of 10% sodium lauryl sulphate (SLS). Observation for skin reactions was performed at 24 and 48 hours after challenge. No skin reactions were observed on the site challenged with tolpyralate in either the test substance sensitisation group or the control group. A concurrent positive control group was not included for this study, but laboratory control data for the positive control article 1-chloro-,2,4-dinitrobenzene (DNCB) from the same the test facility (period of 11 September 2012 to 30 November 2012) was showed an acceptable response.

**10.7.2 Comparison with the CLP criteria**

There was no evidence of a potential for tolpyralate to induce skin sensitisation in either of the available studies. Consequently tolpyralate does not meet any of the criteria for classification.

**10.7.3 Conclusion on classification and labelling for skin sensitisation**

**No classification (conclusive but not sufficient for classification).**

<b>RAC evaluation of skin sensitisation</b>						
<p><b>Summary of the Dossier Submitter’s proposal</b></p> <p>The skin sensitisation potential of tolpyralate was investigated in a local lymph node assay (LLNA) (Anonymous, 2013b) and a guinea pig maximisation test (GPMT) (Anonymous, 2012f). Both studies were negative. The DS proposed no classification based on conclusive data.</p> <p><b>Comments received during public consultation</b></p> <p>One Member State Competent Authority (MSCA) commented on the choice of the highest concentration, which was 50% in both the LLNA and GPMT. As the concentration of 50% did not cause irritation, the MSCA asked why 100% had not been tested. The DS explained that it was not possible to test at a higher concentration as the test material was a solid that required moistening before application.</p> <p><b>Assessment and comparison with the classification criteria</b></p> <p>The LLNA and GPMT are summarised in the following table.</p>						
<b>Skin sensitisation studies</b>						
<b>Type of study; Reference</b>	<b>Method</b>	<b>Observations</b>				
LLNA Anonymous, 2013b	OECD TG 429 GLP 0, 10, 25, 50% w/v tolpyralate in <i>N,N</i> -dimethylformamide 5 females/group	Negative Stimulation indices: <table border="1" style="margin-left: 20px; border-collapse: collapse;"> <tr> <td style="padding: 2px;">Treatment</td> <td style="padding: 2px;">SI</td> </tr> <tr> <td style="padding: 2px;">10% tolpyralate</td> <td style="padding: 2px;">0.5</td> </tr> </table>	Treatment	SI	10% tolpyralate	0.5
Treatment	SI					
10% tolpyralate	0.5					

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

	Positive control: 25% $\alpha$ -hexylcinnamaldehyde	25% tolpyralate	1.1
		50% tolpyralate	1.0
		Positive control	9.2
GPMT Anonymous, 2012f	OECD TG 406 GLP Intradermal induction: 10% in liquid paraffin Topical induction: 50% in acetone (suspension); dermal irritation induced by sodium lauryl sulphate (SLS) pre-treatment Challenge: 50% in acetone 10 females/test group 5 females/control group No concurrent positive control; the laboratory reliability check (1-chloro-2,4-dinitrobenzene) from the respective period (within 2 months of the present study) was stated to have shown an acceptable response	Negative No skin reactions in the test group or the control group	

RAC accepts the DS' justification for the choice of the highest concentration, *i.e.*, that the tested material, being a solid, had to be suspended in a suitable vehicle before application. The highest concentration of 50% in both studies is considered to fulfil the requirements of the respective OECD testing guidelines. RAC also notes that in the GPMT, SLS pre-treatment was applied as prescribed by the guideline for non-irritant substances.

As both studies are negative and neither of them shows any major methodological deficiency, RAC agrees with the DS that **no classification** based on conclusive data is justified.

### 10.8 Germ cell mutagenicity

The genotoxic potential of tolpyralate has been investigated in a range of studies, conducted both *in vitro* and *in vivo*. *In vitro* studies are a bacterial reverse mutation assay, a mammalian chromosomal aberration assay and mammalian gene mutation assay. *In vivo* studies are a mouse micronucleus assay and two comet assays in the rat.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

**Table 20: Summary table of mutagenicity/genotoxicity tests in vitro**

Method, guideline, deviations if any	Test system (Organism, strain)	Test substance	Conc. tested (range)	Results		Remarks (information on cytotoxicity)
				-S9	+S9	
Gene mutation assay in bacteria (Ames) Pre-incubation OECD 471, GLP Wada, K. (2012) DAR: B.6.4.1	<i>S.typhimurium</i> strains TA 1535, TA 1537, TA 98, TA 100; <i>E.coli</i> strain WP2 uvrA	tolpyralate Batch : 20111222-1 Purity: 97.27%	Up to 5000 µg/plate	Neg	Neg	Study consisted of a range finding assay and two main assays.  No evidence of cytotoxicity.
Chromosome aberration test OECD 473, GLP Matsumoto, K. (2012a) DAR: B.6.4.1	Chinese hamster lung cells CHL/IU	tolpyralate Batch : 20111222-1 Purity: 97.27%	6 hour 200-1200 µg/mL	Neg	Neg	
			24 hour 75-300 µg/mL	Neg	Neg	
			48 hour 50-200 µg/mL	Neg	Neg	
Gene mutation test OECD 476, GLP Matsumoto, K. (2012b) DAR: B.6.4.1	Mouse lymphoma cells L5178Y TK <sup>±</sup>	tolpyralate Batch : 20111222-1 Purity: 97.27%	3 hour 78 – 1250 µg/mL	Pos	Pos	Precipitation at 625 and 1250 µg/mL without metabolic activation and at 1250 µg/mL with metabolic activation.
			24 hour 39 – 1250 µg/mL	Pos	N/A	Precipitation at 625 and 1250 µg/mL.

The genotoxic potential of tolpyralate has been investigated in 3 *in vitro* studies, all conducted in accordance with appropriate OECD test guidelines and in compliance with GLP. In a reverse mutation assay (Ames test) and in an *in vitro* chromosome aberration assay there was no evidence of genotoxicity under any of the tested conditions.

In a mammalian cell gene mutation test, there was evidence of genotoxicity in both the three hour test (in the presence and absence of metabolic activation), and in the 24 hour test. As shown below, in both the 3 hour assay and in the 24 hour assay, there were clear and statistically significant increases in mutant frequency, and a clear dose-response relationship. The findings of this study are summarised in Table 21. Clearly tolpyralate induced gene mutations in this assay. There was a slight increase in the ratio of small colonies with increasing exposure to tolpyralate, which, in some instances might indicate the potential of the test substance to induce structural damage to chromosomes. However, given the negative result seen in a chromosome aberration test, this seems unlikely for tolpyralate.

**Table 21: Results of the mammalian cell gene mutation assay**

Exposure	S9	Treatment	Concentration	Relative survival	Relative total	Mutant frequency	Ratio of small
----------	----	-----------	---------------	-------------------	----------------	------------------	----------------

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

time			(µg/mL)	at Day 0 (%)	growth (%)	(× 10 <sup>-6</sup> )	colonies (%)
3 hours	-	Solvent control (DMSO)	1%	100	100	134.3	33
		tolpyralate	78.1	106	102	141.7	34
			156	108	102	125.1	28
			313	102	101	145.3	30
			625 <sup>(a)</sup>	103	86	163.9	40
			1250 <sup>(b)</sup>	70	43	212.3*	47
3 hours	+	Solvent control (DMSO)	1%	100	100	166.9	31
		tolpyralate	78.1	97	112	152.5	23
			156	94	99	155.1	27
			313	87	93	162.3	36
			625	65	52	347.1***	32
			1250 <sup>(b)</sup>	24	14	457.2***	38
24 hours	-	Solvent control (DMSO)	1%	100	100	71.8	32
		tolpyralate	39.1	83	99	84.7	26
			78.1	74	108	101.1	39
			156	73	95	125.6	40
			313	73	76	179.7*	43
			625 <sup>(a)</sup>	60	50	420.0***	49
			1250 <sup>(b)</sup>	15	9	445.1***	50

DMSO                      Dimethyl sulfoxide

MMS                      Methyl methanesulfonate

(a)                      Precipitation of the test substance was observed at the end of the treatment

(b)                      Precipitation of the test substance was observed at the beginning and end of the treatment

Mutant frequency data were analysed by Dunnett's test

Significantly different from the solvent control: \*  $p \leq 0.05$ ; \*\*\*  $p \leq 0.001$

**Table 22: Summary table of mutagenicity/genotoxicity tests in mammalian somatic or germ cells *in vivo***

Method, guideline, deviations if any	Species, strain, sex, No/group	Test substance	Dose levels and sampling times	Results
Micronucleus test OECD 474, GLP	Mouse, CD1	tolpyralate Batch :	24 hour : 0, 500,1000, 2000	Negative No increases in mean frequency of



ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Method, guideline, deviations if any	Species, strain, sex, No/group	Test substance	Dose levels and sampling times	Results
Anonymous (2012g) DAR B.6.4.2	5 males/group	20111222-1 Purity: 97.27%	mg/kg bw, single oral (gavage) dose 48 hour : 2000 mg/kg bw, single oral (gavage) dose	micronucleated polychromatic erythrocytes or PCE to NCE ratio under any tested conditions.
Comet Assay Liver and stomach OECD 489, GLP Anonymous (2014c) DAR B.6.4.2	Rat, Wistar 6 males/group	tolpyralate Batch : 20111222-1 Purity: 97.27%	0, 500, 1000, 2000 mg/kg bw, two oral (gavage) doses  Positive control – 200 mg/kg bw EMS*	Negative No increase in % DNA tail under any tested conditions.
Comet Assay Liver, thyroid and stomach OECD 489, GLP Anonymous (2015a) DAR B.6.4.2	Rat, Wistar 5 males/group	tolpyralate Batch : 20111222-1 Purity: 97.27%	0, 500, 1000, 2000 mg/kg bw, two oral (gavage) doses  Positive control – 200 mg/kg bw EMS*	Negative No increase in % DNA tail under any tested conditions.

\*EMS – ethyl methanesulfonate

The genotoxic potential of tolpyralate was investigated *in vivo* in 3 separate studies: a mouse micronucleus assay and two *in vivo* comet assays in the rat.

In the micronucleus assay, groups of 5 male CD1 mice were administered a single dose of tolpyralate by oral gavage, at dose levels of 0, 500, 1000 or 2000 mg/kg bw. Animals were sacrificed at 24 hours following dose administration. Under the conditions of this study there were no increases in either the mean frequency of micronucleated polychromatic erythrocytes or the PCE to NCE ratio in the bone marrow. A separate group of mice were administered a single dose at only 2000 mg/kg bw and were sacrificed at 48 hours. There is appropriate information available from the ADME studies conducted with tolpyralate to indicate that the bone marrow is sufficiently exposed to the test item following oral administration, with levels of radioactivity in the bone marrow being in the same order as multiple other tissues that are not associated with primary digestive / excretive organs, such as the lung, pancreas and thyroid. Overall, it is concluded that the result of this test was negative.

Two comet assays were conducted: one investigating the genotoxicity in the liver and stomach, and a second study in the liver, stomach and thyroid. In both studies the highest dose level was 2000 mg/kg bw, and the test item was administered by oral gavage on two consecutive days. In both studies animals were sacrificed 3 hours after the final dose, based on the available information, this is after the  $t_{max}$  (0.5-2hours) and so maximum systemic concentration will have been achieved. There was no significant increase in %DNA tail or any other indication of a genotoxic effect of the test item in either study.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

**10.8.1 Short summary and overall relevance of the provided information on germ cell mutagenicity**

The genotoxic potential of tolpyralate was investigated in a range of studies conducted both *in vitro* and *in vivo*. In a bacterial reverse mutation (Ames) test and an *in vitro* chromosomal aberration assay, there was no evidence of genotoxicity under any of the tested conditions. In a mammalian cell gene mutation assay, there was clear evidence of a positive, reproducible and dose related increase in mutant fraction both with and without metabolic activation.

With respect to *in vivo* studies, there was no evidence of genotoxicity in the micronucleus assay under any of the tested conditions. Additionally, two *in vivo* comet assays are available, investigating genotoxic potential in the stomach and liver and in the stomach, liver and thyroid respectively. There was no evidence of genotoxicity in either study. These negative findings from three *in vivo* studies are sufficient to dismiss concerns relating to genotoxic potential arising from the positive *in vitro* gene mutation assay.

**10.8.2 Comparison with the CLP criteria**

The available information indicates that tolpyralate is not genotoxic.

**10.8.3 Conclusion on classification and labelling for germ cell mutagenicity**

No classification (conclusive but not sufficient for classification).

<b>RAC evaluation of germ cell mutagenicity</b>
<p><b>Summary of the Dossier Submitter’s proposal</b></p> <p>The genotoxic potential of tolpyralate has been investigated both <i>in vitro</i> and <i>in vivo</i>. In <i>in vitro</i> studies, an Ames test and an <i>in vitro</i> chromosome aberration assay were negative while a mouse lymphoma assay was positive.</p> <p>The <i>in vivo</i> dataset consists of a mouse micronucleus assay and two comet assays in the rat. All three <i>in vivo</i> studies were negative.</p> <p>According to the DS, the negative findings from three <i>in vivo</i> studies are sufficient to dismiss concerns relating to genotoxic potential arising from the positive <i>in vitro</i> gene mutation assay. Therefore, the DS proposed no classification based on conclusive data.</p>
<p><b>Comments received during public consultation</b></p> <p>One MSCA questioned whether the <i>in vivo</i> tests conducted (one micronucleus and two comet assays) were an appropriate follow-up to the positive mouse lymphoma assay.</p>
<p><b>Assessment and comparison with the classification criteria</b></p> <p>The available genotoxicity studies are summarised in the following table.</p>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

<b>Genotoxicity studies</b>		
<b>Type of study; Reference</b>	<b>Method</b>	<b>Observations</b>
<b><i>In vitro</i></b>		
Ames test Wada, 2012	OECD TG 471 GLP <i>S. typhimurium</i> TA98, TA100, TA1535, TA 1537; <i>E. coli</i> WP2 uvrA Pre-incubation method Up to 5000 µg/plate	Negative ±S9 No cytotoxicity up to the limit concentration
Chromosomal aberration test <i>in vitro</i> Matsumoto, 2012a	OECD TG 473 GLP Chinese hamster lung cells (CHL/IU) 6-hour treatment ±S9 up to 1200 µg/mL 24-hour treatment ±S9 up to 300 µg/mL 48-hour treatment ±S9 up to 200 µg/mL	Negative ±S9 Selection of top concentrations based on cytotoxicity (growth inhibition of at least 50%); in the short-term test +S9 a reduction of 50% not achieved but precipitation observed
Mouse lymphoma assay Matsumoto, 2012b	OECD TG 476 GLP Mouse lymphoma cells L5178Y TK <sup>±</sup> / <sub>-</sub> 3-hour treatment ±S9 up to 1250 µg/mL 24-hour treatment -S9 up to 1250 µg/mL	Positive ±S9 A slight shift towards small colonies with increasing concentrations
<b><i>In vivo</i></b>		
Micronucleus test in the bone marrow Anonymous, 2012g	OECD TG 474 GLP Mouse 5 males/group Sampling at 24 h: single oral (gavage) dose of 0, 500, 1000 or 2000 mg/kg bw Sampling at 48 h: single oral (gavage) dose of 2000 mg/kg bw	Negative Positive control worked properly No increase in PCE to NCE ratio No clinical signs of toxicity
Comet assay Anonymous, 2014c	OECD TG 489 GLP Rat 6 males/group Tissues: liver and stomach Two oral (gavage) doses, at 0 h and at 21 h; sacrifice at 24 h Doses: 0, 500, 1000, 2000 mg/kg bw	Negative Positive control responded appropriately
Comet assay Anonymous, 2015a	OECD TG 489 GLP Rat 5 males/group Tissues: liver, stomach and thyroid Two oral (gavage) doses, at 0 h and at 21 h; sacrifice at 24 h Doses: 0, 500, 1000, 2000 mg/kg bw	Negative Positive control responded appropriately

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

A set of one *in vivo* micronucleus assay and two *in vivo* comet assays (from two different laboratories) is in principle considered as an appropriate follow-up to a positive mouse lymphoma assay.

No evidence of bone marrow exposure and no evidence of systemic toxicity were observed in the mouse micronucleus test itself. In an ADME study in rats (Anonymous, 2013a) the radioactivity in the bone marrow at a  $T_{max}$  of 2 h after a single dose of 200 mg/kg bw tolpyralate was approx. 2–3 µg equiv/g compared to 14–18 µg equiv/g in the plasma and 25–32 µg equiv/g in the liver. This is considered as evidence of bone marrow exposure in the rat. Although bone marrow exposure in the mouse is likely, direct evidence is not available.

The first comet assay in the rat (Anonymous, 2014c) utilised the stomach, representing the site of first contact, and the liver, a site with high systemic perfusion and high exposure to the test substance as confirmed by ADME studies (Anonymous, 2013a; Anonymous, 2014a). The second assay (Anonymous, 2015a) also examined the stomach and the liver and in addition examined the thyroid in order to investigate genotoxic potential specific to this tissue. The tissues were sampled at an appropriate time (3 h after the last exposure;  $T_{max}$  is 0.5–2 h) and the positive controls responded appropriately. Both studies were negative in all examined tissues.

RAC agrees with the DS that the three available *in vivo* studies collectively remove the concern raised by the positive mouse lymphoma assay and that **no classification** is therefore warranted.

### 10.9 Carcinogenicity

The carcinogenic potential of tolpyralate was investigated in two carcinogenicity/chronic toxicity studies; one in the rat and one in the mouse.

**Table 23: Summary table of animal studies on carcinogenicity**

Method Guideline, Deviation(s) from the guideline (if any)	Species Strain Sex no/group	Dose levels duration of exposure	Results																				
Two-year carcinogenicity study Oral (dietary) OECD 451 GLP Batch: 2011222-1 Purity: 97.27% Anonymous (2015b) DAR B.6.5	Rat, Wistar  51/sex/group	104 weeks  0, 5, 20, 2000, 10000 ppm  Equivalent intake at 104 weeks:  Males: 0, 0.196, 0.765, 83.8, 426 mg/kg bw/d  Females: 0, 0.255, 1.01, 108, 554 mg/kg bw/d	<p><u>General toxicity</u></p> <table border="1"> <thead> <tr> <th rowspan="2">Dose level (mg/kg bw/d)</th> <th colspan="2">Survival (%)</th> </tr> <tr> <th>Males</th> <th>Females</th> </tr> </thead> <tbody> <tr> <td>0/0</td> <td>75</td> <td>69</td> </tr> <tr> <td>0.196/0.255</td> <td>75</td> <td>65</td> </tr> <tr> <td>0.765/1.01</td> <td>78</td> <td>71</td> </tr> <tr> <td>83.8/108</td> <td>71</td> <td>71</td> </tr> <tr> <td>426/554</td> <td>75</td> <td>59</td> </tr> </tbody> </table> <p>No overt or serious clinical signs of toxicity. Decreased body weight, relative to controls (&lt;20%) in mid-high and high dose groups.</p> <p><u>Neoplastic effects</u></p>	Dose level (mg/kg bw/d)	Survival (%)		Males	Females	0/0	75	69	0.196/0.255	75	65	0.765/1.01	78	71	83.8/108	71	71	426/554	75	59
Dose level (mg/kg bw/d)	Survival (%)																						
	Males	Females																					
0/0	75	69																					
0.196/0.255	75	65																					
0.765/1.01	78	71																					
83.8/108	71	71																					
426/554	75	59																					

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Method Guideline, Deviation(s) from the guideline (if any)	Species Strain Sex no/group	Dose levels duration of exposure	Results																	
			<table border="1"> <thead> <tr> <th rowspan="2"></th> <th colspan="5">dose level (ppm)</th> </tr> <tr> <th>0</th> <th>5</th> <th>20</th> <th>2000</th> <th>10000</th> </tr> </thead> <tbody> <tr> <td>Malignant squamous cell carcinoma in the eye in males (Total incidence)</td> <td>0/51</td> <td>0/51</td> <td>0/51</td> <td>3/51</td> <td>5/51*</td> </tr> </tbody> </table> <p>*, <math>p \leq 0.05</math>; (by Fisher's exact probability test).</p> <p>There was no incidence of this effect in females and in any of the historical control data.</p>		dose level (ppm)					0	5	20	2000	10000	Malignant squamous cell carcinoma in the eye in males (Total incidence)	0/51	0/51	0/51	3/51	5/51*
	dose level (ppm)																			
	0	5	20	2000	10000															
Malignant squamous cell carcinoma in the eye in males (Total incidence)	0/51	0/51	0/51	3/51	5/51*															
18-month carcinogenicity Oral (dietary) OECD 451 GLP Anonymous (2015c) DAR B.6.5	Mouse, CD1 52/sex/group	78 weeks 0, 70, 700, 7000 ppm  Equivalent intake at 78 weeks: Males: 0, 7.37, 78.5, 793 mg/kg bw/d Females: 0, 7.25, 72.6, 732 mg/kg bw/d	<p>Survival at 78 weeks</p> <table border="1"> <thead> <tr> <th rowspan="2">Dose level (mg/kg bw/d)</th> <th colspan="2">Survival (%)</th> </tr> <tr> <th>Males</th> <th>Females</th> </tr> </thead> <tbody> <tr> <td>0/0</td> <td>67</td> <td>77</td> </tr> <tr> <td>7.37/7.25</td> <td>62</td> <td>71</td> </tr> <tr> <td>78.5/72.6</td> <td>65</td> <td>62</td> </tr> <tr> <td>793/732</td> <td>60</td> <td>73</td> </tr> </tbody> </table> <p>No overt clinical signs of toxicity or increase in cumulative mortality at 78 weeks. Small decreases in body weight, relative to controls were observed in males, but were &lt; 10%.</p> <p><u>Neoplastic effects</u></p> <p>No relevant increases in tumour incidence in any groups.</p>	Dose level (mg/kg bw/d)	Survival (%)		Males	Females	0/0	67	77	7.37/7.25	62	71	78.5/72.6	65	62	793/732	60	73
Dose level (mg/kg bw/d)	Survival (%)																			
	Males	Females																		
0/0	67	77																		
7.37/7.25	62	71																		
78.5/72.6	65	62																		
793/732	60	73																		

### 10.9.1 Chronic / carcinogenicity study in rats

The carcinogenic potential of tolpyralate was investigated in a 2-year dietary study performed in Wistar rats. Four groups (51/sex/group) were administered tolpyralate in the diet at concentrations of 5, 20, 2000 or 10000ppm for a period of 104 weeks. A concurrent control group was administered the basal diet under the same conditions. Mean achieved dosages during the 104-week treatment period were 0.196, 0.765, 83.8 and 426 mg/kg/day for males and 0.255, 1.01, 108 and 554 mg/kg/day for females receiving 5, 20, 2000 and 10000 ppm respectively.

#### *Non-neoplastic findings*

There were no severe or overt clinical signs of toxicity in any of the treated groups. Survival was  $\geq 59\%$  in all treated groups. There were small reductions in body weight when compared to control animals in both sexes at the top two dose levels; these were greater than 10% only in males, and less than 20% in all cases. Non neoplastic findings are summarised in section 10.12

#### *Neoplastic findings*

##### *Eye*

## ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

A small increase in the incidence of malignant squamous cell carcinoma in the eye was observed in males at 83.8 and 426 mg/kg bw/d. This effect was statistically significant at the top dose. As there were no such tumours seen in the control, low and lower mid dose males, and none were evident in the laboratory's historical control data set, these tumours are considered to be related to treatment. This observation is consistent with macroscopic and histopathological findings in the eye.

### *Thyroid*

A slight increase in the incidence of benign follicular cell adenoma in the thyroid was observed in males at the highest tested dose (incidences of 3, 0, 3, 1 and 5 at 0, 5, 20, 2000 and 10000 ppm respectively), occurring without statistical significance. Historical control data from the same laboratory, from 9 studies conducted between 2007 and 2013, shows a mean incidence of 3.92% (range 0/51 -6/51) of this finding in males. Noting the lack of statistical significance and dose-response relationship and the historical control data, the observation of benign follicular cell adenoma in the thyroid is not considered to be a treatment related finding.

### **10.9.2 Chronic / carcinogenicity study in mice**

The carcinogenic potential of tolpyralate was investigated in a 78 week study conducted in the mouse. Groups of 52 CD1 mice of each sex were administered the test item (tolpyralate, batch 20111222-1, purity 97.27 %) in the diet at concentrations of 70, 700 and 7000 ppm, equivalent to 7.37, 78.5 and 793 mg/kg bw/day in males and 7.25, 72.6 and 732 mg/kg bw/day in females.

Observed clinical signs of toxicity which are attributable to administration of the test item were increased incidence in loss of fur and tactile hair in both sexes and small (less than 10%) reductions in body weight in males. Non-neoplastic findings are summarized in section 10.12. There were no increases in either benign or malignant tumors in any treated groups. Changes in the number of tumours were limited to sporadic decreases which occurred without a dose response relationship. Consequently, it was concluded that tolpyralate did not produce a carcinogenic response in this study.

### **10.9.3 Short summary and overall relevance of the provided information on carcinogenicity**

The carcinogenic potential of tolpyralate has been investigated in a rat and a mouse carcinogenicity study (rat, 2 years duration; mouse, 18 months). In both studies the test item was well tolerated, with minimal clinical signs of toxicity other than small decreases in body weights. There were no relevant increases in mortality and survival at study termination was acceptable (>50%) in both studies. As such these studies provide for a valid assessment of the carcinogenicity of tolpyralate.

In the mice, there were no relevant increases in the incidence of tumours in any of the treated groups. Similarly, there were no significant tumour findings in female rats.

In male rats there was an increase in the incidence of squamous cell carcinoma in the cornea affecting 3 and 5 males (6% and 10% of animals) at the mid (83.8 mg/kg bw/d) and high (426 mg/kg bw/d) doses respectively. This type of tumour was not observed in any other rats in the study, and was not evident in historical data from the laboratory that performed the study. Therefore, the increase in corneal squamous cell carcinoma is considered to be related to treatment with tolpyralate.

The Applicant proposed a mode of action for the rat corneal tumours involving the following key stages:

- i. Inhibition of HPPD; reduced catabolism of tyrosine
- ii. Induction and maintenance of high plasma and eye levels of tyrosine
- iii. Sustained damage to the corneal epithelium
- iv. Regenerative hyperplasia, increased DNA synthesis and cell replication, leading to tumour formation

## ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

The effect of 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibition on tyrosine metabolism is discussed at the beginning of Section 10.

As discussed in Section 10.12.1 (repeated dose toxicity), a single dose (1000 mg/kg bw) of tolpyralate produced a significant increase in plasma tyrosine levels in rats, rabbits and mice (Anonymous 2013o; Anonymous 2013p; Anonymous 2013q). The increase was the highest in rats (25-fold), followed by rabbits (20-fold) and then mice (13-fold). These results indicate that rats might be more sensitive to tolpyralate-induced tyrosinemia compared to mice, although it is noted that plasma tyrosine levels were similar to controls after 72 hours in the rat, but were still elevated in mice at this time point. Repeated daily administration of tolpyralate in the diet to female Wistar rats (144 mg/kg bw) and female CD1 mice (1089 mg/kg bw) produced a significant increase in terminal plasma concentrations of tyrosine (Anonymous, 2016a). Although no male rats were included in the repeated dose study, a single gavage dose of tolpyralate (100 or 1000 mg/kg bw) was sufficient to produce a comparable significant increase in male Wistar rat plasma tyrosine levels (Anonymous, 2016b). This study also demonstrated significant increases in tyrosine concentrations in the aqueous humour of the eye following a single dose of tolpyralate; indeed, tyrosine concentrations were higher in the aqueous humour than in the plasma at all dose levels (1, 100 and 1000 mg/kg bw). No information was gained on the reversibility of these effects. No direct evidence that tolpyralate inhibits HPPD in rats, mice or humans is available.

Keratitis was observed in male and female rats in the 28-day, 90-day, 1-year (Anonymous 2016a) and 2-year carcinogenicity studies. Keratitis was also observed in the parents (both P and F1) in the 2-generation study, whilst corneal opacity was recorded in the F1 and F2 offspring. There were no adverse effects in the eyes of mice or dogs treated with tolpyralate. The non-neoplastic eye effects are discussed further in Section 10.12.1.

Such effects in the eyes are reported to be common to substances that inhibit the metabolism of tyrosine and consequently cause tyrosinemia (Antonenko *et al.*, 2015). Therefore, from the information available, it is plausible that the effects in the eye are related to the increase in plasma tyrosine concentrations which are, in turn, due to the inhibitory action of tolpyralate on 4-HPPD.

Chronic keratitis is described as the persistent inflammation of the cornea. It is possible that this persistent inflammatory response may be the cause of the tumorigenesis observed in male rats following life-time exposure to tolpyralate. Eye tumours have been reported in the rat in studies conducted with some other HPPD inhibitors (e.g., tembotrione). However, there are a number of other related substances (e.g., sulcotrione and mesotrione) in which such findings were not reported, even though there was also a high level of keratitis. In addition, the tumours were observed in males only despite comparable levels of keratitis in females. Consequently, although the mode of action is considered plausible, there is insufficient information available to conclude that the corneal tumours were definitively induced as a result of tissue damage and regenerative hyperplasia leading on from elevated tyrosine levels. This uncertainty should be reflected in the classification.

It is widely documented that the rat is particularly sensitive to the effects of 4-HPPD inhibition and it is generally accepted that humans are less sensitive owing to species differences in alternative metabolic pathways. However, humans who have chronically elevated plasma tyrosine levels (through 4-HPPD inhibition) are known to exhibit ocular effects. NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione) is a pharmaceutical drug used to inhibit HPPD. In healthy adult volunteers, a single dose of 1 mg/kg bw of NTBC has been shown to significantly increase plasma tyrosine levels (from ~100 to 1100  $\mu\text{mol/L}$ ) (Hall *et al.*, 2001). Patients treated with this drug (i.e., repeated exposure) have been shown to have greatly elevated plasma tyrosine concentrations which can result in adverse effects in the eyes (Ahmad *et al.*, 2002; Lock *et al.*, 2006; Wisse *et al.*, 2012, Schauwvlieghe *et al.*, 2013). Given the proposed mode of action of tolpyralate, it is possible that tolpyralate could cause adverse eye effects in humans. There is a lack of information on the relative sensitivities of rats and humans to tolpyralate.

Overall, although a plausible mode of action involving inhibition of tyrosine catabolism has been proposed, uncertainties remain in understanding the basis for the ocular tumours seen in male rats treated with

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

tolpyralate. Further, even if this mode of action is applicable, further uncertainties remain about its relevance to humans. There is limited evidence for the carcinogenicity of tolpyralate in rats.

#### 10.9.4 Comparison with the CLP criteria

As there is no information on the carcinogenicity of tolpyralate in humans, a classification in Category 1A would not be appropriate.

There was an increased incidence of squamous cell carcinoma in the cornea of male rats treated with tolpyralate in the diet. No tumours were seen in female rats or in mice. Whilst it is plausible that the tumours may have been a consequence of chronic keratitis (which likely resulted from HPPD inhibition and sustained elevation of plasma tyrosine), it is notable that they were only observed in males and not females despite a comparable level of keratitis in both sexes. Further, whilst humans might be expected to be less sensitive to the effects of HPPD inhibition, there is no definitive information regarding the relative potency of tolpyralate compared to other known HPPD inhibitors (e.g., NTBC) and no definitive information on the relative sensitivity of humans to this carcinogenic effect.

In accordance with the CLP criteria and associated guidance, the following factors are considered in proposing how to classify tolpyralate for carcinogenicity.

**Table 24: Factors considered when assessing tolpyralate for carcinogenicity.**

Factor	Evidence	Classification
Tumour type and background incidence	Ocular tumours, very rare	1B or 2
Multi-site response	No, only eyes	2
Progression of lesions to malignancy	Yes	1B or 2
Reduced tumour latency	No data	1B or 2
Whether responses are in single or both sexes	Males only	2
Whether responses are in a single species or several species	Rat only (mouse negative)	2
Structural similarity to a substance for which there is good evidence of carcinogenicity	No	No impact
Routes of exposure	Tumours after dietary treatment; no significant information on applicability of other routes	No impact
Comparison of absorption, distribution, metabolism and excretion between test animals and humans	Limited data; no differences expected.	No impact
The possibility of a confounding effect of	Tumours were evident at doses observed to cause ocular opacity and keratitis. No evidence that tumours can occur at doses that	2 or 0



ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

excessive toxicity at test doses	don't produce these lesions.	
Mode of action and its relevance to humans	Non-mutagenic. Possible mode of action involving production of excessive levels of tyrosine, tissue damage, regenerative hyperplasia and associated increased DNA replication. Significant uncertainty about this mode of action for tolpyralate and about its relevance to humans	2

Taking into account all of these factors, the observation of ocular tumours in male rats is considered to present limited evidence of carcinogenicity and the criteria for classification in Category 2 appear to be met.

### 10.9.5 Conclusion on classification and labelling for carcinogenicity

**Classification in Category 2 - Suspected human carcinogen**

#### **RAC evaluation of carcinogenicity**

##### **Summary of the Dossier Submitter's proposal**

The carcinogenic potential of tolpyralate was investigated in two carcinogenicity studies, one in the rat and one in the mouse. The only treatment-related neoplastic finding was malignant squamous cell carcinoma in the eye of male rats.

The applicant proposed a mode of action for these tumours involving the following key stages:

1. Inhibition of HPPD; reduced catabolism of tyrosine
2. Induction and maintenance of high plasma and eye levels of tyrosine
3. Sustained damage to the corneal epithelium
4. Regenerative hyperplasia, increased DNA synthesis and cell replication, leading to tumour formation

The DS agreed that tolpyralate produces a significant increase in plasma tyrosine in rats (as demonstrated by the studies Anonymous, 2013o; Anonymous, 2016a; Anonymous, 2016b) and considered it plausible that the eye effects are related to the increase in plasma tyrosine concentrations.

Regarding the hypothesis that the ocular tumours may have been caused by persistent keratitis, the DS noted that eye tumours had been reported in rat studies with some other HPPD inhibitors (e.g., tembotrione) but not with others (e.g., sulcotrione and mesotrione) despite a high level of keratitis with the latter ones. In addition, the tumours were observed only in males although there were comparable levels of keratitis in females. Although the DS considered the proposed mode of action (MoA) plausible, they did not deem the available information sufficient to conclude that the corneal tumours

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

were definitively induced as a result of tissue damage and regenerative hyperplasia from elevated tyrosine levels.

As to human relevance, the DS acknowledged the particularly high sensitivity of the rat to the effects of HPPD inhibition but, on the other hand, pointed out that NTBC is capable of producing significant increases of plasma tyrosine in healthy human subjects (up to 1100 µmol/L) and that ocular effects were observed patients with chronically increased tyrosine concentrations due to NTBC intake.

Overall, the DS considered that there is limited evidence for the carcinogenicity of tolpyralate in rats, thus proposing classification in Category 2.

### **Comments received during public consultation**

Three MSCAs and 1 industry association provided comments during the public consultation.

One MSCA supported the proposed classification with Carc. 2.

The other two MSCAs requested discussion of Category 1B. The following arguments were raised in support of a more stringent classification:

- The tumours are clearly treatment-related.
- According to the definition of "sufficient" evidence (CLP, Annex I, 3.6.2.2.3), a single study in one species and sex might be considered to provide sufficient evidence of carcinogenicity when malignant neoplasms occur to an unusual degree with regard to incidence, site, type of tumour or age at onset. One of the MSCAs considered the tumours to occur to an unusual degree with regard to incidence (rare tumours), unusual site and unusual tumour type (not a spontaneous tumour type).
- The tumours are relevant to humans (relevant MoA; the type of tumour also occurs in humans).
- Genotoxicity may be an additional MoA. A positive mouse lymphoma assay was followed up by a comet assay which however did not investigate the eye or bone marrow. The DS replied that the available comet assay was sufficiently comprehensive as it included tissues from the site of first contact (stomach), point of metabolism (liver) and tissue which is known to be a target for the test item (thyroid).

One of the MSCAs also recommended discussing the limitations of the data presented on hepatic TAT enzyme activity, in particular with regard to representativeness and allometric scaling.

The industry association proposed no classification based on the following arguments:

- The differences between the severity of ocular lesions between male and female rats as well as between rats and mice can be explained by interspecies differences in the activity of TAT (quantified as the maximum rate,  $V_{max}$ ). Human TAT activity is similar to that of mice, a species in which ocular effects from HPPD inhibitors have not been seen, and considerably higher than the TAT activity in rats.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

- In addition, mice and humans, unlike rats, are able to use an alternative pathway for tyrosine catabolism via formation of 4-HPLA if HPPD is inhibited.
- Humans experiencing ocular problems would seek medical help before keratitis can develop into ocular tumours.

In response to the comments, the DS maintained that Category 2 is more appropriate than 1B due to the lack of genotoxicity and due to carcinogenic responses having been observed only in a single sex and a single species. At the same time, they did not consider no classification appropriate for reasons explained in the CLH report.

**Additional key elements**

***Severity of keratitis in the rat carcinogenicity study***

During the public consultation, Industry provided severity scores for keratitis in the 2-year carcinogenicity study in the rat (Anonymous, 2015b). These are presented in the table below.

Dose level (ppm)	Males					Females				
	0	5	20	2000	10000	0	5	20	2000	10000
No. of animals examined	51	51	51	51	51	51	51	51	51	51
Keratitis: total	4	2	4	51	51	0	2	1	51	51
grade +	4	1	4	16	15	0	2	1	33	16
grade ++	0	1	0	29	22	0	0	0	17	35
grade +++	0	0	0	6	14	0	0	0	1	0

**Assessment and comparison with the classification criteria**

***Rat carcinogenicity study (Anonymous, 2015b)***

In the rat carcinogenicity study, tolpyralate was administered via diet for 2 years at dose levels up to 10000 ppm, which corresponded to 426 mg/kg bw/d in males and 554 mg/kg bw/d in females. Terminal body weights were reduced by 18% and 7% in top dose males and females, respectively, and ocular opacity was present in all animals at 2000 and 10000 ppm (vs 3/51 in the controls of both sexes). Survival was not affected.

The only treatment-related neoplastic finding was malignant squamous cell carcinoma in the eye of males. The incidences are shown in the table below. This type of tumour was not encountered in the historical control database.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Dose level (ppm)	Males					Females				
	0	5	20	2000	10000	0	5	20	2000	10000
No. of animals examined	51	51	51	51	51	51	51	51	51	51
Malignant squamous cell carcinoma in the eye	0	0	0	3	5*	0	0	0	0	0

\* statistically significant difference from control,  $p \leq 0.05$  (Fisher's test)


RAC notes that the occurrence of the tumours in males only is consistent with a higher severity of keratitis in this sex. Keratitis graded as severe was present in 16/51 males and 0/51 females at 10000 ppm and in 6/51 males and 1/51 females at 2000 ppm.

**Mouse carcinogenicity study (Anonymous, 2015c)**

In the mouse carcinogenicity study, tolpyralate was administered via the diet for 18 months at dose levels up to 7000 ppm, which corresponded to 793 mg/kg bw/d in males and 732 mg/kg bw/d in females. Body weight was transiently reduced in top dose males and increased in females. Survival was not affected and there were no ocular effects. Tolpyralate did not produce a carcinogenic response in this study.

**Mode of action and human relevance of the rat ocular tumours**

In mammals, HPPD is involved in the catabolism of tyrosine. Inhibition of HPPD leads to a build-up of its substrate 4-hydroxyphenylpyruvate (4-HPPA), which is excreted in urine or converted back to tyrosine. Like other important amino acids, tyrosine is not excreted in the kidney. Thus, HPPD inhibition leads to an increase in plasma tyrosine (tyrosinaemia) and increased urinary excretion of 4-HPPA and its derivatives (including 4-hydroxyphenyllactate, 4-HPLA), collectively known as phenolic acids. The first two steps of the catabolic pathway of tyrosine are outlined below (TAT = tyrosine aminotransferase).



ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

HPPD inhibitors may cause ocular effects (keratitis) in mammals. The relationship between tyrosinaemia, HPPD inhibition and ocular effects has been studied extensively with NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione; also known as nitisinone), a potent HPPD inhibitor used therapeutically in humans with tyrosinaemia type I. Lock *et al.* (1998; 2000; 2006) reported that out of the five animal species tested (rat, mouse, dog, rabbit, rhesus monkey), only rats and dogs were susceptible to ocular effects from NTBC exposure and the corneal lesions in rats administered NTBC were similar to those observed in rats administered tyrosine in a low-protein diet. Interestingly, the interspecies differences in susceptibility to the eye effects only partly correlated with the differences in the extent of tyrosinaemia. Ocular problems have been reported in humans suffering from tyrosinaemia type II and in some patients treated with NTBC.

RAC considers the MoA proposed by the applicant plausible. The absence of ocular tumours in female rats treated with tolpyralate is consistent with a less severe keratitis in this sex.

The applicant ascribed the differences in susceptibility to tyrosinaemia and ocular effects to differences in TAT activity. However, the data obtained with NTBC in several species (Lock *et al.*, 2006) shows that TAT activity alone cannot explain the interspecies differences in susceptibility to tyrosinaemia and ocular effects from exposure to HPPD inhibitors. In addition, the available information on TAT activities does not allow a robust comparison of the human and animal data (discussed in more detail under 'Supplemental information' in the background document).

An additional argument raised by Industry in support of no classification was the existence of an alternative tyrosine catabolism pathway producing 4-hydroxyphenyl lactic acid (4-HPLA) from 4-HPPA in mice and humans but not in rats, with reference to an *in vitro* study with tembotrione (US EPA, 2007) and to an *in vitro* study with tolpyralate (Yokoyama, 2016). However, neither of the studies indicates that this pathway would not be operative in the rat (for details see 'Supplementary information' in the background document).

On the other hand, tyrosinaemia type III patients, whose HPPD is deficient due to a genetic defect, and tyrosinaemia type I patients treated with NTBC do only show plasma tyrosine levels up to ca 1300 µmol/L compared to ca 2500 µmol/L in rats treated with NTBC (Gissen *et al.*, 2003; Ellaway *et al.*, 2001; Lock *et al.*, 2006). None of the 15 patients with tyrosinaemia type III described in literature so far (Ellaway *et al.*, 2001; Najafi *et al.*, 2018; Szymanska *et al.*, 2015) and less than 10% of the tyrosinaemia type I patients treated with NTBC developed ocular effects. Rhesus monkeys did not develop ocular lesions at doses of NTBC that caused a high incidence of ocular opacity in the rat (Lock *et al.*, 2006). This evidence suggests a lower sensitivity of humans compared to rats to the effects of HPPD inhibitors. Still, ocular problems do occur in some patients treated with NTBC, so humans are not insensitive to the adverse effects of HPPD inhibitors.

RAC agrees with Industry that the occurrence of ocular tumours from tolpyralate exposure in humans is not very likely in reality, as tumour formation would be preceded by persistent ocular problems that would lead the individual to seek medical help before tumours could develop. Although this reduces the concern, such risk-based considerations are not relevant to hazard classification.

### **Conclusion on classification**

The ocular tumours occurred only in one species (rat) and one sex (males) and the substance is not genotoxic. In addition, tumour formation in the rat is associated with severe keratitis and humans are generally less sensitive to the effects of HPPD inhibitors. Therefore, RAC agrees with the DS that there is limited evidence of carcinogenicity for tolpyralate and classification with **Carc. 2; H351** is appropriate.

### **Supplemental information - In depth analyses by RAC**

#### **Summary of the mechanistic studies investigating tyrosinaemia and interspecies differences**

##### *1. Study on interspecies differences in plasma tyrosine levels following single oral exposure to tolpyralate (Anonymous, 2013o,p,q)*

A single oral dose of 1000 mg/kg bw tolpyralate was administered to groups of female rats, mice and rabbits and plasma tyrosine levels were measured at several time points after administration. An increase in plasma tyrosine was observed in all three species: in the rat up to 2060 µmol/L (25-fold compared to control), in the mouse up to 660 µmol/L (20-fold) and in the rabbit up to 1790 µmol/L (13-fold).

##### *2. Study on tyrosine levels in plasma and eyes following single exposure to tolpyralate in rats (Anonymous, 2016b)*

Groups of male rats were administered 0, 1, 100 or 1000 mg/kg bw tolpyralate. Tyrosine concentrations in both plasma and aqueous humour were increased at 100 and 1000 mg/kg bw tyrosine 24 h after administration. At 1000 mg/kg bw, tyrosine concentration in the plasma was 2360 µmol/L (vs 94 µmol/L in the control) and in the aqueous humour 2410 µmol/L (vs 200 µmol/L in the control).

##### *3. Study on tyrosinaemia and effects on the eye and cerebellum following chronic exposure to tolpyralate in rats and mice (Anonymous, 2016a)*

Tolpyralate was administered for 1 year via the diet to female rats (2000 ppm) and mice (7000 ppm). NTBC was used as a positive control and the dose levels of NTBC were chosen to induce similar plasma tyrosine increases to those in the tolpyralate groups. In the rat, both tolpyralate and NTBC increased the incidence of keratitis of the cornea and vacuolation of the cerebellum, which suggests a potential relationship between tyrosinaemia and effects in these two organs. No adverse effect in the eye or cerebellum was observed in the mice treated with either tolpyralate or NTBC. The plasma tyrosine levels in the mouse were lower than in the rat (tolpyralate treatment: mouse 750 µmol/L, rat 1730 µmol/L).

##### *4. In vitro interspecies comparative tyrosine catabolism study to investigate tolpyralate-induced HPPD inhibition (Yokoyama, 2016)*

This study employed rat and human hepatocytes. Concentrations of tyrosine and 4-HPLA were measured following addition of tolpyralate or NTBC in the presence of tyrosine. A slight increase in 4-HPLA was observed in both rat and human cultures treated with tolpyralate or NTBC compared to controls (increases by about 15% and 25% in the

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

tolpyralate- and NTBC-treated cultures respectively), which may indicate inhibition of HPPD by tolpyralate and NTBC in both species. The level of 4-HPLA in the human hepatocytes was 3-4 times higher than in the rat hepatocytes (both in the control and treated cultures).

**Sex and species differences in TAT activity**

The applicant proposed that the basis of the species difference in the extent of the tyrosinaemia induced in rats and mice, at steady state, is simply the  $V_{max}$  of TAT, the rate-limiting enzyme. RAC is of the opinion that the assumption of enzyme saturation is uncertain and both  $V_{max}$  (or  $k_{cat}$ ) and  $K_M$  should be considered when comparing the activity of TAT from various species towards tyrosine. The applicant and the DS provided a table comparing the activities of rat, mouse and human TAT (Table 13 in the CLH report, copied below).

<b>Comparison of innate hepatic TAT activities (nmol 4-HPPA/min/mg protein) provided by the DS</b>			
	<b>Rat</b>	<b>Mouse</b>	<b>Human</b>
Male	1.7 ± 0.2	7.8 ± 1.5	7.2 ± 1.2
Female	3.3 ± 0.5	10.5 ± 1.9	

RAC points out that comparison of enzyme performance values obtained in independent experiments should be undertaken with caution. Kinetic measurements with enzymes are susceptible to the influence of many factors such as pH, ionic strength, temperature and concentrations of all assay components (Bisswanger, 2014). In this case, particular caution should be exercised when comparing the human and animal data in the table as the human value apparently comes from a different publication (Henderson *et al.*, 1981) than the rat and mouse data.

To verify the claimed difference between the activity of the rat and mouse TAT, RAC used an additional reference, Lock *et al.* (2000), reporting kinetic parameters obtained in the same laboratory for both species (probably only male animal was used for determination of enzyme activity). The results are provided in the following table.

<b>TAT activity in rat and mouse liver cytosol from Lock <i>et al.</i> (2000)</b>		
	<b>Rat</b>	<b>Mouse</b>
$K_M$ (mM)	4.8	0.69
$V_{max}$ (nmol 4-HPPA formed/min/mg protein)	19	15

The kinetic data by Lock *et al.* (2000) support an interspecies difference between the rat and mouse TAT activity at concentrations below enzyme saturation. RAC has not found any further reference to support an interspecies difference in TAT activity between rats and humans or mice and humans.

Lock and co-workers investigated TAT activity and NTBC-induced tyrosinaemia and ocular effects in two other species, the rabbit and the dog. In addition, they conducted a repeated dose study with NTBC in rhesus monkeys without determining TAT activity

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

(Lock *et al.*, 2006). The study reported TAT activities in the dog and rabbit liver cytosol of 14 and 3.5 nmol 4-HPPA formed/min/mg protein, respectively. Interestingly, the extent of tyrosinaemia was comparable in both species despite the relatively large difference in TAT activities. Upon repeated dose administration, NTBC produced ocular effects in the dog but not in the rabbit or the monkey. This, together with the rat and mouse data on NTBC (Lock *et al.*, 1998; Lock *et al.*, 2000) indicates that differences in TAT activity alone are not able to explain the interspecies differences in susceptibility to tyrosinaemia and ocular effects arising from exposure to HPPD inhibitors.

***In vitro study with tembotrione investigating 4-HPLA production***

This study, summarised in the US EPA assessment report for tembotrione (US EPA, 2017), investigated tyrosine and 4-HPLA levels in suspensions of immobilised hepatocytes from rat, dog, rabbit, mouse and human livers following exposure to tembotrione *in vitro*. Upon tembotrione treatment in a basal medium without addition of L-tyrosine, 4-HPLA was produced only by mouse and human hepatocytes. When tyrosine was added, 4-HPLA was produced by hepatocytes of all five species tested, although the amount of 4-HPLA generated was higher in the mouse (0.94–1.40 µg/mg protein) and human (0.40–0.84 µg/mg protein) cultures than in the rat (0.18 µg/mg protein) cultures. Nevertheless, these data do not demonstrate inability of the rat to produce 4-HPLA upon HPPD inhibition.

**10.10 Reproductive toxicity**

The potential for tolpyralate to adversely affect reproductive performance and the survival, growth and development of offspring has been investigated in a two generation dietary reproductive toxicity study performed in the rat. The potential for tolpyralate to cause developmental toxicity has been investigated in specific developmental toxicity studies conducted in both the rat and the rabbit. In addition a generational range finding study in the rat is available.

**10.10.1 Adverse effects on sexual function and fertility**

**Table 25: Summary table of animal studies on adverse effects on sexual function and fertility**

Study details	Dose levels	Critical effects
Rat, SD 8 / sex / group GLP tolpyralate Batch: 20111222-1	0, 5, 20, 200, 2000, 20000 ppm  Equivalent to; <i>Males:</i> 0, 0.257, 1.04, 10.7, 107, 1093 mg/kg bw/d	<b>Parental toxicity</b> <u>5ppm &amp; 20 ppm</u> - No adverse effects  <u>200ppm</u> Ocular opacity in a single animal in each sex (clinical observation only, not noted at necropsy) Reduced body weight gain in males (13%) Increased relative liver weight in both sexes (male 16%, female 12%)  <u>2000ppm</u> Ocular opacity in both sexes



ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Study details	Dose levels	Critical effects
<p>Purity 97.27% (range finding study)</p> <p>Anonymous (2015d) DAR B.6.6.1</p>	<p>Females 0, 0.503, 1.94, 19.6, 193, 1943 mg/kg bw/d</p> <p>Test item administered from the beginning of rearing until the weaning of F1 pups (Approx. 11 weeks)</p> <p>NOAELs were not determined from this range finding study</p>	<p>Reduced body weight gain in males (14%) Increased relative liver weight in both sexes (male 17%, female 7%) Increased relative kidney weight in both sexes (male 12%, female 9%)</p> <p><u>20000ppm</u> Ocular opacity in both sexes Reduced body weight gain in males (20%) and females (23%) Increased relative liver weight in males (19%) and females (15%) Increased relative kidney weight in males (12%) and females (19%)</p> <p><b>Offspring toxicity</b> <u>Lactation day 4</u></p> <p><u>5, 20 and 200 ppm</u> No adverse effects</p> <p><u>2000ppm</u> Reduced pup viability at day 4 (9% lower than controls) Pelvic dilatation (18.7% incidence) Pale-coloured kidney (9.8% incidence)</p> <p><u>20000ppm</u> Reduced pup viability at day 4 (19% lower than controls) Reduced pup weight (19% males, 18% females) Pelvic dilatation (14.3% incidence) Pale-coloured kidney (14.3% incidence) White material in urinary bladder lumen (4.8% incidence)</p> <p><u>Day 26</u></p> <p><u>5ppm and 20 ppm</u> - No adverse effects</p> <p><u>200ppm</u> Kidney cysts (15.6% incidence) and pelvic dilatation (6.3% incidence)</p> <p><u>2000ppm</u> Kidney atrophy (16.1% incidence), kidney spots (8.9%) kidney cysts (21.4%) and pelvic dilatation (5.4%)</p> <p><u>20000ppm</u> Ocular opacity (18.8% incidence), kidney atrophy (4.2%), kidney spots (2.1%), kidney cysts (8.3%), and pelvic dilatation (15.2%). Kidney absent (2.1% incidence)</p>
<p>Rat, SD 24 / sex / group</p> <p>OECD 416 GLP</p> <p>tolpyralate Batch: 20111222-1</p> <p>Purity 97.27%</p> <p>(main study)</p>	<p>0, 5, 50, 1000ppm</p> <p>Equivalent to; <i>Males:</i> 0, 0.270, 2.70, 54.9 mg/kg bw/d</p> <p><i>Females</i> 0, 0.287, 2.97, 59.3 mg/kg bw/d</p>	<p><b>Parental toxicity</b></p> <p>P generation</p> <p><u>5ppm</u> No adverse effects</p> <p><u>50ppm</u> Increased relative liver weight (8% in both sexes) Ocular keratitis (1/24 males)</p> <p><u>1000ppm</u> Increased incidence of gross eye findings; Ocular opacity (18/24 males, 11/24 females) Increased incidence of microscopic eye findings; Keratitis (21/24 males, 23/24 females) Increased relative organ weights;</p>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Study details	Dose levels	Critical effects
<p>Anonymous (2015e) DAR B.6.6.1</p>		<p>Liver (16% males, 13% females). Kidney (13% males) Testis (10%) Decreased relative organ weights; Brain (6% females)</p>
		<p>F<sub>1</sub> generation</p> <p><u>5ppm</u> Increased incidence of microscopic findings; Dilatation, renal pelvis (3/24 females)</p> <p><u>50ppm</u> Increased incidence of gross kidney findings; Pelvic dilatation (3/24 males) Increased incidence of microscopic eye and kidney findings; Ocular keratitis (1/24 males) Dilatation, renal pelvis (3/24 males, 1/24 females)</p> <p><u>1000ppm</u> Decreased terminal body weight in males (10%). Increased incidence of gross eye findings; Ocular opacity (24/24 males, 12/24 females) Increased incidence of gross kidney findings; Coarse surface (2/24 males, 1/24 females) Cyst(s) (5/24 males, 1/24 females) Depressed area (4/24 males, 5/24 females) Pale in colour (1/24 males) Pelvic dilatation (3/24 males, 3/24 females) Decreased relative organ weights; Prostate (21%) Increased relative organ weights; Liver (22% males, 13% females) Kidney (16% males, 7% females) Testis (12%) Epididymides (13%) Seminal vesicle (19%) Increased incidence of microscopic kidney findings; Basophilic change to renal tubule (10/24 males, 4/24 females) Calcification (7/24 males, 8/24 females) Cortical cysts (6/24 males) Hyaline droplets (5/24 males) Nephropathy (11/24 males, 4/24 females) Dilatation, renal pelvis (2/24 males, 5/24 females) Increased incidence of microscopic eye findings; Keratitis (24/24 males, 24/24 females)</p>
		<p><b>Fertility and reproductive function</b></p>
		<p><u>5ppm and 50 ppm</u> No adverse effects</p> <p><u>1000ppm</u> A small but statistically significant increase in duration of gestation was observed in F1 parents (22.7 days, compared to 22.2 days in controls). Slight reduction in total number of pups delivered and mean number of pups per litter in the F2 generation.</p>
<p><b>Offspring toxicity</b></p>		

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Study details	Dose levels	Critical effects
		<p>F<sub>1</sub> generation</p> <p><u>5ppm and 50 ppm</u> No adverse effects</p> <p><u>1000ppm</u> Reduced pup weight (10%) (Lactation Days 14 and 21).</p> <p><i>Day 4 necropsy</i> Kidney: Pale colour (3.3%) Kidney: Pelvic dilation (6.1%) Kidney: White material in pelvic space/papilla (3.2%)</p> <p><i>Day 26 necropsy</i> Eye opacity (1.9%) Kidney: small in size (4.5%) Kidney: spots (2.4%) Kidney Cysts (12.8%) Kidney: Pelvic dilation (6.1%)</p>
		<p>F<sub>2</sub> generation</p> <p><u>5ppm and 50 ppm</u> No adverse effects</p> <p><u>1000ppm</u> Reduced pup weight (&lt;10%) (Lactation Days 14 and 21).</p> <p><i>Day 4 necropsy</i> Kidney: Pale colour (1.7%) Kidney: Pelvic dilation (3.6%) Kidney: White material in pelvic space/papilla (3.9%)</p> <p><i>Day 26 necropsy</i> Eye opacity (5.6%) Kidney: small in size (1.9%) Kidney Cysts (11.3%)</p>

\*The values for the NOAELs are provided for information only. All NOAEL values in this CLH reports have been taken from the dAR, produced in accordance with Regulation EC 1107/2009.

***Range finding investigation for reproductive toxicity study - Anonymous 2015d***

A range-finding study was performed in the rat in order to determine appropriate dose levels for a subsequent two generation reproductive toxicity study. Groups of 8 CrI:CD(SD) rats /sex / dose were administered dietary concentrations of 0, 5, 20, 200, 2000 or 20000 ppm tolpyralate.

The mean test substance intakes (mg/kg/day) in each treated group throughout the growth and breeding periods were 0.257 and 0.503 in the 5 ppm group, 1.04 and 1.94 in the 20 ppm group, 10.7 and 19.6 in the 200 ppm group, 107 and 193 in the 2000 ppm group, and 1093 and 1943 in the 20000 ppm group for males and females, respectively.

***Parental effects***

No deaths occurred in any animals in the parental generation. Ocular opacity was noted in clinical observations among male rats at 200 ppm or greater from treatment week 5 (during the breeding period). The incidence of observed ocular opacity in males was 1, 3 and 2 out of 8 rats in the 200, 2000 and 20000 ppm groups, respectively, although no statistically significant differences were seen between the control and

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

any of these groups. No other clinical signs of toxicity were found in males in any treated groups at any time point.

There were no clinical signs of toxicity in females in any treated groups during the pre-mating growth through mating and gestation periods. During the lactation period, Ocular opacity was noted at clinical observation in 1, 5 and 8 out of 8 rats in the 200, 2000 and 20000 ppm groups, respectively. Ocular opacity was not observed in the control, 5 or 20 ppm group during this period. The difference in incidence between the control and treated groups reached statistical significance for the two higher dose groups. There were no other clinical signs of toxicity during the lactation period.

Reductions in body weight (not statistically significant) were observed in top dose males from weeks 1-10. In the 200, 2000 and 20000 ppm groups, the body weight gains of males were statistically significantly lower than those in the control group during treatment weeks 0-1 through 0-5, in general. There were no statistically significant changes in body weight gains of males in the 5 or 20 ppm group at any time point.

Female body weights were generally comparable among all groups during the pre-mating growth and gestation periods. However, during the lactation period, females in the 20000 ppm group weighed less than those in the control group, with the differences being statistically significant on lactation days 4 and 14. There was also a trend toward lower body weights in the 2000 ppm group on lactation day 4. No other changes in body weights were found in lactating females in any treated groups. There were no changes in body weight gains during the pre-mating growth and gestation periods. However, at 20000 ppm, female body weight gain was statistically significantly lower than in controls during lactation days 0-4 through 0-14. A similar decrease in body weight gain was seen at 2000 ppm group, although statistically significant differences were limited to the change during lactation days 0-4. The body weight gains of females in the other treated groups were unchanged at any time point.

The food consumption of males was generally comparable among all groups throughout the study. The food consumption of females was also similar among all groups during the pre-mating growth period and gestation period. However, a decrease in food consumption was observed in females in the 2000 and 20000 ppm groups during the lactation period, consistent with the decreased body weight gains. These changes were statistically significant for the 20000 ppm group during lactation days 0-7 and 7-14. There were no apparent changes in food consumption of females in the other treated groups.

At necropsy, ocular opacity was recorded in the gross observations in both sexes at 2000 and 20000ppm, occurring in 2 and 2 males, and 2 and 8 females at 2000 and 20000ppm, respectively.

In the 200, 2000 and 20000 ppm groups, the absolute and relative weights of liver and kidneys were generally increased in both sexes when compared to controls. These differences reached statistical significance in the relative liver weights for males at 200, 2000 and 20000 ppm, and the relative kidney weights for females in the 20000 ppm group. No other statistically significant treatment-related changes in organ weights were noted at 200, 2000 or 20000 ppm. There were no treatment-related changes in organ weights in either sex in the 5 or 20 ppm group.

There were no treatment related effects on any reproductive parameters, in any treated groups, when compared to the control group.

#### *Offspring effects*

There were no treatment-related effects on number of pups delivered or sex ratio. There was no notable difference in pup death at lactation day (LD) 0 in any treated group when compared to controls. As summarised in the following table, on lactation days 1-4 clear signs of toxicity were observed in offspring at dose levels of 2000 ppm or more. Observed effects included increased incidence of pup loss, decreased viability index, decreased body weights, and an increased incidence of renal abnormalities. Additionally an increased incidence of opacity in the eye was observed at the highest dose level.

**Table 26: Litter data (range finding study)**

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE**

\*7 Litters examined as 1 female was not pregnant

Lactation day(s)	Findings	Dietary level (ppm)					
		0	5	20	200	2000*	20000*
0	Total number of pups delivered	114	105	117	113	102	94
	Number of live pups	113	104	116	111	101	91
	Total number of dead pups	1	1	1	2	1	3
	Percent viable pups	99.1	99.0	99.1	98.2	99.0	96.8
	Number of litters with dead pups	1	1	1	2	1	3
	Dead pups per litter (no. litters affected)	1(1)	1(1)	1(1)	2(1)	1(1)	1(3)
1-4	Number of live pups	112	104	108	110	91	73
	Pups dead/lost	1	0	8	1	10	18
	Percent viable pups (relative to day 0)	99.1	100	93.1	99.0	90.1	80.2
	Dead pups per litter (no. litters affected)	1(1)	0(0)	6,2 (2)	1(1)	2, 1,4,1, 2 (5)	6,2,1,4,1,1, 3 (7)

At 20000 ppm, male and female pups weighed consistently less than controls throughout the lactation period. These differences achieved statistical significance on lactation days 7-21 for males, and on lactation days 14 and 21 for females. Likewise, pups in the 200 and 2000 ppm groups also gained less weight than controls, although the differences did not reach statistical significance. There were no differences in body weights in the 5 or 20 ppm groups.

Necropsy of pups culled on lactation day 4 revealed renal and/or urinary tract abnormalities in the 2000 and 20000 ppm groups; these included pale-coloured kidney, pelvic dilatation, and white material in pelvic space/urinary bladder lumen. One pup in the 20 ppm group exhibited pelvic dilatation in the kidney. The major findings at necropsy of weanlings at day 26 (including those found dead) were opacity of the eye and several renal abnormalities. For the ocular lesion, 18.8% of weanlings exhibited opacity of the eye in the 20000 ppm group, compared to 0% in the control and other treated groups. Several weanlings in the 2000 and 20000 ppm groups showed renal atrophy and/or spots on the kidney surface, with the incidence ranging from 2.1% to 16.1%. No similar findings were seen in the control or other treated groups. There also was a slight increase in the litter incidences of other renal findings, such as cysts and pelvic dilatation, in the 200, 2000 and 20000 ppm groups (8.3-21.4% and 5.4-15.2% for cysts and pelvic dilatation, respectively). 3.1% and 1.6% of control weanlings exhibited cysts and pelvic dilatation, respectively.

In the 2000 and 20000 ppm groups, there was a trend towards lower absolute weights of brain, spleen and thymus relative to the control group. These changes were considered to be secondary to lower body weights of weanlings in these groups. No other changes in organ weights were found in 2000 or 20000 ppm group, or lower dose groups.

***Two generation reproductive toxicity study – Anonymous (2015e)***

The potential for tolpyralate to adversely affect fertility and reproduction was investigated in a 2-generation reproductive toxicity study in the rat. Groups of 24 male and female Sprague Dawley rats were administered 0, 5, 50 or 1000ppm tolpyralate in the diet for two successive generations. Parental (P) animals were administered the test item for 10 weeks before mating. Both P and F1 generations received the test item for a minimum of 18 weeks, throughout mating, gestation and lactation before termination and necropsy following weaning of their respective litters. Litters received the same diets as their parents following weaning.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

*Parental toxicity*

No mortalities were observed in the P generation. Two F1 females in the 1000 ppm group were found dead or killed *in extremis* during the lactation period. These animals were noted to have particularly low body weights and exhibited reddish urine. A single F1 male in the 50 ppm group was killed *in extremis* following accidental trauma.

Body weight and body weight gain were unaffected by treatment in both sexes in the P generation at all dose levels. In F1 males receiving 1000 ppm, body weight was 16% lower than control animals at the start of treatment. Body weights in F1 males remained significantly lower than controls throughout the study at the top dose. Body weight gain was similarly reduced compared to controls in F1 males at the highest tested dose, throughout the treatment period.

In F1 females at 1000 ppm, body weights were significantly reduced by 14% when compared to controls at the start of the treatment period. Reduced body weight was observed in this group throughout the pre mating period, gestation and up to lactation day 7. Inconsistent reductions in body weight gains in F1 females were observed at this dose level. No other significant reductions in body weight or body weight gain were observed in parental animals.

The predominant finding at necropsy was ocular opacity. A statistically significant increased incidence was observed in P generation animals at 1000 ppm. The incidence of this lesion was 18/24 and 11/24 in males and females respectively, compared with none in controls and all other treated animals. In F1 animals the incidence of ocular opacity was 24/24 and 12/24 males and females receiving 1000 ppm respectively. Consistent with the observations in the P generation, no ocular opacity was observed in controls or other dose levels. F1 males and females at 1000 ppm were found to have macroscopic lesions in the kidney. These findings included coarse surface, cyst(s), depressed area, pale color and pelvic dilatation. These findings occurred at a relatively low incidence, affecting up to 5 animals per group.

In P males both absolute and relative liver weights were increased when compared to control animals at 50 or 1000 ppm. Relative liver weights were increased by approximately 8% and 16% at 50 ppm and 1000 ppm, respectively. Absolute and relative kidney weights were increased 1000 ppm. Relative kidney weights were approximately 13% higher in males receiving 1000 ppm than in controls. A statistically significant increase in relative testis weight (10% relative to controls) was recorded at the top dose level and a trend of increasing relative weight of both the epididymides and seminal vesicles was observed but occurred without statistical significance.

In P females there were statistically significant increases in absolute and relative liver weights in those animals given 50 or 1000 ppm. Relative liver weights were increased by approximately 8% and 13% at 50ppm and 1000ppm respectively. Relative brain weight was significantly decreased in top dose females by 6% when compared to control animals.

In F1 males there were statistically significant reductions in absolute brain and pituitary weights, but there were no corresponding significant changes when expressed relative to body weight. Absolute and relative prostate weights were decreased in those given 1000 ppm, by 29% and 21% respectively. Relative weights of liver (22%), kidneys (16%) and testes (12%), epididymides (13%), seminal vesicles (19%) were significantly increased when compared to control animals at 1000 ppm. In F1 females there were statistically significant increases in relative liver (13%) and kidney (7%) weights at 1000ppm.

The predominant microscopic lesion was keratitis of the eye. Keratitis was observed in 21/24 P males, 23/24 P female, 24/24 F1 males and 24/24 F1 females in the 1000 ppm groups. Keratitis was also observed in 1/24 P males and 1/24 F1 males in the 50 ppm group. Keratitis was not observed in any animals in control or 5 ppm groups on in any females at 50 ppm.

Various microscopic alterations were noted in the kidneys of both sexes. In the P generation all of the observed kidney abnormalities occurred with similar incidence in the control and 1000 ppm groups and were concluded not to be treatment related. In the F1 generation, statistically significant increased incidences of basophilic changes to the renal tubule (males 10/24, females 4/24), calcification (males 7/24, females 8/24) and nephropathy (males 11/24, females 4/24) were recorded in both sexes at 1000 ppm. An increase in

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

cortical cysts was also observed in 6/24 males at the top dose level, this effect occurred with a weak dose response in females but without statistical significance. Hyaline droplets were observed in 5/24 males. Dilatation of the renal pelvis was observed inconstantly in either gross or microscopic observations of F1 parental animals of both sexes receiving 5 or 50ppm tolpyralate, occurring without a clear dose response relationship but is consistent with an effect of the test item upon the kidney.

*Reproductive toxicity*

Mating, fertility and gestation indices were high and comparable to controls in all treated animals. There were no treatment related effects on the number of implantation sites. Gestation length was generally similar amongst all treated animals although a slight but statistically significant increase in gestation length was observed in F1 females at 1000 ppm (22.7 days at 1000ppm when compared to 22.2 days in controls). A similar trend was noted in P females at the top dose level, but did not achieve statistical significance. A statistically significant increase in the number of days until mating was observed in the P generation at 1000ppm, but was not apparent in the F1 generation, More detailed analysis of the data relating to number of days until mating showed that the range was large, and where the mean value was increased it was typically caused by a small number of animals. There was no clear evidence of a relevant increase in mean number of days until mating.

A reduction in both the total number of pups delivered and the mean number of pups per litter was observed in the F2 generation at 1000ppm.

Sex ratio was similar among the control and all treated groups with the exception of a slight decrease in sex ratio (male:total) in F1 pups at 1000 ppm. This effect was not observed in the F2 pups it is not considered to be a genuine treatment related effect.

*Offspring toxicity*

At the top dose, a decrease in pup viability on lactation day 0 was noted in the F1 and F2 generation. However, considering the individual litter data, it is noted that 9 of the 11 dead pups in the F2 generation were from the same litter (total litter loss), with the remaining deaths (1 pup each) in 2 separate litters. Therefore, given the inconsistencies between the findings in the F1 and F2 generations, the apparent decrease in viability is not considered to represent a treatment related effect. There were no consistent effects of pup viability on subsequent days. Litter data is summarised in the table below.

There was also a decrease in the total number of pups delivered in the F2 generation at the top dose. However, this was not statistically different to controls or other groups and it is noted that there were no similar findings (e.g. on post-implantations loss) in the rat developmental study, which employed doses of up to 500 mg/kg bw/day.

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE**

**Table 27: Litter data (2 generation study in the rat)**

Day 0 % viable pups = (no. of pups alive on LD 0/ no. of pups delivered) x 100

Lactation day(s)	Litter	Findings	Dietary level (ppm)			
			0	5	50	1000
0	F1	Total number of pups delivered	289	304	328	299
		Number of live pups	287	303	320	288
		Total number of dead pups	2	1	8	11
		Percent viable pups	99.4	99.6	97.6	96.3
		Number of litters with dead pups	2	1	3	8
		Dead pups per litter (no. litters affected)	1,1 (2)	1(1)	2,2,6 (3)	3,2,1,1,1,1, 1,1 (8)
	F2	Total number of pups delivered	304	311	303	239
		Number of live pups	301	307	297	228
		Total number of dead pups	3	4	6	11
		Percent viable pups	98.9	98.8	98.1	90.6
		Number of litters with dead pups	2	4	5	3
		Dead pups per litter (no. litters affected)	2,1 (2)	1,1,1,1 (4)	2,1,1,1,1 (5)	9,1,1 (3)
1-4	F1	Number of live pups	279	301	316	272
		Percent viable pups (relative to day 0)	97.2	99.3	98.8	94.4
	F2	Number of live pups	299	298	281	223
		Percent viable pups (relative to day 0)	99.3	97.1	94.6	97.8

Day 1-4 % viable pups = (no. of pups alive LD 4 / no. of pups alive on LD 0) x 100

There were no changes in relative organ weights that were representative of an adverse effect of the test item.

Of those pups subjected to necropsy on or before lactation day 4, a significant increase in kidney lesions, including pale colour (F1) , pelvic dilatation (F1 and F2) and observation of white material / substance in the pelvic space / papilla (F2) was noted in pups at the top dose only, as tabulated below.

**Table 28: Gross findings - lactation day 4 (2 generation study in the rat)**

Litter	Findings	Dietary level (ppm)			
		0	5	50	1000
F1 pup	No. of litters examined	22	22	23	21
	Kidney: Pale in color	0.0	0.0	0.0	3.3*
	Kidney: Pelvic dilatation	0.0	0.0	0.0	6.1**
	Kidney: White material in pelvic space/papilla	0.0	0.0	0.0	3.2



**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE**

F2 pup	No. of litters examined	23	23	22	18
	Kidney: Pale in colour	0.0	0.0	0.0	1.7
	Kidney: Pelvic dilatation	0.0	0.0	0.0	3.6*
	Kidney: White material in pelvic space/papilla	0.0	0.0	0.0	3.9*

Values represent the number of litters examined and group mean percent litter incidences.

Data were statistically analysed by Dunnett-type test following Kruskal-Wallis test.

Significantly different from control: \*,  $p \leq 0.05$ ; \*\*,  $p \leq 0.01$ .

Amongst pups subjected to necropsy at 26 days of age an increase in the incidence of opacity of the eye was observed in both F1 and F2 generations from the 1000 ppm groups. This increase was statistically significant in the F2 generation. There was zero incidence of opacity of the eye in control animals or those from the 5 ppm or 50 ppm groups. Additionally, an increase in the incidence of kidney lesions was recorded in F1 and F2 pups from the highest dose groups. In F1 pups, there was a statistically significant increase in the incidence of observation of small kidneys and cysts, when compared to control animals. An increase in the incidence of white spots and pelvic dilatation was also observed at the top dose level, but without statistical significance. In F2 pups an increase in the incidence of small kidneys and cysts was noted in animals from the 1000 ppm group, but did not achieve statistical significance.

**Table 29: Gross findings – 26 days (2 generation rat study)**

Litter	Findings	Dietary level (ppm)			
		0	5	50	1000
F1 pup	No. of litters examined	22	23	23	21
	Eye: Opacity	0.0	0.0	0.0	1.9
	Kidney: small in size	0.0	0.0	0.0	4.5*
	Kidney: Spot(s) (white)	0.9	0.0	0.0	2.4
	Kidney: Cyst(s)	3.3	3.7	6.7	12.8*
	Kidney: Pelvic dilatation	0.0	1.5	1.7	4.6
F2 pup	No. of litters examined	24	24	22	20
	Eye: Opacity	0.0	0.0	0.0	5.6*
	Kidney: Small in size	0.0	0.0	0.0	1.9
	Kidney: Cyst(s)	4.7	3.3	3.5	11.3
	Kidney: Pelvic dilatation	2.1	3.1	1.7	3.1

Values represent the number of litters examined and group mean percent litter incidences.

Gross pathological examination of weanlings was performed at 26 days of age.

Data were statistically analysed by Dunnett-type test following Kruskal-Wallis test.

Significantly different from control: \*,  $p \leq 0.05$ ; \*\*,  $p \leq 0.01$ .

### 10.10.2 Additional studies relevant to reproductive toxicity

There were no additional studies in relation to fertility and reproductive function.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

### 10.10.3 Short summary and overall relevance of the provided information on sexual function and fertility

The potential for tolpyralate to have an adverse effect on sexual function and fertility was investigated in a 2-generation reproductive toxicity study conducted in the rat.

In the parental generations the predominant adverse finding was ocular opacity and associated keratitis, this effect occurred in both P and F1 generations and in both sexes at dose levels of 50 and 1000 ppm. Other parental effects also observed at both 50 and 1000 ppm were decreased body weight and/or body weight gain and increased relative liver weight. Additionally an increased incidence of adverse histopathological findings in the kidney, including nephropathy, was seen in F1 males at  $\geq 50$  ppm and F1 females at the top dose level. Relative kidney weights were increased in both sexes at 1000 ppm. No signs of parental toxicity were observed in any animals receiving 5 ppm tolpyralate.

There were no treatment-related effects on sexual development, oestrous cycle, mating index, or sperm parameters. Gestation length and number of days until mating were slightly increased in some groups, but these effects were considered incidental and not related to administration of the test item.

In offspring, there were reductions in pup weights recorded at 1000ppm in both generations and both sexes. Other observations at the top dose level included increased incidence of ocular opacity and gross kidney lesions. Additionally an increased incidence of kidney cysts was observed at  $\geq 50$ ppm in F1 animals which was not statistically significant and was not seen in F2 animals.

In an additional study using the model pharmaceutical NTBC, it was demonstrated that inhibition of tyrosine catabolism in developing rats, resulting in increased plasma tyrosine, was associated with lesions in the eyes, urinary system and kidneys to those seen with tolpyralate.

### 10.10.4 Comparison with the CLP criteria

The potential effects of tolpyralate on fertility and reproductive performance were investigated in a rat dietary 2-generation study. In this study, there were no adverse effects on fertility or reproductive performance up to doses causing parental toxicity. On this basis, classification of tolpyralate is not warranted.

### 10.10.5 Adverse effects on development

The potential for tolpyralate to have adverse effects on development has been investigated in two specific studies; one in the rat, and one in the rabbit.

**Table 30: Summary table of animal studies on adverse effects on development**

Study Species	Dose levels	Critical effects
Rat, SD 23-24 females / group Vehicle: 1% carboxymethyl-cellulose OECD 414 GLP Batch: 20111222-1 Purity 97.27% Anonymous (2013c)	0, 1, 10, 500 mg/kg bw/d  Oral gavage GD 6-19	<b>Maternal toxicity</b> <u>1 and 10 mg/kg bw/d</u> No adverse effects <u>500 mg/kg bw/d</u> Reduced body weight gain (8%). Reduced food consumption until day 15, by 6-20%.  <b>Developmental toxicity</b> <u>1 and 10 mg/kg bw/d</u>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Study Species	Dose levels	Critical effects
DAR B.6.6.2		<p>No adverse effects</p> <p><u>500 mg/kg bw/d</u></p> <p>Decreased fetal weight (6.1% in both sexes)</p> <p>Increased total foetal incidence and litter incidence of skeletal variations: 97 foetuses/24 litters compared to 29/15 in controls. Findings occurring with a dose related incidence or at increased incidence when compared to controls were; discontinuous rib cartilage (61/23), supernumerary rib (57/18), bipartite ossification of thoracic centrum in (3/3) and 27th presacral vertebrae (3/3).</p>
<p>Rat, SD</p> <p>12 females/ group</p> <p>Not guideline (limited observations – see study summary)</p> <p>Not GLP</p> <p>Anonymous (2016c)</p> <p>DAR B.6.6.2</p>	<p>1000 ppm tolpyralate in the diet (approx. 88 mg/kg bw)</p> <p>or</p> <p>10 ppm NTBC in the diet (approx.. 0.84 mg/kg bw)</p> <p>or</p> <p>control diet</p> <p>Test item administered from gestation day 0 until study termination.</p>	<p><b>Maternal toxicity</b></p> <p><i>Tolpyralate</i> - plasma tyrosine concentration 2016.2 µmol/L (control value 66.5 µmol/L); ocular opacity in 10/11 animals</p> <p><i>NTBC</i> - plasma tyrosine concentration 2158.0 µmol/L; Opacity in the eye in 11/11 animals.</p> <p><b>Findings in pups at termination (PND 21)</b></p> <p><i>Tolpyralate</i> - plasma tyrosine concentration 3197.3 µmol/L (control value 191.4 µmol/L); ocular opacity in 1.14% of pups</p> <p>Increased incidence of abnormalities in the urinary system and kidney: small kidney (2/64, 0 in controls), pale discolouration (4/64, 0), rough surface (4/64, 0), dilation of renal pelvis (3/64, 2/61) and red contents of urinary bladder (1/52, 0).</p> <p><i>NTBC</i> - plasma tyrosine concentration 3651.5 µmol/L; ocular opacity in 7.96% pups. Decreased pup viability at PND 4</p> <p>Increased incidence of abnormalities in the urinary system and kidney: small kidney (6/52, 0 in controls), pale discolouration (4/52, 0), rough surface (2/52, 0), dilation of renal pelvis (3/52, 2/61) and red contents of urinary bladder (1/52, 0).</p>
<p>Rabbit, (Japanese White</p> <p>25 females / group</p> <p>Vehicle: 1% carboxymethyl-cellulose</p> <p>OECD 414</p> <p>GLP</p> <p>Batch: 20111222-1</p> <p>Purity 97.27%</p> <p>Anonymous (2013)</p> <p>DAR B.6.6.2</p>	<p>0, 0.5, 5, 500 mg/kg bw/d</p> <p>Oral gavage</p> <p>GD 6-27</p>	<p><b>Maternal toxicity</b></p> <p>No adverse effects at any tested dose</p> <p><b>Developmental toxicity</b></p> <p><u>0.5 and 5 mg/kg bw/d</u></p> <p>No adverse effects</p> <p><u>500 mg/kg bw/d</u></p> <p>Increased incidence of total skeletal variations affecting 98.48% of foetuses (compared to 34.85% in controls). Specific skeletal variations occurring at increased incidence when compared to controls were as follows:</p> <p>Supernumary rib in 197 fetuses from 22 litters (54/21 in controls) and 27<sup>th</sup> presacral vertebrae occurred (196/22 vs. 14/10) ; unossified 1<sup>st</sup> cervical centrum (3/3 vs 0), incomplete ossification of cervical centrum (1/1 vs 0), supernumary ossification (1<sup>st</sup> + 2<sup>nd</sup> cervical vertebrae) (12/4 vs 0); dumbell ossification of thoracic centrum (1/1 vs 0).</p>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

**Rats**

**Developmental toxicity study – Anonymous, 2013c**

Groups of 23 - 24 presumed pregnant Sprague Dawley rats were administered tolpyralate by oral gavage at doses of 0, 1, 10 or 500 mg/kg/day tolpyralate in 1% aqueous sodium carboxymethylcellulose on days 6 to 19 of gestation.

There were no mortalities amongst dams in any treated groups. No significant clinical signs of toxicity were observed in any treated animals. Loss of fur was observed in 2 out of 24 dams in both the 10 and 500 mg/kg bw groups. There were no statistically significant changes in body weight in any of the treated groups when compared to controls, although there were some transient reductions in body weight in the top dose group. Body weight gain was significantly reduced in dams receiving 500 mg/kg bw/day throughout the study. A statistically significant reduction in food consumption of approximately 6-20% was observed in dams receiving 500 mg/kg bw/day from the start of treatment until day 15. After day 15, food consumption was comparable to control animals for the remainder of the study.

There were no statistically significant differences in the mean numbers of corpora lutea, implantation sites or pre-implantation losses between the control and any treated groups. A statistically significant decrease in gravid uterine weight was observed in the 1 and 500 mg/kg groups, but there was no dose-response. There were no statistically significant differences in the mean number of live foetuses, resorptions or foetal deaths in any treatment group. Foetal weight in the 500 mg/kg group was statistically significantly less than those in the control group (6.1% in both sexes). Statistically significant increases in placental weight and sex ratio (male : female) were observed in the 10 mg/kg bw/day group but are regarded as incidental in the absence of a similar effect in the top dose group.

The total number of litters with malformed pups was 4/23 (17.4%), 3/24 (12.5%), 7/24 (29.2%) and 8/24 (33.3%) in the control, 1, 10 and 500 mg/kg groups, respectively. Similarly, the incidences of dams having foetuses with variations were 20/23 (87.0%), 19/24 (79.2%), 22/24 (91.7%) and 24/24 (100.0%). Although a treatment related trend was evident, no statistically significant differences in these incidences were found.

**Table 31: Findings in the rats developmental toxicity study**

Parameter	Dose (mg/kg bw/day)			
	0	1	10	500
<b>Foetal examinations.</b>				
Values represent number of foetuses. Values in parenthesis represent litter incidence.				
External examinations				
Number of foetuses examined	322	311	330	325
Total number of foetuses with external malformations	0 (0)	0 (0)	1(1)	4(2)
Short tail	0 (0)	0 (0)	1(1)	0(0)
Cleft Palate	0 (0)	0 (0)	0 (0)	1(1)
Misshapen urethral orifice	0 (0)	0 (0)	0 (0)	3(1)
Visceral observations				
Number of foetuses examined	167	163	171	169
Total number of foetuses with visceral malformations	1(1)	0 (0)	3 (3)	1 (1)
Dilated cerebral ventricle	0 (0)	0 (0)	1 (1)	0(0)
Retrosophageal subclavian	0 (0)	0 (0)	1 (1)	1 (1)
Abnormal lung lobation	0 (0)	0 (0)	1 (1)	0 (0)
Persistant truncus arteriosus	0 (0)	0 (0)	1 (1)	0 (0)

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE**

Membranous ventricular septum defect	0 (0)	0 (0)	1 (1)	0 (0)
Left subclavian artery arising from pulmonary artery	1 (1)	0 (0)	0 (0)	0 (0)
Total number of foetuses with visceral variations	13(9)	14 (9)	14(11)	14(13)
Thymic remnant in the neck	11 (7)	12 (8)	12 (9)	9 (8)
Dilated renal pelvis	1 (1)	3 (3)	1 (1)	1 (1)
Left umbilical artery	0 (0)	0 (0)	1 (1)	2 (2)
Right subclavian from aortic arch	1 (1)	0 (0)	0 (0)	2 (2)
<b>Skeletal observations</b>				
Number of foetuses examined	155	148	159	156
Total number of foetuses with skeletal malformations	3 (3)	3 (3)	5 (5)	6(6)
Split cartilage of ventral arch	1 (1)	0 (0)	0 (0)	0 (0)
Fused cervical arch	2 (2)	1 (1)	2 (2)	2 (2)
Dumbbell-shaped cartilage of cervical centrum	0 (0)	0 (0)	0 (0)	1 (1)
Split cartilage of thoracic centrum	0 (0)	1 (1)	1 (1)	2 (2)
Dumbbell-shaped cartilage of thoracic centrum	0 (0)	1 (1)	0 (0)	1 (1)
Rib cartilage not fused to sternum	0 (0)	0 (0)	1 (1)	0 (0)
Fused caudal centrum	0 (0)	0 (0)	1 (1)	0 (0)
Total number of foetuses with skeletal variations **	29 (15)	42 (18)	58(22)	97(24)**
Discontinuous rib cartilage (false rib)	20 (14)	20 (13)	34(20)	61(23)**
Supernumerary rib	11 (10)	14(9)	26(13)	57(18)**
Bipartite ossification of thoracic centrum	1 (0)	2(2)	2(2)	3(3)
27th presacral vertebrae	1 (0)	2(1)	1(1)	3(3)

Data were statistically analysed by Dunnett-type test following Kruskal-Wallis test.

\*  $p \leq 0.05$ ; \*\*  $p \leq 0.01$

\*\* Only selected individual skeletal variations (those deemed to be treatment related) are listed

Numbers in parenthesis represent litter incidence

There was no statistical difference in the incidence of total external malformations in any treated group. At 500 mg/kg, a single foetus had both cleft palate and local oedema. This is most likely to be a sporadic finding. Three foetuses from a single litter had a misshapen external urethral orifice. Although this is considered a rare abnormality, it is noted that these foetuses were all from the same litter. In a further study (Anonymous, 2013e), it was shown that this finding was genetic in origin and not related to treatment (see Section 10.10.5.3).

The total numbers of foetuses with visceral malformations were 1, 0, 3 and 1 at 0, 1, 10 and 500 mg/kg, respectively. In the control group, one foetus had an aberrant left subclavian artery. At 10 mg/kg, three foetuses from different litters each exhibited different visceral malformations (dilated cerebral ventricle, abnormal lung and multiple cardiovascular anomalies). At 500 mg/kg, a single visceral malformation (retroesophageal subclavian artery) was seen in one foetus. These findings are regarded to be sporadic and not related to the administration of the test item.

The total numbers of foetuses with skeletal malformations were 3, 3, 5 and 6 at 0, 1, 10 and 500 mg/kg, respectively. Findings occurring in a dose dependent manner or at increased incidence when compared to controls were split cartilage of thoracic centrum in a single foetus in the 1 and 10 mg/kg bw groups and 2 foetuses (1 each from 2 separate litters) at 500 mg/kg. Dumbbell-shaped cartilage of cervical centrum, fused cervical arch and dumbbell shaped cartilage of thoracic centrum thoracic centrum were observed in 1, 2 and

## ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

1 fetuses in the top dose group. There was no statistically significant increase in any skeletal malformations in any of the treated groups, when compared to control animals. Therefore, these findings are not considered to be related to treatment.

The total number foetuses with skeletal variations was 29, 42, 58 and 97 at 0, 1, 10 and 500 mg/kg, respectively. The most frequently observed variations were discontinuous rib cartilage and supernumerary rib. Discontinuous rib cartilage occurred at an incidence of 20, 20, 34 and 61 in the 0, 1, 10 and 500 mg/kg bw groups. Supernumerary rib occurred with fetal incidence of 11, 14, 26 and 57 in the 0, 1, 10 and 500 mg/kg bw groups. Other dose-related skeletal variations observed were 27<sup>th</sup> presacral vertebrae and bipartite ossification of thoracic centrum. These findings occurred with zero incidences in controls and are considered to be treatment related.

Overall, it is concluded that treatment of dams with relatively high exposure levels of tolpyralate have the potential to decrease foetal weight and induce various skeletal variations in rats. Although malformations were seen in this study, they were not considered to have been treatment-related.

### *Additional study into effect of elevated plasma tyrosine - Anonymous 2016c.*

A supplementary study investigating the effect of increased tyrosine levels on the development of Sprague-Dawley rats was conducted. In this non-standard study, tolpyralate or NTBC were administered to groups of 12 pregnant dams at dietary concentrations of 1000ppm or 10ppm respectively. The mean exposure of the test items to the dams throughout the study period was calculated to be 88.87 mg/kg bw/d and 0.84 mg/kg bw/d for tolpyralate and NTBC respectively. Dams were allowed to give birth and treatment was continued until PND 21 when the study was terminated and all animals were sacrificed. A control group received the diet without either of these substances added. As discussed elsewhere in this CLH report, NTBC is a pharmaceutical used to inhibit HPPD and increase plasma levels of tyrosine. There was limited analysis, consisting of the observation of clinical signs, and measurement of body weight, food consumption, plasma tyrosine concentration and reproductive parameters, selected organ weights and histopathology in dams. Comprehensive developmental analysis, including assessment of variations/malformations was not conducted.

At the end of the treatment period, the mean plasma tyrosine concentrations in dams treated with NTBC and tolpyralate were 2158.0 µmol/L and 2016.2 µmol/L, respectively. An increased incidence of ocular opacity was evident in both groups from lactation day 4 and 7, affecting 11/11 and 10/11 dams, respectively. There were no relevant changes in body weight parameters. No effect on gestation index, gestation length, number of implantations or delivery index was reported. There were no histopathological findings that were attributed to either test item.

Percentage viability of pups at post-natal (PND) 0 was unaffected by treatment with either NTBC or tolpyralate, with 1 (0.57%), 1 (0.61%) and 3 (1.78%) pups being found dead in the control, NTBC and tolpyralate groups respectively. At PND 4 there was a decrease in percentage viability in the NTBC group when compared to controls. No such finding was evident in the tolpyralate group, 10 (6.81%), 41 (22.34%) and 13 (9.03%) pups were dead/lost on PND 4.

Ocular opacity was seen in pups in both treated groups on PND 5-21, affecting 7.96% and 1.14% of pups in the NTBC and tolpyralate, respectively, compared to 0% in controls. Mean pup body weight was reduced in both treated groups at PND21. Mean plasma tyrosine concentrations were significantly increased in both treated groups and PND4 and PND21 by approximately 35 fold in comparison to controls (> 3000 µmol/L in exposed animals, approx. 100 µmol/L in controls). Pathological and histopathological analysis was limited in this study. The predominant findings were increases in various gross and histopathological lesions in the urinary system and kidneys. These findings were minimal in both severity and incidence.

This limited study was conducted to investigate the effects of elevated plasma tyrosine on the development of rats. Serum tyrosine concentrations were increased significantly in both dams and pups of both treated groups along with increased incidence of lesions in the eyes, urinary system and kidney. Additionally, NTBC was found to cause an increase in pup death at PND 4.

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE**

*Summary of developmental toxicity study in the rat*

Administration of tolpyralate resulted in some signs of maternal toxicity at the highest tested dose. Dams receiving 500 mg/kg exhibited reduced body weight gain throughout the treatment period. Reductions in both body weight and food consumption compared to controls were observed in these animals periodically. In the 500 mg/kg bw/day group a reduction in mean foetal weight (both sexes) was observed, and may be related to administration of tolpyralate.

There were no statistically significant or clear treatment related increases in skeletal malformations, visceral variations, visceral malformations or external variations. There was an increase in total skeletal variations and in the incidence of both discontinuous rib cartilage and supernumerary rib in foetuses from the 500 mg/kg bw/day group. However, these findings are considered to be of low toxicological significance.

**Rabbits**

***Developmental toxicity study – Anonymous 2013d***

Groups of 25 artificially inseminated Japanese white rabbits (Kbl:JW) were administered tolpyralate by oral gavage in a 1% solution of aqueous sodium carboxymethyl cellulose, at dose levels of 0, 0.5, 5 or 500 mg/kg bw/day on gestation days 6 to 27.

There were no treatment related increases in mortality or clinical signs of toxicity, other than small transient changes in body weight gain, at any tested dose level.

No statistically significant differences in gravid uterine weights, numbers of corpora lutea, implants and live foetuses, percent incidence of pre-implantation losses, percent incidences of resorptions and foetal deaths, foetal sex ratio, foetal body weights and placental weights were observed between treated and control groups.

*Skeletal findings*

There was no dose related or statistically significant increases in skeletal malformations.

A statistically significant and dose related increase in the total incidence of skeletal variations was observed, with 98.48% of foetuses in the 500 mg/kg bw/day group having at least one skeletal variation, the predominant finding was an increase in the incidence of supernumerary ribs, supernumerary ossification site (1<sup>st</sup> and 2<sup>nd</sup> cervical vertebrae) and 27 presacral vertebrae. Each of these individual effects occurred with a statistically significant increased incidence at the top dose level, and is considered to be related to the administration of the test item.

**Table 32: Developmental effects observed in rabbits**

Parameter	Dose (mg/kg bw/day)			
	0	0.5	5	500
<b>Fetal examinations.</b> Values represent number of foetuses. Values in parenthesis represent litter incidence.				
<b>Number of foetuses examined</b>	<b>200(24)</b>	<b>184(22)</b>	<b>186(22)</b>	<b>213(22)</b>
<b>Skeletal variations - Bodies</b>	<b>67(23)</b>	<b>50(21)</b>	<b>74(18)</b>	<b>210(22)</b>
Supernumerary rib	54(21)	40(18)	67(17)	197(22)**
Unossified 1 <sup>st</sup> cervical centrum	0(0)	0(0)	0(0)	3(3)*
Incomplete ossification of cervical centrum	0(0)	0(0)	0(0)	1(1)
Supernumary ossification (1 <sup>st</sup> + 2 <sup>nd</sup> cervical vertebrae)	0(0)	0(0)	0(0)	12(4)**
Dumbell ossification of thoracic centrum	0(0)	0(0)	0(0)	1(1)
27th presacral vertebrae	14(10)	22(12)	25(9)	196(22)**

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE**

*Summary of developmental toxicity in the rabbit*

The potential for tolpyralate to have an adverse effect on development was investigated in a specific study in the rabbit. The test item was well tolerated by the parental animals with minimal clinical signs of toxicity being observed. Signs of maternal toxicity were limited to small transient reductions in body weight gain and food consumption at the top dose level.

There were no abnormalities observed in the maternal animals at necropsy which were attributed to the administration of the test item. There was no dose related or statistically significant increase in visceral abnormalities or skeletal malformations. Examination for skeletal variations showed a statistically significant increase in total skeletal variations in the 500 mg/kg bw/day group when compared to the control group. Supernumerary ribs, supernumerary ossification sites and 27<sup>th</sup> presacral vertebra were noted in 92.55, 7.08 and 91.60% of foetuses respectively, all of which were significantly increased in incidence over the control group. However, these findings are considered to be of low toxicological concern.

**10.10.5.1 Supplementary studies relevant to effects on development**

*Genetic analysis of the external malformation observed in a developmental toxicity study in rats*

Following the observation of an uncommon abnormality in a study of the developmental toxicity of tolpyralate performed in the rat, where a number of foetuses in the highest dose group were found to have a misshapen urethral orifice, a progeny test was conducted to determine whether the abnormality was treatment related or genetic in origin. It was hypothesised that the misshapen urethral orifice seen in the developmental toxicity study was caused by a recessive mutation carried by both the dam and the sire which produced the affected litter.


**Table 33: Summary of study of genetic analysis of the external malformation observed in a developmental toxicity study in rats**

Study details	Remarks
Rat, SD and WKY/NCrCrIj 1 male (SD) mated first with 4 females (WKY/NCrCrIj), then with 4 F1 females. Not guideline Not GLP Anonymous (2013e)	<p><u>F1 offspring</u></p> <p>No pups from the F1 generation had external genital abnormalities.</p> <p><u>N2 offspring</u></p> <p>A total of 96 N2 foetuses were examined (58 males and 38 females), of these 7 female foetuses from 5 litters (25 female foetuses) were observed to have the same misshapen genital orifice as was observed in the earlier developmental toxicity study on tolpyralate. The proportion of affected female foetuses of 7 in 25 agrees with the 1:3 hypothesis for autosomal recessive inheritance. In addition to the misshapen urethral orifice, multiple malformations (cleft palate/lip, brachydactyly, anal atresia and short tail) were seen in 7 N2 fetuses (4 male and 3 female) from 4 litters.</p>

In the developmental toxicity study in the rat described earlier, 3 fetuses from a single litter were found to have a misshapen urethral orifice. In this supplementary study, the male rat which had previously sired the affected litter was mated with a further 4 wild type (WKY/NCrCrIj) females to produce the F1 generation. Selected females from the F1 generation were then back-crossed with the suspected male to produce the N2 generation. The offspring were examined for developmental abnormalities, particularly relating to the external genitalia. The following diagram illustrates the predicted occurrence of the abnormality if it is due to a recessive mutant allele.



ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE



The F1 generation consisted of 26 males and 27 females. No pups from the F1 generation had external genital abnormalities. A total of 96 N2 foetuses were examined (58 males and 38 females), of these 7 female foetuses from 5 litters (25 female foetuses) were observed to have the same misshapen genital orifice as was observed in the earlier developmental toxicity study on tolpyralate. The proportion of affected female foetuses of 7 in 25 agrees with the 1:3 hypothesis for autosomal recessive inheritance. In addition to the misshapen urethral orifice, multiple malformations (cleft palate/lip, brachydactyly, anal atresia and short tail) were seen in 7 N2 fetuses (4 male and 3 female) from 4 litters.

This study indicates that the misshapen urethral orifice observed in the developmental toxicity study of tolpyralate in the rat is likely to be caused by a recessive, female specific mutant allele present in both the male and female which sired the affected litter, and is not related to the administration of tolpyralate.

#### 10.10.6 Short summary and overall relevance of the provided information on adverse effects on development

The developmental toxicity of tolpyralate was investigated in 2 standard studies conducted in rats and rabbits. Further information is also available from the 2-generation study conducted in rats and a supplementary study that was conducted to investigate the effects of increased plasma tyrosine levels on the development of rats

In the standard developmental studies in the rat and rabbit, there were increases in total skeletal variations and certain other specific variations. Notable observations were unossified/partially ossified cervical and thoracic centrum, supernumerary ribs and 27<sup>th</sup> presacral vertebrae. These findings were evident only at the highest test dose of 500 mg/kg bw/day in both studies, and occurred in the absence of any marked maternal toxicity other than small changes in body weight and body weight gain. Whilst these are considered to be related to treatment, they are considered to be of minimal toxicological significance.

## ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

In a 2-generation study, pup viability on lactation day 0 was decreased in both the F1 and F2 generations. However, the findings were not consistent across the F1 and F2 generations, with the effects in the F2 generation being due primarily to one litter. Viability on subsequent days was not affected. Whilst there was also a decrease in the total number of pups delivered at the top dose in the F2 generation, this was not found to be statistically different to controls or other treated groups. Overall, these findings are not considered to represent a treatment related effect.

In the supplementary study, in which pregnant rats were treated with 88.87 mg/kg bw/d tolpyralate or 0.84 mg/kg bw/d NTBC, the mean plasma tyrosine concentration in dams was increased to 2158.0 µmol/L and 2016.2 µmol/L respectively. Pup viability was unaffected by treatment with either substance on lactation day 0 but, by day 4, there was a decrease in the NTBC group. Mean pup body weight was reduced in both treated groups at PND21. Mean plasma tyrosine concentrations were significantly increased in both treated groups at PND4 and PND21: exceeding 3000 µmol/L in all cases in comparison to approximately 100 µmol/L in control animals. Pathological and histopathological analysis was limited in this study. The predominant findings were increases in various gross and histopathological lesions in the urinary system and kidneys. These findings were minimal in both severity and incidence; they were consistent with the repeated dose toxicity of tolpyralate. No further information on developmental parameters was provided by this study.

### 10.10.7 Comparison with the CLP criteria

A classification for developmental toxicity is warranted where there is evidence from humans or experimental animals of an adverse effect on the development of the conceptus either before or after birth. Such effects shall have been observed in the absence of other toxic effects, or shall not be secondary non-specific consequences of the other toxic effects.

In standard developmental studies in the rat and the rabbit there were increases in total skeletal variations and certain other specific variations, in particular, unossified/partially ossified cervical and thoracic centrum, supernumerary ribs and 27<sup>th</sup> presacral vertebrae. These effects were evident only at the highest test dose of 500 mg/kg bw/day in both studies. In accordance with section 3.7.2.3.3 of Annex I of CLP, small changes in common foetal variants (such as those observed in skeletal examinations) and/or foetal weights may be considered of low or minimal toxicological significance. Therefore, it is considered that the increases in skeletal variations are not sufficient to support classification for developmental toxicity. In conclusion, the criteria for classification are not met.

### 10.10.8 Adverse effects on or via lactation

Information relating to the potential for tolpyralate to have adverse effects either on or via lactation is available from the two-generation reproductive toxicity study in the rat. In this study there was a significant decrease in pup viability on lactation day 0, which was not seen subsequently. The decreased viability at the start of lactation, which was not seen later in the lactation period, is not consistent with an adverse effect on either quantity or quality of milk or an effect via lactation. Pup weights consistently decreased at the highest tested dose throughout the lactation period, most notably from day 14 onwards, in both F1 and F2 generations, by around 10% when compared to controls. Other adverse effects seen in the offspring were increased incidence of ocular opacity and gross kidney lesions at the top dose level and an increased incidence of kidney cysts at  $\geq 50$ ppm in F1 animals.

### 10.10.9 Comparison with the CLP criteria

Classification for effects on or via lactation might be assigned where: there is human evidence that indicates a hazard to babies during the lactation period; the results of one- or two-generation studies in animals provide clear evidence of adverse effects in the offspring owing to transfer in the milk or adverse effect on the quality of the milk; toxicokinetic studies indicate the likelihood that the substance is present in potentially toxic levels in breast milk.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

In the case of tolpyralate, there is no human data to inform on this end-point. In the available two-generation study in rats, signs of toxicity in pups which may be indicative of reduced quality or quantity of milk were slightly reduced body weights (approximately 10%) in both F1 and F2 off spring, particularly from lactation days 14 onwards. Although there were some reductions in maternal body weight (particularly in F1) during the lactation period, they were minimal and inconsistent; consequently the reduced pup weights cannot be concluded to be solely secondary to maternal toxicity. The gross abnormalities observed in offspring were consistent with adverse effects observed in other studies. Gross pathological examination was performed on lactation days 4 and 26. On LD4 there were effects on the kidney but not on the eye, the effects on the kidney are likely have been present before the onset of lactation. It is not possible to conclude whether the effects on the eye at LD26 were due to exposure to tolpyralate in the milk or in the diet, as weaning is considered to be complete by this point. In conclusion, there is no clear evidence of adverse effects in the offspring owing to transfer of tolpyralate in the milk, and classification is not warranted for this end point.

#### 10.10.10 Conclusion on classification and labelling for reproductive toxicity

No classification (conclusive but not sufficient for classification).

### RAC evaluation of reproductive toxicity

#### Summary of the Dossier Submitter's proposal

The DS proposed no classification for fertility and sexual development based on the results of a 2-generation study in the rat.

No classification was also proposed for developmental toxicity. Although an increased incidence of skeletal variations was observed in both the rat and the rabbit prenatal developmental toxicity (PNDT) studies, these were considered to be of minimal toxicological significance.

The two-generation study showed some effects potentially relevant for classification for adverse effects on or via lactation (reduced pup viability on PND 0, reduced pup weights, ocular and kidney lesions). However, as these could not be unequivocally attributed to intake of the substance via milk, the DS proposed no classification for this endpoint.

#### Comments received during public consultation

Two MSCAs and 1 Industry association commented on reproductive toxicity.

The Industry association supported the DS proposal of no classification. They emphasised that the toxicological characteristics of tolpyralate are essentially the same as those of NTBC, including ocular opacity, kidney lesions and foetal skeletal variations. Industry argued that all these effects were secondary to tyrosinaemia, which is less likely to occur in humans than in rats. In their position paper, Industry also summarised a negative developmental toxicity study in the rabbit employing a dose level of 1000 mg/kg bw/d. The DS examined the study report and confirmed that this study was negative.

The two MSCAs proposed classification for developmental effects, one in Category 2 and

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

the other in Category 1B. The following findings were mentioned in support of classification:

- Increased incidence of skeletal variations in the rat and rabbit PNDT studies
- Reduced foetal weight in the rat PNDT study
- Low incidence of malformations (left umbilical artery, right subclavian from aortic arch, split cartilage of thoracic centrum) in the treated groups of the rat PNDT study
- More pronounced kidney effects in the F1 generation compared to the P generation, which indicates increased sensitivity of foetuses and juveniles compared to adults
- Increased number of dead pups on lactation day 0 in the 2-generation study

In their response the DS emphasised the following:

- The observed skeletal variations are of minimal toxicological significance (referring to CLP, Annex I, 3.7.2.3.3)
- The small reduction in foetal body weight (by 6.1%) in the rat PNDT study is secondary to maternal toxicity and does not justify classification
- The incidence of the malformations in the rat PNDT study was low and within the historical control data provided by the applicant
- The presence of kidney findings in F1 adults and not in P adults could indicate increased susceptibility during development. However, the effects in the kidney were not considered developmental effects and were covered by the proposed STOT RE classification
- The increased pup death occurred inconsistently between the two generations. In the F1 generation, the dead pups were associated with a small number of deaths (1-3) across 8 litters. In the F2 generation, the increased number of deaths was predominantly associated with the loss of 9 pups from a single litter. Therefore, in the F2 the effect was not considered treatment-related by the DS. As the effect on pup death in the F1 was small and not confirmed in the F2, it was not considered related to treatment overall.

### **Additional key elements**

#### ***Historical control data for the rat PNDT study (Anonymous, 2013c)***

In response to a comment in the public consultation, the DS provided historical control data (HCD) on several anomalies including split cartilage of thoracic centrum, left umbilical artery and right subclavian artery arising from aortic arch. The HCD on these three anomalies are presented in the table below.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Year of animals receipt	Affected foetuses (litters)	Total foetuses (litters)
<b><i>Split cartilage of thoracic centrum</i></b>		
2009a	1 (1)	175 (24)
2013	0 (0)	168 (24)
2014	1 (1)	58 (8)
2015	5 (4)	175 (24)
2016	0 (0)	177 (12)
2017	0 (0)	174 (24)
<b><i>Left umbilical artery</i></b>		
2009a	0 (0)	163 (24)
2009b	1 (1)	54 (8)
2013	1 (1)	180 (24)
2014	2 (2)	61 (8)
2015	3 (2)	187 (24)
2017	3 (3)	181 (24)
<b><i>Right subclavian artery arising from aortic arch</i></b>		
2009a	0 (0)	163 (24)
2009b	0 (0)	54 (8)
2013	1 (1)	180 (24)
2014	0 (0)	61 (8)
2015	1 (1)	187 (24)
2017	2 (2)	181 (24)

***An additional rabbit PNDT study***

The additional PNDT study in the rabbit referred to in the public consultation is summarised below.

<b>An additional PNDT study in the rabbit</b>		
Type of study	Method	Observations
PNDT study	Non-guideline Doses: 0, 1000 mg/kg bw/d 8 females/group	<u>Maternal toxicity</u> Transient reductions in bw gain and food consumption, adjusted bw not affected  <u>Developmental toxicity</u> Increased incidence of skeletal variations (supernumerary rib, 27 presacral vertebrae)

**Assessment and comparison with the classification criteria**

***Adverse effects on sexual function and fertility***

The two-generation study and the one-generation range-finding study are summarised in the following table.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Generational studies		
Type of study; Reference	Method	Observations
1-generation reproductive range-finding, dietary, rat Anonymous, 2015d	Non-guideline GLP Doses: 0, 5, 20, 200, 2000, 20000 ppm; corresponding to 0, 0.26/0.50, 1.0/1.9, 11/20, 107/193, 1090/1940 mg/kg bw/d (m/f) 8 parental animals/sex/dose	<p><u>Parental findings</u></p> <p>20000 ppm (1090/1940 mg/kg bw/d):</p> <ul style="list-style-type: none"> <li>• ↓ bw gain (by 20%/23% m/f)</li> <li>• ↓ food consumption in f during lactation (by up to 20%)</li> <li>• ↑ liver weight (relative by 19%/15% m/f)</li> <li>• ↑ kidney weight (relative by 12%/19% m/f)</li> <li>• Ocular opacity (m 2/8, f 8/8)</li> </ul> <p>2000 ppm (107/193 mg/kg bw/d):</p> <ul style="list-style-type: none"> <li>• ↓ bw gain (m)</li> <li>• ↑ liver and kidney weight</li> <li>• Ocular opacity</li> </ul> <p>200 ppm (11/20 mg/kg bw/d):</p> <ul style="list-style-type: none"> <li>• ↓ bw gain (m)</li> <li>• ↑ liver weight</li> <li>• Ocular opacity (low incidence)</li> </ul> <p>≤ 20 ppm (1.0/1.9 mg/kg bw/d): no adverse effects</p> <p><u>Reproductive findings</u></p> <p>No treatment related effects</p> <p><u>Offspring findings</u></p> <p>20000 ppm:</p> <ul style="list-style-type: none"> <li>• ↑ pup mortality PND 1-4 (80% viable pups vs 99% in the controls)</li> <li>• ↓ pup weight (by up to ≈ 20%) throughout the lactation period</li> <li>• Renal abnormalities on PND 4 and 26 (pelvic dilatation, kidney cysts, kidney atrophy, white material in the urinary bladder)</li> <li>• Ocular opacity on PND 26 (19% vs 0% in the controls)</li> </ul> <p>2000 ppm:</p> <ul style="list-style-type: none"> <li>• ↑ pup mortality PND 1-4 (90% viable pups vs 99% in the controls)</li> <li>• ↓ pup weight (by ≈ 10%, not stat. sign.)</li> <li>• Renal abnormalities on PND 4 and 26 (pelvic dilatation, kidney cysts, kidney atrophy)</li> </ul> <p>200 ppm:</p> <ul style="list-style-type: none"> <li>• Renal abnormalities on PND 26 (kidney cysts, pelvic dilatation)</li> </ul> <p>≤ 20 ppm: no adverse effects</p>
2-generation reproductive,	OECD TG 416 GLP	<p><u>Parental findings</u></p> <p>1000 ppm (55/59 mg/kg bw/d) – P generation:</p>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

<p>dietary, rat Anonymous, 2015e</p>	<p>Doses: 0, 5, 50, 1000 ppm; corresponding to 0, 0.27/0.29, 2.7/3.0, 55/59 mg/kg bw/d (m/f) 24 parental animals/sex/dose</p>	<ul style="list-style-type: none"> <li>• ↑ liver and kidney (m) weight</li> <li>• Ocular opacity and keratitis (high incidence)</li> <li>• 1000 ppm – F1 generation:</li> <li>• Mortality f 2/24 during lactation</li> <li>• ↓ bw and bw gain (m ↓ terminal bw by 10%)</li> <li>• ↑ liver weight</li> <li>• Macroscopic and histopathological kidney findings (nephropathy, calcification, basophilic change of renal tubules, cortical cysts)</li> <li>• Ocular opacity and keratitis (high incidence)</li> </ul> <p>50 ppm (2.7/3.0 mg/kg bw/d) – P generation:</p> <ul style="list-style-type: none"> <li>• ↑ liver weight</li> <li>• Keratitis (single animal)</li> </ul> <p>50 ppm – F1 generation:</p> <ul style="list-style-type: none"> <li>• Keratitis (single animal)</li> </ul> <p>5 ppm (0.27/0.29 mg/kg bw/d): no adverse effects</p> <p><u>Reproductive findings</u></p> <p>1000 ppm:</p> <ul style="list-style-type: none"> <li>• ↑ duration of gestation in F1 (22.7 days vs 22.2 days in controls, stat. sign.)</li> <li>• ↓ no. of pups per litter (10.9 vs 12.7, not stat. sign.) and no. of implantation sites (11.9 vs 13.6, not stat. sign.) in F2</li> </ul> <p>≤ 50 ppm: no adverse effects</p> <p><u>Offspring findings</u></p> <p>1000 ppm – F1 generation:</p> <ul style="list-style-type: none"> <li>• ↓ pup weight (by ≈ 10% PND 14 and 21)</li> <li>• ↓ pup viability index (P 96.3 vs 99.4, stat. sign.; F1 90.6 vs 98.9, not stat. sign.); ↑ no. of pups found dead on PND 0</li> <li>• Gross kidney findings on PND 4 and in weanlings (cysts, pelvic dilation, white material in the pelvic space)</li> <li>• Eye opacity in weanlings (1.9%)</li> <li>• Delayed preputial separation (45.7 vs 41.7, stat. sign.) and vaginal opening (35.4 vs 31.4, stat. sign.)</li> </ul> <p>1000 ppm – F2 generation:</p> <ul style="list-style-type: none"> <li>• ↓ pup weight (by ≈ 7% PND 14 and 21)</li> <li>• Gross kidney findings on PND 4 and in weanlings (cysts, pelvic dilation, white material in pelvic space)</li> <li>• Eye opacity in weanlings (5.6%)</li> </ul> <p>≤ 50 ppm: no adverse effects</p>
--	---	---

These two studies showed no effects on fertility and sexual function except for a reduction in the number of implantation sites and delayed puberty onset. Both effects are

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

discussed below.

Reduced number of implantation sites and reduced litter size

A reduction in the mean number of implantation sites (by 1.7) and a corresponding reduction in mean litter size (1.8) were observed at the top dose in the F1/F2 generation, relative to controls. The decreases were not statistically significant. The finding is difficult to interpret in the absence of HCD. RAC notes that no effect on these two parameters was observed in the dose-range finding study at a 2-fold higher dose and only a slight reduction (by 0.9) at a 20-fold higher dose (albeit with a lower number of animals). Overall, RAC does not consider that the reduced number of implantation sites supports classification.

Delayed sexual maturation

A statistically significant delay in preputial separation (PS, by 4 days) and vaginal opening (VO, by 4 days) was observed at the top dose in the 2-generation study. Although the delayed sexual maturation was associated with reduced body weight (bw on PND 21 was reduced by 10/11% in m/f and there was no significant difference in bw on the day of PS/VO), RAC is of the opinion that a delay in puberty onset by 4 days cannot be fully explained by the observed body weight reductions. As other MoAs cannot be excluded, the effect has to be considered for classification.

<b>Sexual maturation in the 2-generation study</b>				
<b>Dose (ppm)</b>	<b>0</b>	<b>5</b>	<b>50</b>	<b>1000</b>
Dose (mg/kg bw/d) m/f	0	0.27/0.29	2.7/3.0	55/59
<b><i>Preputial separation</i></b>				
Day of preputial separation	41.7	41.4	42.9	45.7**
Bw on the day of prep. separation (g)	225	218	226	223
Bw on PND 21 (g)	64.9	64.8	64.6	58.1**
<b><i>Vaginal opening</i></b>				
Day of vaginal opening	31.4	31.9	31.8	35.4**
Bw on the day of v. opening (g)	116	121	118	126
Bw on PND 21 (g)	63.6	63.4	62.3	56.3**

\* Significantly different from control,  $p \leq 0.05$ ; \*\* Significantly different from control,  $p \leq 0.01$

Conclusion on classification

Delayed sexual maturation by 4 days in both sexes was observed at the top dose in the 2-generation study in association with some body weight reduction. Although there were no other effects related to fertility (e.g., no effect on sperm parameters or on the reproductive outcome), RAC considers delayed puberty onset as an adverse effect on its own (cf. CLP, Annex I, 3.7.1.3) and proposes classification in **Category 2** for adverse effects on sexual function and fertility.



ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

**Adverse effects on development**

The developmental toxicity of tolpyralate was investigated in two standard PNDT studies, one in the rat and one in the rabbit. A follow-up study to the rat PNDT study tested the hypothesis that one of the observed malformations (misshapen urethral orifice) was of genetic origin. In addition, one non-standard developmental toxicity study in the rat is available, investigating developmental consequences of hypertyrosinaemia. All studies are summarised in the following table.

Developmental toxicity studies		
Type of study; Reference	Method	Observations
<b>Rat</b>		
PNDT study, gavage Anonymous, 2013c	OECD TG 414 GLP Doses: 0, 1, 10, 500 mg/kg bw/d Dosing GD 6-19 23-24 females/group	<u>Maternal toxicity</u> 500 mg/kg bw/d: <ul style="list-style-type: none"> <li>• ↓ food consumption until GD 15 (by 6-20%); no effect on corrected terminal bw</li> </ul> ≤ 10 mg/kg bw/d: no adverse effects  <u>Developmental toxicity</u> 500 mg/kg bw/d: <ul style="list-style-type: none"> <li>• ↓ foetal weight (by 6%)</li> <li>• ↑ incidence of skeletal variations (discontinuous rib cartilage, supernumerary rib)</li> <li>• Misshapen urethral orifice (3 foetuses in 1 litter)</li> </ul> ≤ 10 mg/kg bw/d: no adverse effects
Follow-up to the PNDT study, testing if the misshapen urethral orifice is of genetic origin Anonymous, 2013e	Non-guideline Non-GLP 1 male (suspected of a recessive mutation) was mated with 4 females of a different strain; then the same male was mated with 4 F1 females, producing N2 offspring F1 and N2 offspring examined for external genital anomalies	<u>F1 offspring</u> 26 males, 27 females No external genital abnormalities  <u>F2 offspring</u> 58 males, 38 females 7 female foetuses from 5 litters had the same misshapen genital orifice observed in the tolpyralate-treated group in the PNDT study Anonymous (2013c); this agrees with the 1 : 3 hypothesis for autosomal recessive inheritance
Developmental toxicity study, investigations into developmental consequences of hypertyrosinaemia, dietary	Non-guideline Non-GLP Tolpyralate group: 1000 ppm (corresponding to 89 mg/kg bw/d) NTBC group: 10 ppm (corresponding to 0.84	<u>Maternal findings</u> 1000 ppm tolpyralate (89 mg/kg bw/d): <ul style="list-style-type: none"> <li>• Ocular opacity (10/11, starting from LD 7)</li> <li>• Plasma tyrosine concentration 2020 µmol/L (vs 66.5 µmol/L in control)</li> </ul>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

<p>Anonymous, 2016c</p> <p>mg/kg bw/d</p> <p>Control group</p> <p>Administration GD 0 – PND 21, terminated on PND 21</p> <p>12 females/group</p> <p>Comprehensive developmental analysis (malformations, variations) not conducted</p>		<p>10 ppm NTBC:</p> <ul style="list-style-type: none"> <li>Ocular opacity (11/11, starting from LD 4)</li> <li>Plasma tyrosine concentration 2160 µmol/L</li> </ul> <p><u>Offspring findings</u></p> <p>1000 ppm tolpyralate:</p> <ul style="list-style-type: none"> <li>Plasma tyrosine concentration 3200 µmol/L (vs 191 µmol/L in control)</li> <li>Ocular opacity (1.1% of pups vs 0 in control)</li> <li>Abnormalities of the kidney: small kidney (2/64 vs 0 in control), rough surface (4/64 vs 0 in control)</li> </ul> <p>10 ppm NTBC:</p> <ul style="list-style-type: none"> <li>Plasma tyrosine concentration 3650 µmol/L</li> <li>Increased pup mortality at PND 4 (22% vs 9.0% in control)</li> <li>Ocular opacity (8.0% of pups)</li> <li>Abnormalities of the kidney: small kidney (6/52), rough surface (2/52)</li> </ul>
<p><b>Rabbit</b></p>		
<p>PNDT study, gavage</p> <p>Anonymous, 2013d</p>	<p>OECD TG 414</p> <p>GLP</p> <p>Doses: 0, 0.5, 5, 500 mg/kg bw/d</p> <p>Dosing GD 6-27</p> <p>25 females/group</p>	<p><u>Maternal toxicity</u></p> <p>No adverse effects</p> <p><u>Developmental toxicity</u></p> <p>500 mg/kg bw/d:</p> <ul style="list-style-type: none"> <li>↑ incidence of skeletal variations (supernumerary rib, 27 presacral vertebrae)</li> </ul> <p>≤ 5 mg/kg bw/d: no adverse effects</p>
<p><u>Rat PNDT study</u></p> <p>The rat PNDT study showed a small reduction in foetal weight and an increased incidence of skeletal variations (discontinuous rib cartilage, supernumerary rib) in the absence of maternal toxicity at the top dose of 500 mg/kg bw/d. Although these effects are not sufficiently severe to warrant classification, RAC notes that probably a higher dose, possibly the limit dose of 1000 mg/kg bw/d, would have been tolerated by the dams.</p> <p>As to the litter containing 3 fetuses with the misshapen urethral orifice, RAC agrees with the DS conclusion that this finding can be attributed to a recessive mutant allele present in both the male and female which sired the affected litter as shown in the study Anonymous (2013e).</p> <p>Regarding the incidences of several anomalies mentioned in the public consultation (left umbilical artery, right subclavian from aortic arch, split cartilage of the thoracic centrum),</p>		

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

RAC agrees with the DS that these are within the ranges of relevant HCD provided by the applicant after the public consultation.

Rabbit PNDT study

The only developmental effect at the top dose of 500 mg/kg bw/d was the increased incidence of skeletal variations (supernumerary rib, 27 presacral vertebrae) in the absence of maternal toxicity. An additional study testing 1000 mg/kg bw/d with a limited number of animals (8 females per group) confirmed this finding. The effect is not considered sufficiently severe to warrant classification.

Rat study investigating developmental consequences of tyrosinaemia

In this mechanistic study, pregnant females were exposed to tolpyralate via diet from the beginning of gestation until PND 21. The study confirmed the eye and kidney findings seen in the 2-generation study and showed that comparable effects were caused by NTBC at a dose level causing a similar degree of tyrosinaemia. RAC considers the proposed causal relationship between tyrosinaemia and the eye and kidney effects plausible.

NTBC additionally caused an increased incidence of pup mortality on PND 4.

Rat 1-generation and 2-generation studies

Reduced pup viability on the day of birth was observed in the P/F1 generation of the main 2-generation study. The data on pup viability in this study are presented below.

<b>Pup mortality in the 2-generation study (Anonymous, 2015e)</b>				
<b>Dose (ppm)</b>	<b>0</b>	<b>5</b>	<b>50</b>	<b>1000</b>
Dose (mg/kg bw/d) m/f	0	0.27/0.29	2.7/3.0	55/59
<b>F1: PND 0</b>				
Number of live pups	287	303	320	288
Number of dead pups	2	1	8	11
Dead pups per litter (no. of litters affected)	1,1 (2)	1 (1)	1,6,1 (3)	2,1,1,1,3,1,1,1 (8)
% found dead	0.6	0.4	2.4	3.7*
Viability index (%)	99.4	99.6	97.6	96.3*
<b>F1: PND 1-4</b>				
Number of dead pups	1	1	0	0
Dead pups per litter (no. of litters affected)	1 (1)	1 (1)	0 (0)	0 (0)
% found dead	0.4	0.4	0.0	0.0
% lost	2.4	0.3	1.2	5.4
Viability index on LD 4 (%)	97.2	99.3	98.8	94.6
<b>F2: PND 0</b>				
Number of live pups	301	307	297	228

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Number of dead pups	3	4	6	11
Dead pups per litter (no. of litters affected)	2,1 (2)	1,1,1,1 (4)	1,1,1,2,1 (5)	9,1,1 (3)
% found dead	1.1	1.2	1.9	9.4
Viability index (%)	98.9	98.8	98.1	90.6
<b>F2: PND 1-4</b>				
% lost	0.6	2.5	6.6	2.1
Viability index on LD 4 (%)	99.4	97.6	93.4	97.9

\* Significantly different from control,  $p \leq 0.05$

The reduction in pup viability on PND 0 was statistically significant in the first generation but not in the second generation and no such finding was reported at a 20-fold higher dose in the dose-range finding study.

On the other hand, the dose range-finding study reported increased pup mortality on PND 1-4 from 2000 ppm (107/193 mg/kg bw/d). The data on pup mortality in the dose-range finding study are presented in the following table. Although the reduction in pup viability at 2000 ppm was not statistically significant, 5 out of 7 litters were affected at this dose and the mortality was even more pronounced at the top dose, which indicates a treatment-related effect. In addition, increased pup mortality on PND 1-4 was seen with other HPPD inhibitors (NTBC: Anonymous, 2016c; sulcotrione: RAC, 2011; mesotrione: RAC, 2018) and may be secondary to tyrosinaemia.

<b>Pup mortality in the 1-generation dose-range finding study (Anonymous, 2015d)</b>						
<b>Dose (ppm)</b>	<b>0</b>	<b>5</b>	<b>20</b>	<b>200</b>	<b>2000<sup>#</sup></b>	<b>20000<sup>#</sup></b>
Dose (mg/kg bw/d) m/f	0	0.26/0.50	1.0/1.9	11/20	107/193	1090/1940
<b>PND 0</b>						
Number of live pups	113	104	116	111	101	91
Number of dead pups	1	1	1	2	1	3
Dead pups per litter (no. of litters affected)	1 (1)	1 (1)	1 (1)	2 (1)	1 (1)	1,1,1 (3)
<b>PND 1-4</b>						
Number of dead pups	1	0	8	1	10	18
Dead pups per litter (no. of litters affected)	1 (1)	0 (0)	6,2 (2)	1 (1)	2,1,4,1,2 (5)	6,2,1,4,1,1,3 (7)
Viability index on PND 4 (%)	99.0	100	93.8	99.1	90.0	79.7**

<sup>#</sup> 7 litters examined as 1 female was not pregnant

Significantly different from control: \*,  $p \leq 0.05$ ; \*\*,  $p \leq 0.01$

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

RAC is of the view that the increased pup mortality observed on PND 0 in the main study and on PND 1-4 in the range-finding study is an adverse effect on development warranting classification.

Classification is further supported by the occurrence of various renal abnormalities in pups in the generational studies (pelvic dilation, kidney cysts, white material in pelvic space, kidney atrophy). The presence of renal findings (nephropathy, calcification, basophilic change of renal tubules, cortical cysts) in F1 but not in P adults indicates persistence of the effects and increased sensitivity of foetuses and juveniles to the renal toxicity of tolpyralate.

Conclusion on classification for development

RAC proposes classification in **Category 2** for adverse effects on development based on increased pup mortality and an increased incidence of renal findings in the offspring in the rat generational studies. Classification in Category 1B is not considered appropriate due to the low incidence and shallow dose-response relationship for pup mortality and in view of the relatively low severity and incidence of the kidney findings.

**Adverse effects on or via lactation**

Statistically significant reductions in pup body weight on PND 14 and 21 were observed at the top dose of 1000 ppm (55/59 mg/kg bw/d m/f) in the 2-generation study (data provided in the table below). As the animals started to feed on the diet before PND 14, this reduction in body weight gain cannot be unequivocally attributed to an effect on or via lactation.

Pup body weights (g) in the 2-generation study (Anonymous, 2015e)									
	Dose (ppm)	Males				Females			
		PND 0	PND 7	PND 14	PND 21	PND 0	PND 7	PND 14	PND 21
<b>F1</b>	<b>0</b>	7.0	18.1	39.2	64.9	6.6	18.0	39.4	63.6
	<b>5</b>	6.9	18.0	39.7	64.8	6.5	18.0	39.4	63.4
	<b>50</b>	7.0	18.5	39.6	64.6	6.5	17.8	38.7	62.3
	<b>1000</b>	6.9	16.2	35.9*	58.1**	6.5	16.4	36.0	56.3**
<b>F2</b>	<b>0</b>	7.3	20.0	41.9	64.4	6.8	19.0	40.5	62.0
	<b>5</b>	6.9	19.5	40.9	63.8	6.4	18.3	40.3	62.4
	<b>50</b>	7.0	19.6	42.4	65.7	6.6	18.7	41.1	62.8
	<b>1000</b>	7.3	19.2	39.0*	60.9	6.8	18.4	37.4**	57.9**

Significantly different from control: \*, p ≤ 0.05; \*\*, p ≤ 0.01

Statistically significant reductions in pup body weights were also observed in the one-generation dose-range finding study at 20000 ppm (1090/1940 mg/kg bw/d). The effect in male pups was a significant effect already on PND 7 (reduction by 17% compared to controls; maternal body weight in this period was lower by ca. 10% than in controls). However, the relatively low magnitude of effect at such a high dose level is not

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

considered sufficient to trigger classification.

**Pup body weights (g) in the 1-generation range-finding study (Anonymous, 2015d)**

	Dose (ppm)	Males				Females			
		PND 0	PND 7	PND 14	PND 21	PND 0	PND 7	PND 14	PND 21
<b>F1</b>	<b>0</b>	6.7	18.4	38.4	63.0	6.3	17.7	37.4	61.0
	<b>5</b>	6.9	19.3	39.9	65.5	6.6	18.5	38.9	63.3
	<b>20</b>	6.5	15.9	36.2	60.8	6.0	15.5	36.1	60.1
	<b>200</b>	6.6	17.5	36.7	60.3	6.3	16.9	36.2	58.0
	<b>2000</b>	6.5	16.4	35.5	56.7	6.4	16.5	35.7	56.2
	<b>20000</b>	6.4	15.3**	32.3**	51.3**	5.9	15.4	32.5**	50.1**

Significantly different from control: \*, p ≤ 0.05; \*\*, p ≤ 0.01

The reduced pup viability between PND 1 and 4 in the one-generation dose-range finding study and the kidney lesions are considered to be manifestations of developmental toxicity.

In conclusion, RAC agrees with the DS that **classification** for adverse effects on or via lactation **is not warranted**.

**Overall conclusion of reproductive toxicity**

RAC recommends that tolpyralate be classified as **Repr. 2; H361fd (suspected of damaging fertility or the unborn child)**.

**10.11 Specific target organ toxicity-single exposure**

Information relating to the potential for tolpyralate to cause specific target organ toxicity is available from the acute toxicity data presented in Sections 10.1 to 10.3. In addition an acute neurotoxicity study in the rat is available.

**Table 34: Summary table of animal studies on STOT SE**

Study Batch / purity Intakes (mg/kg bw/d)	Doses	Adverse Effects

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

<p><b>Acute neurotoxicity in the rat</b>  Rat, SD  10 / sex / group  Oral gavage; vehicle: 1% Methylcellulose  OECD 424  GLP  Batch 20111222-1  Purity 97.27%  Anonymous (2013f)  DAR B.7.1</p>	<p>0, 500, 1000, 2000 mg/kg bw  Single dose  14 day observation period</p>	<p><u>1000 mg/kg bw</u>  Reduced approach response in males on day 1.    <u>2000 mg/kg bw</u>  Reduced body weight in week 1 of observation period by 14% and 24% in males and females respectively. Body weight comparable to controls in week 2.    Reduced activity and rearing counts and reduced approach response in males at day 1 observation, attributed to general systemic toxicity.</p>
---	--	---

The potential for tolpyralate to cause acute neurotoxicity was investigated in a study performed in the rat, according to OECD Test Guideline 424 and in compliance with GLP. Groups of 10 Sprague Dawley Crl:CD (SD) rats of each sex were administered 0, 500, 1000 or 2000 mg/kg bw tolpyralate, formulated in 1% (w/v) methylcellulose as a single oral gavage dose. The animals were observed for 14 days following treatment; clinical condition, body weight and food consumption were recorded. On days 1 (2h post dosing), 8 and 15 neurobehavioural screening was performed. Following termination brain weight and anatomical measurements were taken and microscopic and histopathological examination relevant for evaluation of neurotoxicity was performed.

There were no mortalities or clinical signs of toxicity which were attributed to administration of the test item. Small reductions in body weight gain (14% and 24% in males and females respectively) were observed in animals receiving 2000 mg/kg bw tolpyralate over the first 8 days of the observation period. Body weight gain in these animals was comparable to controls over the second week of the observation period. Body weight parameters in all other treatment groups were comparable to controls. There were no treatment related changes in food consumption.

There were no changes in home cage or in-hand observations that were attributable to administration of the test item. At the day 1 observation (2h following dose administration) there was a reduction in group mean activity and rearing counts in males from all treated groups, achieving statistical significance in the 2000 mg/kg group. The reduction in activity appeared to occur in a dose dependent manner and is likely to indicate general toxicity of the test item, although it should be noted that the activity of the control group was above the historical control range for both parameters. There was no comparable effect observed at the 8 and 15 day observations.

In females there was a statistically significant reduction in mean activity at day 15 amongst animals which received 1000 and 2000 mg/kg bw. This finding did not occur in a dose dependent manner, was within the historical control range and was not observed in females at day 1 or 8 observation, consequently it is not considered to be related to administration of the test item.

The day 1 observation showed a reduced approach response in males given 1000 or 2000 mg/kg and slightly reduced touch response in males given 2000 mg/kg. These effects appeared to occur in a dose dependent manner and were still evident on Day 8. The incidence of these responses was within the historical control range and they were not observed at the day 15 observation or at any point in females. Any changes in activity or response parameters occurring at the first observation on day 1 are attributed to general toxicity as opposed to a specific neurotoxic effect of tolpyralate.

There were no treatment related changes in brain size or weight, gross pathology or histopathology.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

**10.11.1 Short summary and overall relevance of the provided information on specific target organ toxicity – single exposure**

Information relating to the potential for tolpyralate to cause specific target organ toxicity following a single exposure is available from the specific acute toxicity studies conducted via the oral, dermal and inhalation routes (summarised in sections 10.1-10.3) and from the acute neurotoxicity study. All studies were conducted in the rat. Based on the clinical and behavioural observations in the described studies, there were no effects that are indicative of specific target toxicity following a single dose of tolpyralate.

**10.11.2 Comparison with the CLP criteria**

STOT-SE categories 1 and 2 are assigned on the basis of clear evidence of significant or severe toxicity to a specific target organ that arises from a single exposure to a substance. STOT-SE category 3 is assigned for the transient effects of respiratory tract irritation and narcotic effects.

The available acute studies do not provide any indication that tolpyralate meets the classification criteria for specific target-organ toxicity category 1, 2 or 3 following a single exposure.

**10.11.3 Conclusion on classification and labelling for STOT SE**

No classification (conclusive but not sufficient for classification).

**RAC evaluation of specific target organ toxicity – single exposure (STOT SE)**

**Summary of the Dossier Submitter’s proposal**

Information relating to specific target organ toxicity following single exposure is available from the acute toxicity studies via the oral, dermal and inhalation routes and from the acute neurotoxicity study (Anonymous, 2013f) in the rat. According to the DS, the clinical and behavioural observations in these studies did not show any effects indicative of specific target toxicity following single exposure. Therefore, the DS proposed no classification for STOT SE.

**Comments received during public consultation**

No comments were received on this hazard class.

**Assessment and comparison with the classification criteria**

In the acute neurotoxicity study conducted according to OECD TG 424 (GLP compliant; Anonymous, 2013f), male and female rats were administered a single dose of up to 2000 mg/kg bw tolpyralate and observed for 14 days. Top dose males showed significantly reduced activity 2 hours after administration of the test item. There was no comparable



ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

effect on day 8 or day 15. RAC agrees with the DS that this finding can indicate general toxicity and is not sufficient for classification.

No clinical signs of toxicity were observed in the acute toxicity studies (Anonymous, 2012a,b,c) or within the first few days of the repeated dose studies.

No human information related to STOT SE is available.

RAC agrees with the DS that the available studies do not show effects requiring classification in STOT SE categories 1, 2 or 3 and therefore **no classification** is appropriate.

**10.12 Specific target organ toxicity-repeated exposure**

Information relating to the potential for tolpyralate to cause specific organ toxicity following repeated exposure has been investigated in a range of studies conducted in the rat, mouse and dog. Data informing on repeat dose toxicity of tolpyralate are also available from the carcinogenicity studies conducted in both the rat and the mouse. Effects observed in these studies that are relevant to STOT-RE are summarised in this section, whilst neoplastic effects are discussed in section 10.9. Further information is also available from the 2-generation study in the rat (refer to section 10.10 for full details).

**Table 35: Summary table of animal studies on STOT RE**

Method Guideline, Deviation(s) from the guideline (if any)	Species Strain Sex no/group	Dose levels duration of exposure	Relevant adverse effects

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Method Guideline, Deviation(s) from the guideline (if any)	Species Strain Sex no/group	Dose levels duration of exposure	Relevant adverse effects
<p>28-day oral (dietary) OECD 407 GLP Batch 20101217 Purity 98.53% Anonymous (2013g) DAR B.6.3.1</p> <p>CLP guideline value for classification (mg/kg bw/d) Cat 1 = 30 Cat 2 = 300</p>	Rat, Wistar 6/sex/group	<p>0, 50, 500, 5000, 20000 ppm Equivalent to Males: 0, 4.49, 45.9, 447, 1799 mg/kg bw/d Females: 0, 4.98, 46.9, 496, 1907 mg/kg bw/d</p>	<p>No treatment-related deaths or overt signs of toxicity in any dose group <u>4.49/4.98 mg/kg bw/d:</u> Hyaline deposition in kidney males (1/6). Thyroid follicular cell hypertrophy in males (2/6). Keratitis in the eye in males (1/6). <u>45.9/46.9 mg/kg bw/d:</u> Increased relative liver weight in males (16%). Hyaline deposition in kidney males (3/6). Thyroid follicular cell hypertrophy in males (6/6), Keratitis in the eye in both sexes (m 4/6, f 6/6). <u>447/496 mg/kg bw/d:</u> Increased relative liver weight in both sexes (males 16%, 13% females). Hyaline deposition in kidney males (2/6). Thyroid follicular cell hypertrophy in both sexes (m 4/6, f 1/6). Pancreatic single acinar cell necrosis in males (3/6). Keratitis in the eye in both sexes (m 3/6, f 3/6). <u>1799/1907 mg/kg bw/d:</u> Increased relative liver weight in both sexes (males 23%, 16% females). Increased relative kidney weight in males (16%). Hyaline deposition in kidney males (4/6). Centrilobular hepatocellular hypertrophy in males (4/6). Thyroid follicular cell hypertrophy in males (4/6). Single acinar cell necrosis in both sexes (m 2/6, f 1/6). Keratitis in the eye in both sexes (m 5/6, f 6/6).</p>
<p>90-day oral (dietary) OECD 408 GLP Batch 20101217 Purity 98.53% Anonymous (2013h) DAR B.6.3.2</p> <p>CLP guideline value for classification (mg/kg bw/d) Cat 1 = 10</p>	Rat, Wistar 10/sex/group	<p>0, 5, 20, 2000, 20000 ppm Equivalent to Males: 0, 0.32, 1.34, 133, 1363 mg/kg bw/d Females: 0, 0.38, 1.58, 159, 1647 mg/kg bw/d</p>	<p>No treatment-related deaths or overt signs of toxicity in any dose group <u>0.32/0.38 mg/kg bw/d:</u> No adverse effects. <u>1.34/1.58 mg/kg bw/d:</u> Hyaline droplet deposition in males (2/10) <u>133/159 mg/kg bw/d:</u> Increased relative liver weight in both sexes (25% in males, 8% in females). Increased relative kidney weight in males (10%). Keratitis of cornea in both sexes (m 7/10, f 10/10). Hyaline droplet deposition in males (2/10). Thyroid follicular cell hypertrophy in both sexes (m 9/10, f 4/10). Increased incidence of pancreatic single acinar cell necrosis in both sexes (m 3/10, f 1/10). <u>1363/1647 mg/kg bw/d:</u> Increased relative liver weight in both sexes (22% in males, 13% in females). Increased relative kidney weight in both sexes (14%</p>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Method Guideline, Deviation(s) from the guideline (if any)	Species Strain Sex no/group	Dose levels duration of exposure	Relevant adverse effects
Cat 2 = 100			in males, 11% in females). Keratitis of cornea in both sexes (m 6/10, f 10/10). Hepatocellular hypertrophy in both males (5/10). Hyaline droplet deposition in males (4/10). Follicular cell hypertrophy in both sexes (m 9/10, f 2/10). Increased incidence of single acinar cell necrosis in the pancreas in both sexes (m 8/10, f 1/10).
One year repeated dose toxicity study Oral (dietary) OECD 452 Batch: 2011222-1 Purity: 97.27% Anonymous (2015i) DAR B.6.5 Guidance value for classification (mg/kg bw/d) Cat 1 = 2.5 Cat 2 = 25	Rat, Wistar  21/sex/dose	52 weeks  0, 5, 20, 2000, 10000/20000 ppm (males/females)  Equivalent intake at 52 weeks: Males: 0, 0.229, 0.925, 97.0 and 482 mg/kg bw/d Females: 0, 0.303, 1.18, 126 and 1336 mg/kg bw/d	No treatment-related deaths or overt signs of toxicity in any dose group. Decreased body weight, relative to controls (<20%) in mid-high and high dose groups.  <u>0.925/1.18mg/kg bw/d</u>  Loss of fur in males (6/21), Pancreatic acinar cell fibrosis in males (7/21).  <u>97.0/126mg/kg bw/d</u>  Loss of fur in both sexes (12/21 males, 21/21 females). Ocular opacity in both sexes (20/21 males, 20/21 females). Increased urinary ketones and decreased urinary pH in both sexes. Increased relative liver weight (16% in males, 10% in females), relative kidney weight (17% in males, 16% in females), incidence of fatty liver in males (11/21), incidence of basophilic change to renal tubule in males (8/9) and incidence of vacuolation of the cerebellum (males). Pancreatic acinar cell fibrosis in males (11/21). Pancreatic acinar cell necrosis in males (7/21). Thyroid follicular cell hypertrophy in both sexes (3/21 males, 2/21 females). Ocular keratitis in both sexes (20/21 males, 20/21 females).  <u>482/1336mg/kg bw/d</u>  Loss of fur in both sexes (17/21 males, 20/21 females). Ocular opacity in both sexes (20/21 males, 21/21 females). Increased urinary ketones and decreased urinary pH in both sexes. Increased relative liver weight (13% in males, 16% in females), relative kidney weight (23% in males, 15% in females), incidence of fatty liver in males (14/21), incidence of basophilic change to renal tubule in males, (9/21) and incidence of vacuolation of the cerebellum (both sexes). Pancreatic acinar cell fibrosis in males (12/21 males). Pancreatic acinar cell necrosis in both sexes. Thyroid follicular cell hypertrophy in both sexes (8/21 males, 12/21 females). Ocular keratitis in both sexes (20/21 males, 20/21 females).
Two-year carcinogenicity study	Rat, Wistar  51/sex/dose	104 weeks  0, 5, 20, 2000, 10000 ppm	<u>General toxicity</u>  No overt or serious clinical signs of toxicity. Decreased body weight, relative to controls (<20%) in mid-high and high dose groups.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Method Guideline, Deviation(s) from the guideline (if any)	Species Strain Sex no/group	Dose levels duration of exposure	Relevant adverse effects
<p>Oral (dietary) OECD 451 GLP Batch: 2011222-1 Purity: 97.27% Anonymous (2015f) DAR B.6.5 Guidance value for classification (mg/kg bw/d) Cat 1 = 1.25 Cat 2 = 12.5</p>		<p>Equivalent intake at 104 weeks: Males: 0, 0.196, 0.765, 83.8, 426 mg/kg bw/d Females: 0, 0.255, 1.01, 108, 554 mg/kg bw/d</p>	<p><u>Non-neoplastic effects</u> <u>0.196/0.255mg/kg bw/d</u> No adverse effects <u>0.765/1.01 mg/kg bw/d</u> No adverse effects <u>83.8/108 mg/kg bw/d</u> WBC counts increased in males. Relative liver weight increased (23%) in males. Increased relative kidney weight (23%) in males. Corneal opacity and associated keratitis in both sexes (all animals), coarse surface of the kidney in males (11/51), pancreatic acinar cell fibrosis in both sexes (males 46/51, females 23/51), pancreatic fat infiltration in males (26/51), degeneration of the sciatic nerve in females (12/51), vacuolation of the cerebellum in both sexes (males 40/51, females 41/51). Colloid degeneration of the thyroid in females (16/51). <u>426/554 mg/kg bw/d</u> Leukocyte count increased in males, relative liver weight increased (25%) in males, relative kidney weight increased (17%) in males, corneal opacity and associated keratitis in both sexes (all animals), increased haematopoiesis in the bone marrow in males (23/51), pancreatic acinar cell fibrosis in both sexes (males 47/51, females 22/51), pancreatic fat infiltration in males (24/51) and acinar cell necrosis in females (16/51). Colloid degeneration of the thyroid in both sexes (males 25/51, females 23/51), degeneration of the sciatic nerve (males 22/51, females 15/51) and vacuolation of the cerebellum in both sexes (males 44/51, females 44/51).</p>
<p>90-day oral (dietary) OECD 408 GLP Batch 20111222-1 Purity 97.27% Anonymous (2013i) DAR B.6.3.2 CLP guideline value for classification (mg/kg bw/d)</p>	<p>Mouse, CD1 10/sex/group</p>	<p>0, 50, 500, 2000, 7000 ppm Equivalent to Males: 0, 7.17, 70.8, 284, 1056 mg/kg bw/d Females: 0, 7.94, 81.5, 331, 1176, mg/kg bw/d</p>	<p>No treatment-related deaths or overt signs of toxicity in any dose group <u>7.17/7.94 mg/kg bw/d:</u> No adverse effects. <u>70.8/81.5 mg/kg bw/d:</u> No adverse effects. <u>284/331 mg/kg bw/d:</u> Hepatocellular hypertrophy in males (3/10). Thyroid follicular cell hypertrophy in males (1/10). <u>1056/1176 mg/kg bw/d:</u> Hepatocellular hypertrophy in both sexes (m 10/10, f 1/10). Thyroid follicular cell hypertrophy in males (4/10). Hepatocellular necrosis (focal and single cell) in females (1/10).</p>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Method Guideline, Deviation(s) from the guideline (if any)	Species Strain Sex no/group	Dose levels duration of exposure	Relevant adverse effects
Cat 1 = 10 Cat 2 = 100			
18-month carcinogenicity Oral (dietary) OECD 451 GLP Anonymous. (2015) DAR B.6.5	Mouse, CD1 52/sex/group	78 weeks 0, 70, 700, 7000 ppm  Equivalent intake at 78 weeks: Males: 0, 7.37, 78.5, 793 mg/kg bw/d Females: 0, 7.25, 72.6, 732 mg/kg bw/d	<u>General toxicity</u> No overt clinical signs of toxicity or increase in cumulative mortality at 78 weeks. Small decreases in body weight, relative to controls were observed in males, but were < 10%. <u>Non-neoplastic effects</u> Increased incidence of calculi in the gall bladder in both sexes in all treated groups. <u>78.5/72.6 mg/kg bw/d</u> Increased incidence of hepatocellular hypertrophy in both sexes (males 8/52, females 6/52). <u>793/732 mg/kg bw/d</u> Increased incidence of glomerulonephritis in females (19/52). Increased relative liver weight in both sexes (males 14%, females 21%). Increased incidence of hepatocellular hypertrophy in both sexes (males 12/52, females 17/52). Increased incidence of hypertrophy of the seminal vesicle (17/31) and coagulating gland (16/31) in terminal kill animals only).
28-day oral (dietary) Non guideline (similar to OECD 409) GLP Batch 20111222-1 Purity 97.27% Anonymous (2013j) DAR B.6.3.1 CLP guideline value for classification (mg/kg bw/d)  Cat 1 = 30	Dog, Beagle (HRA) 2/sex/group	0, 200, 2000, 20000 ppm  Equivalent to Males: 0, 7, 69, 709 mg/kg bw/d Females: 0, 7, 72, 711, mg/kg bw/d	No treatment-related deaths or overt signs of toxicity in any dose group <u>7 mg/kg bw/d:</u> No adverse effects <u>69/72 mg/kg bw/d:</u> No adverse effects <u>709/711 mg/kg bw/d:</u> Kidney tubular regeneration and urinary cast in a single male.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Method Guideline, Deviation(s) from the guideline (if any)	Species Strain Sex no/group	Dose levels duration of exposure	Relevant adverse effects
Cat 2 = 300			
90-day oral (dietary) OECD 409 GLP Batch 20111222-1 Purity 97.27% Anonymous (2013k) DAR B.6.3.2 CLP guideline value for classification (mg/kg bw/d) Cat 1 = 10 Cat 2 = 100	Dog, Beagle (HRA) 4/sex/group	0, 200, 2000, 20000 ppm Equivalent to Males: 0, 6.47, 64.6, 699mg/kg bw/d Females: 0, 6.98, 65.3, 670 mg/kg bw/d	No treatment-related deaths or overt signs of toxicity in any dose group <u>6.47/6.98 mg/kg bw/d:</u> No adverse effects. <u>64.6/65.3 mg/kg bw/d:</u> No adverse effects. <u>699/670 mg/kg bw/d:</u> Increased relative adrenal weight in males (34%). Ocular opacity and keratitis in a single female.
1 year oral (dietary) MAFF 12-Nousan-No. 8147, 2-1-14 (2000) GLP Batch 20111222-1 Purity 97.27% Anonymous (2014d) DAR B.6.5 CLP guideline value for classification (mg/kg bw/d)	Dog Beagle (HRA) 4/sex/group	0, 100, 1000, 10000 ppm Equivalent to Males: 0, 2.91, 28.1, 321 mg/kg bw/d Females: 0, 2.62, 28.5, 295 mg/kg bw/d	No treatment-related deaths or overt signs of toxicity in any dose group <u>2.91/2.61 mg/kg bw/d:</u> No adverse effects. <u>28.1/28.5 mg/kg bw/d:</u> No adverse effects. <u>321/295 mg/kg bw/d:</u> Increased relative liver weight in males (20%). Enlargement of the internal iliac lymph node in males with accompanying adverse histopathology (2/4).

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Method Guideline, Deviation(s) from the guideline (if any)	Species Strain Sex no/group	Dose levels duration of exposure	Relevant adverse effects
Cat 1 = 2.5 Cat 2 = 25			
28-d dermal OECD 410 GLP Batch 20111222-1 Purity 97.27% Anonymous (2013I) DAR B.6.3.3 CLP guideline value for classification (mg/kg bw/d) Cat 1 = 20 Cat 2 = 200	Rat, SD 10/sex/group	0, 100, 300, 1000 mg/kg bw/d 6 hours/day	No treatment-related deaths or overt signs of toxicity in any dose group  <u>100 mg/kg bw/d:</u> No adverse effects.  <u>300 mg/kg bw/d:</u> No adverse effects.  <u>1000 mg/kg bw/d:</u> Increased relative liver weight in females (9%) Increased relative adrenal weight in males (15%). Acinar cell apoptosis and inflammatory cell infiltration in the pancreas in both sexes (m 3/6, f 1/6).

**Rat**

28 day study

In a preliminary range-finding study intended to determine appropriate dose levels for a subsequent 90 day study, Wistar rats were fed dietary concentrations of tolpyralate at up to 20000 ppm for a period of 28 days.

Increased relative liver weights were noted in males at dose levels  $\geq 45.9$  mg/kg bw/d and females at  $\geq 496$  mg/kg bw/d with associated centrilobular hypertrophy only observed in males at 1799 mg/kg bw/d. Increased deposition of hyaline droplets in the proximal tubular cells in the kidney and hypertrophy of follicular cells in the thyroid were observed in males at  $\geq 4.49$  mg/kg bw/d. Single acinar cell necrosis in the pancreas was observed in males treated at  $\geq 447$  mg/kg bw/d and females at 1907 mg/kg bw/d. Opacity and keratitis were recorded in the eye in males at  $\geq 4.49$  mg/kg bw/d and females at  $\geq 46.9$  mg/kg bw/d

90-day study

In a 13 week dietary study, tolpyralate was administered to the groups of Wistar rats, up to a maximum concentration of 20000 ppm. Adverse treatment related effects were observed in the eye, liver, kidney, pancreas and thyroid. Increased absolute and relative liver weight was observed in both sexes at doses  $\geq 133$  mg/kg bw/d, this was accompanied by hepatocellular hypertrophy in males receiving 1363 mg/kg bw/d, the highest tested dose. An increase in kidney weight was observed in males receiving  $\geq 133$  mg/kg bw/d and females at 1647 mg/kg bw/d. Increased incidence of deposition of hyaline droplets in the proximal tubular cells in the kidney was observed in males treated at  $\geq 1.34$  mg/kg bw/d. Follicular cell hypertrophy in the thyroid was observed in both sexes at  $\geq 133$  mg/kg bw/d. Single acinar cell necrosis in the pancreas was

## ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

observed in males treated at  $\geq 133$  mg/kg bw/d and in females at 1647 mg/kg bw/d. Ocular opacity and keratitis were observed in both sexes  $\geq 133$  mg/kg bw/d.

### 1 year dietary

The long term toxicity of tolpypalate was investigated in a 52 week dietary study in the rat. The test item was administered to groups of Wistar rats, up to a maximum concentration 10000 (males) or 20000 ppm (females). This study was conducted concurrently to the 2 year rat carcinogenicity study, in the same species, strain and test facility. However, they were completely separate studies; this one year study cannot be viewed as a 'satellite' group within the 2 year study.

### *Clinical signs*

There were no treatment related changes in mortality in either sex at any dose level. Treatment related clinical signs of toxicity were decreases in body weight (10-14% relative to controls) in both sexes at  $\geq 482$  mg/kg, loss of fur in males at  $\geq 0.925$  mg/kg bw/d and in females at  $\geq 126$  mg/kg bw/d. Opacity of the eye was noted in clinical observations in both sexes at doses  $\geq 97.0$  mg/kg bw/d.

### *Ophthalmology*

Corneal opacity and neovascularisation were significantly increased in both sexes at  $\geq 97.0$  mg/kg bw/d.

### *Urinalysis*

Urinalysis showed increased urinary ketones and decreased urinary pH in both sexes at doses  $\geq 97.0$  ppm, these effects are regarded as treatment related but are of unknown toxicological significance.

### *Organ weights*

Relative liver weight was significantly increased by 10-16% relative to controls in both sexes as doses  $\geq 97.0$  mg/kg bw/d. Significant increases in relative kidney weight were observed in males at  $\geq 97.0$  mg/kg bw/d and in females at 1336 mg/kg bw/d.

### *Gross pathology*

An increased incidence of opacity of the eye was observed in both sexes at doses  $\geq 97.0$  mg/kg bw/d. Statistically significant increases in the incidence of loss of fur were observed in both sexes at dose levels  $\geq 97.0$  mg/kg bw/d, consistent with the clinical observations. Increased incidence of soiled fur (genital) was observed in females at dose levels  $\geq 126$  mg/kg bw/d and is considered to be treatment-related, but is of unknown toxicological significance.

### *Histopathology*

A significant increase in the incidence of fatty liver, characterised by fatty changes to centrilobular hepatocytes, was observed in males at doses  $\geq 97.0$  mg/kg bw/d. No microscopic liver effects were observed in females. A dose related increase in pancreatic acinar cell fibrosis (single cell) was observed in males at  $\geq 0.925$  mg/kg. Increased incidence of pancreatic acinar cell necrosis was observed in both sexes at  $\geq 97.0$



## ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

mg/kg bw/d. A significant increase in the incidence of adverse pathology in the kidney (renal tubule; basophilic change) was observed in males at  $\geq 97.0$  mg/kg bw/d. Increased incidence of thyroid follicular cell hypertrophy was observed in both sexes at doses  $\geq 97.0$  mg/kg bw/d. A significant increase in vacuolation of the cerebellum was observed in males at  $\geq 97.0$  mg/kg bw/d and in females at  $\geq 1336$  mg/kg bw/d. A significant increase in keratitis was observed in the eye in both sexes as doses  $\geq 97.0$  mg/kg bw/d. The effects were observed in 20/21 males and 21/21 females in both dose groups.

### 2 year dietary

The chronic toxicity of tolpyralate was investigated in a combined chronic toxicity / carcinogenicity study in the rat. Neoplastic findings are discussed in section 10.9. Effects relevant to STOT-RE are discussed here.

### *Organ Weights*

Absolute brain weights were reduced by 8% and 7% in males receiving 83.8 and 426 mg/kg bw/d respectively. No decrease in relative brain weights was recorded. In the absence of an effect on relative brain weight or a comparable effect in females, this is not considered to be a relevant finding. Relative liver weight was significantly increased in males by 23% and 25% when compared to control animals at 83.8 and 426 mg/kg bw/d respectively. Relative kidney weight was significantly increased in males at 83.8 and 426 mg/kg bw/d by 11% and 17% respectively when compared to control animals. No relevant changes in organ weights were observed in females.

### *Haematology*

There were increases in WBC counts in males in the top two dose groups, most notably in total leukocyte count which was increased by 31% and 60% relative to controls at dose levels of 83.8 and 426 mg/kg bw/d respectively. This effect is of unclear toxicological significance, but may be secondary to an inflammatory response following chronic administration of the test item and is not considered to be indicative of specific toxicity to the blood.

### *Gross pathology*

Relevant gross findings were ocular opacity in the majority of animals at dose levels of  $\geq 83.8$  mg/kg bw/d. In 2 and 6 males in the groups receiving 83.8 and 426 mg/kg bw/d respectively, masses were observed in the eyes. A trend of increased incidence of luminal dilation of the bile duct was observed in both sexes at doses of  $\geq 0.765/1.01$  mg/kg bw/d, this effect was only statistically significant in males at 83.8/108 mg/kg bw/d and occurred with low incidence (maximum of 5/51 animals) and was not strongly dose dependent, consequently this is not considered to be a relevant finding. In males a dose related increase in the observation of coarse surface of the kidney was recorded at doses  $\geq 83.8$  mg/kg bw/d, additionally a statistically significant increase in the incidence of kidney cysts was observed in males receiving 426 mg/kg bw.

### *Histopathology*

A significant increase in the incidence of haematopoiesis in the bone marrow was observed in males at dose levels of  $\geq 83.8$  mg/kg bw/d. This effect was statistically significant in bone marrow taken from the femur when all animals (found dead, killed *in extremis* and terminal sacrifice) were considered. This effect was also observed in the bone marrow taken from the sternum, achieving statistical significance at doses  $\geq 83.8$  mg/kg bw/d, in the animals found dead or killed in extremis only, although the control incidence in this group was low. This effect was observed inconsistently and at low incidence and is not indicative of specific toxicity to the bone marrow.

Increased incidence of pancreatic acinar cell atrophy/fibrosis was observed in both sexes at doses  $\geq 83.8/108$  mg/kg bw/d, affecting 22 and 23 females and 46 and 47 males at 83.8/108 and 426/554 mg/kg bw/d respectively. A significant increase in the observation of fat infiltration in the pancreas was observed in males at  $\geq 83.8$  mg/kg bw but was not evident in females. A trend of increased incidence of pancreatic acinar cell necrosis was observed in both sexes, occurring at low incidence in males, affecting 1 and 2 animals at

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE**

83.8 and 426 mg/kg bw/d respectively compared to zero incidences in control animals. Increased incidence of acinar cell necrosis was also observed in females and was significantly increased at the highest dose level, and was observed in 16/51 animals compared to 7/51 controls.

A treatment related increase in the incidence of chronic nephropathy was observed in the kidney in both sexes. In males a dose response was evident with incidence increased over controls at doses  $\geq 0.765/1.01$  mg/kg bw/d but statistical significance was not achieved at any dose level. In females the effect was more apparent with a statistically significant increase observed at both 108 mg/kg bw/d and 554 mg/kg bw/d.

Increased incidence of colloid degeneration in the thyroid was recorded in both sexes, and was significantly increased relative to control animals at  $\geq 108$  mg/kg bw/d in females and at 426 mg/kg bw in males. An increased incidence of follicular cell hyperplasia was recorded in males at  $\geq 108$  mg/kg bw/d but at low incidence and without statistical significance.

A clear increase in the incidence of vacuolation of the molecular layer of the cerebellum was observed in both sexes at doses  $\geq 83.8/108$  mg/kg bw/d, affecting 40 - 44 animals in each group compared to 8 and 9 incidences in male and female controls respectively.

A treatment related increase in the number of observations of degeneration of the sciatic nerve was recorded in both sexes at doses  $\geq 83.8/108$  mg/kg bw/d.

Consistent with macroscopic findings, a significant increase in the incidence of keratitis in the eye was observed in all animals at doses  $\geq 83.8/108$  mg/kg bw/d.

**Table 36: Summary of non-neoplastic histopathological findings in the 90 day repeated dose toxicity study in the rat.**

Organ: Lesion	Sex and dose level (mg/kg bw/d)									
	Male					Female				
	0	0.196	0.765	83.8	426	0	0.255	1.01	108	554
Bone marrow (femur):[N=]	[51]	[51]	[51]	[51]	[51]	[51]	[18a]	[15a]	[15a]	[51]
Hematopoiesis, increased	13	14	16	20	23*	18	7	4	2	17
Muscle [N=] (m. triceps surae): Atrophy, striated muscle fiber	[51]	[51]	[51]	[51]	[51]	[51]	[18a]	[15a]	[15a]	[51]
	6	2	8	9	14*	0	0	0	1	1
Pancreas: [N=]	[51]	[51]	[51]	[51]	[51]	[51]	[51]	[51]	[51]	[51]
Atrophy/fibrosis, acinar cell	14	12	14	46**	47**	10	10	6	23**	22**
Infiltration, fat	3	2	0	26**	24**	11	6	7	7	10
Necrosis, acinar cell, single cell	0	0	0	1	2	7	6	6	7	16*
Kidney: [N=]	[51]	[51]	[51]	[51]	[51]	[51]	[51]	[51]	[51]	[51]
Nephropathy, chronic	38	38	42	45	45	6	4	9	24**	18**
Thyroid: [N=]	[51]	[51]	[51]	[51]	[51]	[51]	[51]	[51]	[51]	[51]
Degeneration, colloid										

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Organ: Lesion	Sex and dose level (mg/kg bw/d)									
	Male					Female				
	0	0.196	0.765	83.8	426	0	0.255	1.01	108	554
Hyperplasia, C-cell	9	11	8	15	25**	0	3	1	16**	23**
Hyperplasia, follicular cell	9	11	9	4	7	14	12	10	3**	3**
	3	2	3	8	6	1	0	0	2	2
Cerebellum: [N=]	[51]	[51]	[51]	[51]	[51]	[51]	[51]	[51]	[51]	[51]
Vacuolation, molecular layer	8	5	9	40**	44**	9	13	11	41**	44**
Nerve (sciatic): [N=]	[51]	[51]	[51]	[51]	[51]	[51]	[51]	[51]	[51]	[51]
Degeneration, nerve fiber	7	6	6	13	22**	4	2	3	12*	15**
Eye: [N=]	[51]	[51]	[51]	[51]	[51]	[51]	[51]	[51]	[51]	[51]
Keratitis	4	2	4	51**	51**	0	2	1	51**	51**

[N]: Number of animals examined at the site. Figures represent the incidence of the lesion.

a: Not subjected to statistical evaluation because the organs of terminal kill animals without macroscopic lesions were not histopathologically examined.

\*,  $p \leq 0.05$ ; \*\*,  $p \leq 0.01$  (by Fisher's exact probability test).

### 28 day dermal

The repeat dose toxicity of tolpyralate via the dermal route was investigated in a 28 day study in the rat. Minimal adverse effects were observed in the adrenals liver and pancreas at the highest tested dose of 1000 mg/kg bw/day.

### Mouse

#### 90 day dietary

In a study of sub chronic toxicity, CrIj:CD1(ICR) mice were administered tolpyralate in the diet, up to a maximum concentration of 7000 ppm for a period of 13 weeks. Adverse treatment related effects were decreased platelet count and histopathological changes in the thyroid (follicular cell hypertrophy) in males at 1056 mg/kg bw/d. Centrilobular hepatocellular hypertrophy was observed in males treated at  $\geq 284$  mg/kg bw/d and females treated at 1176 mg/kg bw/d, and is considered to be indicative of a non-adverse adaptive response, in the absence of significant effect on liver weight or other indication of liver damage. Total bilirubin was decreased in a dose dependent manner in both sexes at all dose levels, but is not indicative of an adverse effect of the test item. Hepatocellular necrosis was observed in a single female at 1176 mg/kg bw/d.

#### 18 month dietary

The chronic toxicity of tolpyralate was investigated in a combined chronic toxicity / carcinogenicity study in the mouse. Neoplastic findings are discussed in section 10.9. Effects relevant to STOT-RE are discussed here.

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE**

*Organ weights*

A significant increase in relative liver weight of 30% was identified in females receiving 732 mg/kg bw/d. This effect was less obvious in males with relative liver weights being increased by 14% at 793 mg/kg bw/d without statistical significance.

*Histopathology*

An increase in the incidence of calculi in the gallbladder was evident in both sexes at dose levels  $\geq 7.37/7.25$  mg/kg bw/d.

A dose related increase in glomerulonephritis was observed in females that was statistically significant at 732 mg/kg bw/d.

An increased incidence in hepatocellular hypertrophy in the centrilobular region was recorded in both sexes at doses  $\geq 78.5/72.6$  mg/kg bw/d.

In males a dose related increase in hypertrophy of both the seminal vesicle and the coagulating gland was observed in animals which survived until study termination, achieving statistical significance at the top dose level. This was not evident when all animals were considered but may be toxicologically relevant.

**Table 37: Summary of non-neoplastic findings in the 18 month carcinogenicity study (oral route)**

	Sex and dose level (ppm)							
	Male				Female			
Organ/lesion	0	70	700	7000	0	70	700	7000
Number of animals examined	[52]	[52]	[51] <sup>a</sup>	[52]	[52]	[52]	[52]	[52]
Gallbladder [N=]	[52]	[52]	[51]	[52]	[52]	[52]	[52]	[52]
Calculi	6	14*	18**	16*	4	11*	17**	20**
Kidney [N=]	[52]	[27] <sup>c</sup>	[29] <sup>c</sup>	[52]	[52]	[52]	[52]	[52]
Glomerulonephritis	14	0	3	8	7	8	12	19**
Liver [N=]	[52]	[52]	[51]	[52]	[52]	[52]	[52]	[52]
Hypertrophy, hepatocyte, centrilobular	2	4	8*	12**	0	0	6*	17**
Seminal Vesicle (Terminal Kill) [N=]	[35]	[32]	[33]	[31]	-	-	-	-
Hypertrophy	9	13	15	17*	-	-	-	-
Coagulating Gland (Terminal Kill)[N=]	[35]	[32]	[33]	[31]				
Hypertrophy	10	10	14	16*				

[N=]: Number of animals examined at the site. Figures represent the incidence of the lesion.

\*,  $P \leq 0.05$ ; \*\*,  $P \leq 0.01$  (Fisher's exact probability test).

a: One animal (Animal no. 113) was excluded from the effective number of animals because of accidental

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

death.

c: Examined on the animals that showed macroscopic lesions at terminal kill and on all the animals killed *in extremis* or found dead during the study. Not subjected to statistical analysis.

### **Dog**

#### *90 day dietary*

The sub chronic toxicity of tolpyralate *via* the oral route was investigated in a dietary study conducted in the dog over a period of 13 weeks. In males, both the left and total relative adrenal weights were increased by approximately 30% at the highest tested dose of 699 mg/kg bw/d, when compared to control animals. Ocular opacity and keratitis was observed in a single female at 670 mg/kg bw/d.

#### *1 year dietary*

The repeated dose oral toxicity of tolpyralate was investigated in a dietary study performed in the dog over a period of 52 weeks. Animals were administered the test item in the diet at concentrations of 0, 100, 1000 and 10000ppm, corresponding to 2.91, 28.1 and 321 mg/kg/day in males and 2.62, 28.5 and 295 mg/kg/day in females. The test item was well tolerated and produced no mortalities. Clinical signs of toxicity were body weight loss and suppressed body weight gain at the highest tested dose.

A significant increase in relative liver weight (approximately 20% relative to controls) was observed in males at 321 mg/kg bw/d, this effect was not seen in females. Enlargement of the internal iliac lymph node was observed in two males at 321 mg/kg bw/d, accompanied with corresponding microscopic changes to the tissue. This effect was not observed at any other dose level or in females and therefore, is not considered to represent an adverse effect of the test item.

### **Short summary and overall relevance of the provided information on specific target organ toxicity – repeated exposure**

Information relating to the potential for tolpyralate to cause specific organ toxicity following repeated exposure is available from a range of repeated dose toxicity studies, conducted in the rat, mouse and dog over a range of durations and *via* both the oral and dermal routes. Findings that are considered to be treatment related adverse effects and are relevant to humans are discussed below.

#### *Eye*

Adverse effects on the eye were observed in all studies conducted in the rat. Typically, ocular opacity and associated keratitis were observed in all oral studies conducted in the rat. In the 28 day oral study, adverse effects on the eye were observed at all tested dose levels (i.e.,  $\geq 4.49$  mg/kg bw/d). In the 90 day dietary study ocular effects were recorded at doses  $\geq 133$  mg/kg bw/d. In the 1 year study, eye effects were observed from 97 mg/kg bw/d. In the 2 year chronic toxicity / carcinogenicity study, eye effects were observed at doses  $\geq 83.8$  mg/kg bw/d. Effects in the eye were also observed in both the parents and offspring in the 2-generation study. Corneal opacity and keratitis were observed in both sexes at 54.9/59.3 mg/kg bw/day in both the P and F1 parents. A single incidence of corneal opacity and keratitis was observed in P and F1 males treated with 2.7 mg/kg bw/d tolpyralate. In the offspring, corneal opacity was noted in both the F1 and F2 generations of the high dose group.

With the exception of a single incidence of ocular opacity in the 90 day study in the dog, in one female in the top dose group, there were no effects on the eye in other species.

#### *Kidney*

## ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

In the rat an increased incidence of hyaline deposition was observed in males in the 28 and 90 day repeat dose studies and in the 2 generation reproductive toxicity study, the lowest dose at which this effect was observed was 1.34 mg/kg bw/d (in the 90-day study). However, this finding was not observed in the 2-year carcinogenicity study at any dose. The hyaline deposition is likely to be associated with  $\alpha_2\mu$ -globulin, although this has not been confirmed and therefore cannot be dismissed as being of no relevance to humans. In all studies in the rat, increased relative kidney weight was observed. The lowest dose at which this effect was observed was 54.9 mg/kg bw/d (in the parents of the 2-generation study). Further, in the 2-generation reproductive toxicity study, a variety of adverse kidney effects were observed in parental animals at the top dose of 54.9 mg/kg bw/d, including; basophilic change to the renal tubule, calcification, cysts, hyaline deposition and drug induced nephropathy. In both generations of offspring a variety of gross findings were observed in the kidney, including; pale colour, pelvic dilation and white material in the pelvic space/papilla also at the top dose level of 59.3 mg/kg bw/d. In the 1 year study basophilic change was observed in males from 97 mg/kg bw/d. In the 2-year carcinogenicity study, chronic nephropathy in the kidney of males was observed from 0.765 mg/kg bw/day, but was not statistically significant at any dose. The effect was more apparent in females, with a statistically significant increase observed at both 108 mg/kg bw/d and 554 mg/kg bw/d.

In the chronic toxicity study in the mouse, an increased incidence of glomerulonephritis was recorded in females at 732 mg/kg bw/d. Other than a single incidence of tubular regeneration in the 28-day range finding study in the dog which is unlikely to represent a treatment related finding, there were no signs of kidney toxicity in any other species.

### *Liver*

The predominant adverse finding in the liver was increased relative liver weight, occurring in most studies in the rat. Increases in relative liver weight in excess of 10% were observed at dose levels of 54.9 mg/kg bw/d (in the 2-generation study). At high doses some evidence of hepatocellular hypertrophy was observed. In the mouse, hepatocellular hypertrophy was observed in both the 90 day and 18 months studies at dose levels  $\geq 72.6$  mg/kg bw/d, increased liver weight was also observed at high dose levels (732 mg/kg bw/d) and hepatocellular necrosis was observed in a single female in the 90 day study at 1176 mg/kg bw/d. Increased relative liver weight was also observed in the 1 year dog study in males at the highest dose of 321 mg/kg bw/d.

### *Pancreas*

Pancreatic acinar cell fibrosis and/or necrosis were observed in most studies conducted in the rat. In some cases pancreatic fat infiltration was also observed. The lowest dose at which this effect was observed was seen in the 1 year study in the rat in which the start of a trend of increased incidence of pancreatic acinar cell fibrosis was observed in males from 0.925 mg/kg bw/d, affecting 7/21 males in this group, there was no evidence of necrosis in this group. In all other studies in the rat, including the 2 year study that was conducted concurrently to the 1 year study and under the same conditions, there was no evidence of this effect at dose levels relevant for classification. It is concluded that the observation of this effect at 0.925 mg/kg bw/d in the 1 year study is anomalous. In addition, the effect was marginal at this dose level, was not statistically significant and was not accompanied by any indication of necrosis.

### *Cerebellum*

Vacuolation of the cerebellum was observed in the rat, in both sexes in both the 1 and 2 year chronic toxicity studies, at dose levels of  $\geq 83.8$  mg/kg bw/d. This was not observed in any other studies in the rat or in any other species

### *Sciatic nerve*

Degeneration of the sciatic nerve was observed in the rat, in both sexes in the 2 year chronic toxicity study. This effect was recorded in females at dose levels of  $\geq 108$  mg/kg bw/d and in males at 426 mg/kg bw/d. This was not observed in any other studies in the rat or in any other species

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

*Gall bladder*

In the 18 month chronic study in the mouse, an increased incidence of calculi in the gall bladder was observed at all dose levels. This was not observed in any other studies in the mouse or in any other species and is of minimal toxicological significance.

**10.12.1 Comparison with the CLP criteria**

Table 38 below summarises the effects occurring at or below the relevant guidance values for classification with STOT RE.

**Table 38: Summary of effects seen following repeated exposure to tolpyralate at doses relevant for classification.**

Study	Effects occurring below the guidance value for classification in category 1	Effects occurring below the guidance value for classification in category 2
Rats (Wistar), 28 days  Guidance values for classification <i>Cat 1 ≤ 30 mg/kg bw/day</i> <i>30 &lt; Cat 2 ≤ 300 mg/kg bw/day</i>	4.94/4.98 mg/kg bw/day  Hyaline deposition in kidney in 1/6 males.  Thyroid follicular cell hypertrophy in 2/6 males.  Ocular opacity and keratitis in 1/6 males.	≥45.9/46.9 mg/kg bw/day  Hyaline deposition in kidney in males.  Increased relative liver weight in males (16%).  Thyroid follicular cell hypertrophy in males.  Ocular opacity and keratitis in both sexes.
Rats (Wistar), 90 days.  <i>Cat 1 ≤ 10 mg/kg bw/day</i> <i>10 &lt; Cat 2 ≤ 100 mg/kg bw/day</i>	1.34/1.58 mg/kg bw/day  Hyaline deposition in kidney in 2/10 males.	It is noted that the next dose was 133/159 mg/kg bw/day. Effects seen at this dose level included;  Hyaline deposition in kidney in 2/10 males.  Ocular keratitis in 7/10 males and 10/10 females  Increased relative liver weight in males (25%)  Increased relative kidney weight males (10%)  Thyroid follicular cell hypertrophy in both sexes (males 9/10, females 4/10).
Rats (Wistar), 1 year  <i>Cat ≤ 1 2.5 mg/kg bw/day</i> <i>2.5 &lt; Cat 2 ≤ 25 mg/kg bw/day</i>	0.925/1.18 mg/kg bw/d  Pancreatic acinar cell fibrosis in 7/21 males	It is noted that the next dose was 97/126 mg/kg bw/day. Effects seen at this dose level included;  Ocular keratitis in 20/21 males and 21/21 females  Increased relative liver weight in both sexes (16% in males, 10% in females)  Fatty change in centrilobular hepatocytes in males (11/21)

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Study	Effects occurring below the guidance value for classification in category 1	Effects occurring below the guidance value for classification in category 2
		<p>Increased relative kidney weight in both sexes (17% in males, 7% in females)</p> <p>Basophilic change to renal tubule in males (8/21)</p> <p>Pancreatic acinar cell necrosis in males (7/21)</p> <p>Pancreatic acinar cell fibrosis in males (11/21)</p> <p>Vacuolation of cerebellum in males (6/21)</p>
<p>Rats (Wistar), 2 years</p> <p><i>Cat 1 ≤ 1.25 mg/kg bw/day</i></p> <p><i>1.25 &lt; Cat 2 ≤ 12.5 mg/kg bw/day</i></p>	<p>None</p>	<p>None</p>
<p>Rats (SD), 2 generation study</p> <p><i>Cat 1 ≤ 10 mg/kg bw/day</i></p> <p><i>10 &lt; Cat 2 ≤ 100 mg/kg bw/day</i></p>	<p><u>P</u></p> <p>Increased liver weight in both sexes (8%)</p> <p><u>F1 parents</u></p> <p>Ocular keratitis in one animal of each sex</p> <p><u>F1 pups</u></p> <p>None</p> <p><u>F2 pups</u></p> <p>None</p>	<p><u>P</u></p> <p>Ocular opacity and keratitis in both sexes</p> <p>Increased liver (16% males, 13% females), kidney (13% males) and testis (10%) weight.</p> <p>Decreased brain weight (6% females)</p> <p><u>F1 parents</u></p> <p>Ocular opacity and keratitis.</p> <p>Decreased prostate weight (21%).</p> <p>Increased Liver (22% male, 13% female), Kidney (16% male, 7% female), Testis (12%), Epididymides (13%), Seminal vesicle (19%) weights.</p> <p>Increased incidence of microscopic kidney abnormalities;</p> <p>Basophilic change to renal tubule (10/24 males, 4/24 females)</p> <p>Calcification (7/24 males, 8/24 females)</p> <p>Cortical cysts (6/24 males)</p> <p>Hyaline droplets (5/24 males)</p> <p>Nephropathy (11/24 males, 4/24 females)</p>



ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Study	Effects occurring below the guidance value for classification in category 1	Effects occurring below the guidance value for classification in category 2
		<p><u>F1 pups</u></p> <p>Increased incidence of gross kidney lesions; Pale colour Pelvic dilation White material in pelvic space/papilla</p> <p><u>F2 pups</u></p> <p>Increased incidence of gross kidney lesions Pale colour Pelvic dilation White material in pelvic space/papilla</p>
<p>Mouse (CrljCD1), 90 days.</p> <p><i>Cat 1</i> ≤ 10 mg/kg bw/day</p> <p>10 &lt; <i>Cat 2</i> ≤ 100 ≤ mg/kg bw/day</p>	None	None
<p>Mouse (CrljCD1), 18 month</p> <p><i>Cat 1</i> 1.7 ≤ mg/kg bw/day</p> <p>1.7 &lt; <i>Cat 2</i> ≤ 17 mg/kg bw/day</p>	None	Increased incidence of calculi in the gall bladder in both sexes.
<p>Dog (Beagle- HRA), 28 days</p> <p>Guidance values for classification*</p> <p><i>Cat 1</i> ≤ 30 mg/kg bw/day</p> <p>30 &lt; <i>Cat 2</i> ≤ 300 mg/kg bw/day</p>	None	None
<p>Dog (Beagle- HRA), 90 days</p> <p><i>Cat 1</i> ≤ 10 mg/kg bw/day</p> <p>10 &lt; <i>Cat 2</i> 100 ≤ mg/kg bw/day</p>	None	None
<p>Dog (Beagle- HRA), 1 year</p> <p><i>Cat 1</i> ≤ 2.5 mg/kg bw/day</p> <p>2.5 &lt; <i>Cat 2</i> ≤ 25 mg/kg bw/day</p>	None	None
<p>Rats (Wistar), 28 days (dermal)</p> <p>Guidance values for classification</p> <p><i>Cat 1</i> ≤ 60 mg/kg bw/day</p> <p>60 &lt; <i>Cat 2</i> ≤ 600 mg/kg bw/day</p>	None	None

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Study	Effects occurring below the guidance value for classification in category 1	Effects occurring below the guidance value for classification in category 2
-------	---	---

\*Guidance values for the rat have been used in absence of specific values for the dog, to aid comparison

As described above, information relating to the potential for tolpyralate to cause specific target organ toxicity following repeated exposure (STOT-RE) is available from a range of repeated dose toxicity studies in the rat, mouse and dog *via* both the oral and dermal routes. In addition, information is available from combined chronic and carcinogenicity studies in both the rat and the mouse and in the two-generation reproductive toxicity study in the rat. As shown in the table, effects occurring at dose levels relevant for classification were only observed in the rat.

In the rat, a variety of changes in relative organ weights were observed in both sexes. There were no accompanying adverse histopathological findings in any of the organs in which changes in relative weights were increased, at dose levels relevant for classification. Consequently none of the effects on organ weight represent an effect sufficient for classification for STOT-RE.

In both the 28-day and 90-day studies in the rat an increase in the incidence of thyroid follicular cell hypertrophy was observed in males at dose levels relevant for classification. Whilst this finding is considered to be treatment related it does not represent a significant change affecting function or morphology and, in isolation, is not considered sufficient for classification for STOT-RE.

Ocular opacity and associated keratitis was observed consistently following repeated administration of tolpyralate to rats. These adverse effects are considered to be of significant concern and, in a number of studies, were observed at doses below the relevant guidance values for classification. As summarised at the beginning of Section 10, tolpyralate is considered to be an inhibitor of the enzyme 4-hydroxyphenylpyruvate dioxygenase (HPPD) and as a consequence has the potential to inhibit the catabolic pathway of tyrosine. The Applicant has proposed that inhibition of 4-HPPD resulting in sustained elevation of plasma tyrosine may lead to the effects that have been seen in the eyes of rats give repeated doses of tolpyralate. As ECHA’s Risk Assessment Committee has already seen when considering proposals to classify sulcotrione, mesotrione and tembotrione, these effects are common to substances that inhibit the catabolism of tyrosine and consequently cause significantly elevated levels of this amino acid in the plasma. It has been reported that a plasma tyrosine concentration of 1000 µmol/L must be exceeded before corneal lesions occur in rats (Lewis & Botham, 2013).

The following studies provide some evidence for the inhibition of HPPD by tolpyralate and that this may be related to the observed ocular toxicity. They demonstrate how a single dose of tolpyralate influences plasma tyrosine levels in rats, rabbits and mice, and tyrosine levels in the aqueous humour in rats. One study compares the effects of repeated administration of tolpyralate on the eyes and cerebellum in rats and mice. An *in vitro* study comparing the effect of tolpyralate on rat and human hepatocellular metabolism of tyrosine is also provided.

*(a) Mechanistic studies on the effect of a single administration of tolpyralate*

**Table 39: Summary of mechanistic studies on the effect of a single administration of tolpyralate on plasma tyrosine levels**

Study details	Remarks
Measurement of plasma tyrosine concentration after single-dose oral administration of SL-573 TGAI in rats	No effects on clinical condition or body weight.  In control animals, plasma tyrosine concentration remained in the same

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE**

Study details	Remarks
<p>A single dose (1000 mg/kg bw) of tolpyralate was administered to groups of 5 female rats (CrI:CD(SD)) by oral gavage. Plasma tyrosine concentrations were determined before and at 1, 2, 4, 6, 8, 24, 48 and 72 hours after administration. One group of female rats was used per time point.</p> <p>Concurrent control groups of 5 female rats were performed</p> <p>Anonymous (2013o)</p>	<p>range from before to 72 hours after administration. In the animals treated with 1000 mg/kg tolpyralate, plasma tyrosine concentration was increased to 261.0 µmol/L at 1 hour after administration, compared to 59.4 µmol/L in the control group. It was further increased to 414.2, 603.2, 801.4, and 977.4 µmol/L at 2, 4, 6, and 8 hours after administration, respectively. After it reached a maximum value of 2055.8 µmol/L at 24 hours, at 72 hours post-dosing plasma tyrosine levels were comparable to controls.</p>
<p>Measurement of plasma tyrosine concentration after single-dose oral administration of SL-573 TGAI in mice</p> <p>A single dose (1000 mg/kg bw) of tolpyralate was administered to groups of 5 female mice (CrI:CD1(ICR)) by oral gavage. Plasma tyrosine concentrations were determined before and at 1, 2, 4, 6, 8, 24, 48 and 72 hours after administration. One group of female mice was used per time point.</p> <p>Concurrent control groups of 5 female rats were performed.</p> <p>Anonymous (2013p)</p>	<p>No effects on clinical condition or body weight.</p> <p>In control animals, plasma tyrosine concentration remained in the same range from before to 72 hours after administration. In the animals treated with 1000 mg/kg tolpyralate, plasma tyrosine concentration was increased to 379.4 µmol/L at 1 hour after administration, compared to 87.8 µmol/L in the control group. It was further increased to 526.0, 580.4, 601.2, and 663.0 µmol/L at 2, 4, 6, and 8 hours after administration, respectively. The plasma tyrosine concentrations at 24 and 48 hours post-dosing were 502.0 and 340.8 µmol/L, respectively. At 72 hours post-dosing, plasma tyrosine levels were still higher in the treated group (270.4 µmol/L) compared to the controls (107.8 µmol/L).</p>
<p>Measurement of plasma tyrosine concentration after single-dose oral administration of SL-573 TGAI in rabbits</p> <p>A single dose (1000 mg/kg bw) of tolpyralate was administered to groups of 5 female rabbits (Kbl:NZW) by oral gavage. Plasma tyrosine concentrations were determined before and at 1, 2, 4, 6, 8, 24, 48 and 72 hours after administration. One group of female rabbits was used per time point.</p> <p>Concurrent control groups of 5 female rats were performed</p>	<p>No effects on clinical condition or body weight.</p> <p>In control animals, plasma tyrosine concentration remained in the same range from before to 72 hours after administration. In the animals treated with 1000 mg/kg tolpyralate, plasma tyrosine concentration was increased to 292.6 µmol/L at 1 hour after administration, compared to 95.2 µmol/L in the control group. It was further increased to 415.0, 672.6, 811.0, and 978.8 µmol/L at 2, 4, 6, and 8 hours after administration, respectively. At 24 and 48 hours post-dosing, plasma tyrosine concentrations were 1788.2 and 1053.6 µmol/L, respectively.</p>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Study details	Remarks
Anonymous (2013q)	

Overall, a single oral administration of tolpyralate at 1000 mg/kg bw/d to rats, rabbits and mice caused a clear increase in plasma tyrosine levels compared to controls. The increase was the highest in rats (25-fold), followed by rabbits (20-fold) and then mice (13-fold). These results indicate that rats might be more sensitive to tolpyralate-induced tyrosinemia compared to mice, although it is noted that plasma tyrosine levels were similar to controls after 72 hours in the rat, but were still elevated in mice at this time point.

*(b) Mechanistic study on the effect of repeated administration of tolpyralate (Anonymous, 2016a)*

Tolpyralate was administered to female rats and mice at dietary concentrations of 2000 and 7000ppm respectively, corresponding to mean systemic intakes of 144 mg/kg bw/day and 1089 mg/kg bw/day in rats and mice respectively. Negative and positive control groups were included. The positive control was 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC). This is a known inhibitor of HPPD, used therapeutically to treat humans that suffer from a genetic trait that causes tyrosine deficiency.

**Table 40: Summary of study to investigate the effect of chronic oral administration of tolpyralate and NTBC on the cornea and cerebellum in rats and mice**

Study details	Remarks
52 week dietary study 20 females per group  <u>Rat, Wistar</u> tolpyralate -144 mg/kg bw/day NTBC – 0.06 mg/kg bw/day  <u>Mouse, CD1</u> tolpyralate 1089 mg/kg bw NTBC 14.2 mg kg bw/day  Anonymous (2016a)	<p><b><u>Rat</u></b></p> <p><i>Mortality and clinical signs of toxicity</i></p> <p>There were no treatment related mortalities or covert clinical signs of toxicity in either treated group.</p> <p><i>Terminal plasma tyrosine concentrations (µmol/L)</i></p> <p>Control: 57.8; tolpyralate 1732.5; NTBC 1603.3</p> <p><i>Gross findings</i></p> <p>Increased incidence of rough surface of the cornea, tylosis of the hind limb and accentuated lobular pattern of the liver in both tolpyralate and NTBC treated groups.</p> <p><i>Histopathology</i></p> <p>Increased incidence of keratitis of the cornea (tolpyralate = 18/19 , NTBC =12/20)</p> <p>Increased incidence of vacuolation of the cerebellum (tolpyralate = 16/19 , NTBC =12/20)</p> <p><b><u>Mouse</u></b></p> <p><i>Mortality and clinical signs of toxicity</i></p> <p>There were no treatment related mortalities or covert clinical signs of toxicity in either treated group.</p> <p><i>Terminal Plasma tyrosine concentrations (µmol/L)</i></p>

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Study details	Remarks
	Control 83.4, tolpyralate: 745.2, NTBC 963.4  <i>Gross findings</i>  Increased incidence of abnormal contents and distention of the gall bladder in both treated groups.  <u>Histopathology</u>  No effects in the cornea or cerebellum.

Only female animals were used in this study. Treatment with both tolpyralate and NTBC caused elevated plasma tyrosine in both species when compared to controls. In the rat, control, tolpyralate and NTBC tyrosine levels were 57.8, 1732.5 and 1603.3 µmol/L, respectively. In the mouse, control, tolpyralate and NTBC tyrosine concentrations were 83.4, 745.2 and 963.4 µmol/L, respectively.

In line with the findings of the more conventional studies of repeated dose toxicity, the effects of tolpyralate in the rat were increased incidence of keratitis of the cornea (tolpyralate = 18/19, NTBC =12/20) and increased incidence of vacuolation of the cerebellum (tolpyralate = 16/19, NTBC =12/20). The potential reversibility of these effects was not studied. There were no adverse effects in the eye or brain in the mouse following chronic exposure to tolpyralate or NTBC at the tested dose levels.

Irrespective of the comparable levels of plasma tyrosine seen following tolpyralate and NTBC treatment, both the incidence and severity of the corneal keratitis appeared higher in the rats administered tolpyralate. This may indicate that the effects of tolpyralate on the eye in this study may not have been solely attributable to elevated plasma tyrosine concentration.

(c) *Determination of tyrosine concentrations in rat plasma and aqueous humour following a single oral dose of tolpyralate (Anonymous, 2016b)*

A second study investigated the tyrosine concentration in plasma and the aqueous humour of the eye in the male rat following a single oral dose of tolpyralate. The study was not conducted in accordance with a specific test guideline and does not claim GLP compliance. Groups of 8 male Wistar rats were administered 0, 1, 100 or 1000 mg/kg bw tolpyralate by oral gavage. 24 hours following dose administration the tyrosine concentration was determined in the plasma and in the eye.

**Table 41: Summary of study to determine tyrosine concentration in plasma and aqueous humour of male rats – single oral dose of tolpyralate**

Study details	Remarks																	
Rat, Wistar  8 males/group  0, 1, 100, 1000 mg/kg bw by single gavage   Anonymous (2016b)	<p><u>Effects on tyrosine concentration</u></p> <table border="1" style="margin-left: auto; margin-right: auto;"> <thead> <tr> <th rowspan="2">tolpyralate dose (mg/kg bw)</th> <th colspan="2">Tyrosine concentration (µmol/L)</th> </tr> <tr> <th>Plasma</th> <th>Eye</th> </tr> </thead> <tbody> <tr> <td>0</td> <td>94.1</td> <td>170</td> </tr> <tr> <td>1</td> <td>110.3</td> <td>197</td> </tr> <tr> <td>100</td> <td>1803.6</td> <td>2039</td> </tr> <tr> <td>1000</td> <td>2360.4</td> <td>2413</td> </tr> </tbody> </table>	tolpyralate dose (mg/kg bw)	Tyrosine concentration (µmol/L)		Plasma	Eye	0	94.1	170	1	110.3	197	100	1803.6	2039	1000	2360.4	2413
tolpyralate dose (mg/kg bw)	Tyrosine concentration (µmol/L)																	
	Plasma	Eye																
0	94.1	170																
1	110.3	197																
100	1803.6	2039																
1000	2360.4	2413																

From this study, it is concluded that a single dose of tolpyralate to male rats can cause a significant increase in tyrosine levels in the plasma and in the eye at dose levels ≥100 mg/kg bw. The reversibility of these effects was not explored. A dose of 1 mg/kg bw did not significantly increase tyrosine concentrations when

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

compared to control animals.

(d) Tyrosine metabolism in rat and human hepatocytes; effect of 4-HPPD inhibition by tolpyralate (Yokoyama H, 2016)

Additionally, an *in vitro* metabolism study was conducted in cultured rat and human hepatocytes. Levels of tyrosine and its metabolite DL-4-hydroxyphenylacetic acid (4-HPLA) were measured over the course of 4 hours following the addition 300µmol/L tolpyralate or NTBC in the presence of 100 mg/L L-tyrosine. Mean concentration of both 4-HPLA and tyrosine were measured at 2 and 4 hour time points by LC/MS/MS.

**Table 42: Tyrosine metabolism in rat and mouse hepatocytes: effect of tolpyralate and NTBC**

Study details	Remarks					
<p><i>In vitro</i> primary human and rat hepatocytes</p> <p>300µmol/L tolpyralate or NTBC</p> <p>Yokoyama, H. (2016)</p> <p>Only limited information available - number of replicate samples not known.</p>	<u>Mean tyrosine concentration</u>					
	Species	Hepatocyte Batch Code	Time	Tyrosine concentration (µg/mg protein)		
				Control	tolpyralate (300µmol/L)	NTBC (300µmol/L)
	Rat	UHU	0	58.5	-	-
			2	49.9	50.8	49.7
			4	43.2	48.4	47.0
	Human	PTL	0	73.3	-	-
			2	58.4	62.1	64.3
			4	54.5	57.3	58.1
		FDX	0	97.2	-	-
			2	88.5	94.5	86.2
			4	74.9	85.9	79.7
	<u>Mean 4-HPLA concentration</u>					
	Species	Hepatocyte Batch	Time	4-HPLA concentration (µg/mg protein)		
				Control	tolpyralate (300µmol/L)	NTBC (300µmol/L)
Rat	UHU	0	-	-	-	
		2	0.582	0.615	0.726	
		4	0.730	0.845	0.937	
Human	PTL	0	-	-	-	
		2	1.49	1.60	1.93	
		4	2.37	2.65	2.94	
	FDX	0	-	-	-	

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Study details	Remarks				
		2	2.28	2.55	2.86
		4	3.09	3.77	3.96

In both human and rat hepatocytes the level of tyrosine decreased with time; there was no clear difference between samples treated with tolpyralate or NTBC when compared to controls or between humans and rats. The level of 4-HPLA appeared to increase over time in both species, with more 4-HPLA being detected in the human samples than in the rat. A slight trend towards increased 4-HPLA was observed in samples treated with either tolpyralate or NTBC compared to controls, possibly indicating inhibition of 4-HPPD, but this is considered inconclusive. The relevance of these findings is unclear and, owing to lack of methodological details, the study is considered to be of limited value.

Although the findings of this last study are somewhat inconclusive, the observation from the other studies that tolpyralate treatment can increase circulating tyrosine levels in rats and mice (and indeed rabbits) is consistent with the view that this substance inhibits HPPD. It appears that the rat, especially the male rat, is more sensitive than the mouse. However, these studies do not provide a clear picture of the relative sensitivity of humans to rats.

Humans who have chronically elevated plasma tyrosine levels (e.g. through HPPD inhibition) are known to exhibit ocular effects (Ahmad *et al.*, 2002; Lock *et al.*, 2006; Wisse *et al.*, 2012, Schauwvlieghe *et al.*, 2013). Therefore, although the rat is clearly a sensitive species, tolpyralate could cause similar effects in humans. It is generally accepted that humans are less sensitive to the effects of inhibition of 4-HPPD than rats, owing to species differences in alternative metabolic pathways (see also the introduction to this subject at the beginning of Section 10). However, there is insufficient information available to make a comparison of the relative potency of tolpyralate in rats and humans with respect to impact on plasma tyrosine levels. Consequently, it is concluded that the hazardous effects of tolpyralate observed experimentally in rats are of relevance to humans. In the rat studies, effects on the eyes were generally observed only at dose levels relevant for classification in Category 2, with only the finding of keratitis in 1/6 males in the 28-day dietary study matching the criteria for a Category 1 classification. Therefore, it is proposed that these effects most appropriately meet the criteria for classification in STOT RE Category 2.

Hyaline deposition in the kidney of males rats was noted in the 28-day, 90-day studies and in the F1 parents of the 2-generation study. Whilst it is likely this is associated with a<sub>2</sub>u-globulin, this has not been confirmed and this finding cannot be dismissed as being of no relevance to humans. In the 2 generation reproductive toxicity in the rat, a range of histopathological abnormalities were observed in the kidney in both sexes of the parents; including basophilic change to renal tubule, calcification, cortical cysts, hyaline droplets and nephropathy, all at the highest dose level of 54.9 mg/kg bw/d. Effects were also observed in the kidney of the F1 and F2 offspring and included pale colour, pelvic dilation and white material in pelvic space/papilla. The hyaline deposition was noted at doses relevant for classification with STOT-RE 1 in both the 28- and 90-day studies. However, it is noted that the effect did not occur in the 2-year carcinogenicity study at doses relevant for classification. Given the low incidence of the hyaline deposition in the low dose groups of the 28- and 90-day studies (1/6 and 2/10 males respectively), the fact that this was not seen in the 2-year study and the fact that other kidney effects were only observed at higher doses, it is proposed that these effects also support classification in STOT-RE Category 2.

### 10.12.2 Conclusion on classification and labelling for STOT RE

<b>Classification in Category 2 – H373 – may cause damage to eyes and kidneys through</b>
---

prolonged or repeated exposure.

## **RAC evaluation of specific target organ toxicity – repeated exposure (STOT RE)**

### **Summary of the Dossier Submitter’s proposal**

The DS proposed classification with STOT RE 2 (eyes, kidneys) based on increased incidence of various kidney effects and ocular opacity associated with keratitis in the rat studies.

The DS also discussed findings in the liver, pancreas, cerebellum, sciatic nerve and gall bladder but did not consider them sufficient for classification.

### **Comments received during public consultation**

3 MSCAs commented on this hazard class.

2 MSCAs supported the proposed classification in Category 2 for effects on the eye and the kidney. The third MSCA, while supporting classification for eye and kidney effects, requested Category 1 because ocular effects occurred below the guidance value (GV) for STOT RE 1 in the 28-day and 2-generation rat studies. The DS replied that due to the low incidence of ocular effects below the GV for Category 1, Category 2 is more appropriate.

All three MSCAs pointed out the very large dose spacing (a 100-fold interval) in several rat studies. As a result, effects on several other organs below the GVs for classification cannot be excluded. The DS agreed that the dose spacing was very large and that effects on some organs below the GVs for classification cannot be excluded. However, they decided not to classify in the absence of evidence of an adverse effect below the GVs.

One MSCA proposed to additionally classify for effects on the thyroid based on increased incidence of follicular cell hypertrophy in the rat below the GVs for classification. The DS explained that whilst the finding is treatment-related, it does not represent a significant change affecting function or morphology and in the absence of other thyroid histopathological findings is not considered sufficient for classification.

### **Additional key elements**

#### ***Additional non-guideline 90-day study in the rat***

A very brief summary of an additional, non-guideline 90-day study in the rat has been provided by Industry. A data sheet showing  $\alpha_2$ -globulin accumulation in the kidney of male rats was submitted via an MSCA during the public consultation (in the reproductive toxicity section of the comments) and the information on ocular effects and tyrosine levels was provided to ECHA in November 2018. The key information is summarised in the following table.



ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

90-day dietary study in the rat		
Type of study; Reference	Method	Observations
90-day, dietary, rat  ISK, study no. AN-2850 (conducted in 2009)	Non-guideline Purity: > 99%  Strain: Wistar Hannover [BrlHan:WIST@jcl(GALAS)]  Doses: 0, 50, 500, 5000 ppm; corresponding to 0, 3.6/4.2, 37/43, 380/458 mg/kg bw/d (m/f)  5/sex/dose  Additional investigations: measurement of plasma tyrosine, staining of kidney samples with polyclonal goat anti-α2u-globulin  Limited reporting	5000 ppm (380/458 mg/kg bw/d): <ul style="list-style-type: none"> <li>• Plasma tyrosine 2340/2260 μmol/L m/f</li> <li>• Corneal opacity (m 3/5, f 4/5 vs none in controls), keratitis (m 3/5, f 5/5 vs none in controls)</li> <li>• Hyaline droplet deposition (incidence not reported) and increased positive response to α2u-globulin antibody in the kidneys of males</li> </ul> 500 ppm (37/43 mg/kg bw/d): <ul style="list-style-type: none"> <li>• Plasma tyrosine 1680/1410 μmol/L m/f</li> <li>• Corneal opacity (m 2/5, f 5/5 vs none in controls), keratitis (m 3/5, f 3/5 vs none in controls)</li> <li>• Increased positive response to α2u-globulin antibody in the kidneys of males</li> </ul> 50 ppm (3.6/4.2 mg/kg bw/d): <ul style="list-style-type: none"> <li>• Plasma tyrosine 510/330 μmol/L m/f</li> <li>• Increased positive response to α2u-globulin antibody in the kidneys of males</li> </ul> 0 ppm: <ul style="list-style-type: none"> <li>• Plasma tyrosine 270/230 μmol/L m/f</li> </ul>
<p>In response to the information on α2u-globulin accumulation in this study, the DS agreed that the hyaline droplet accumulation in males treated with tolpyralate is not relevant to humans. However, they pointed out the kidney findings in the 2-generation study, where kidney effects not normally associated with α2u-globulin accumulation were observed in the offspring including females, and also the occurrence of glomerulonephritis in female mice in the chronic study. The DS remained of the opinion that classification with STOT RE 2 for kidney effects is justified.</p>		
<p><b>Assessment and comparison with the classification criteria</b></p> <p>Repeated dose toxicity of tolpyralate was investigated in rats, mice and dogs. Information from reproductive toxicity studies and from mechanistic studies is also available. The following target organs have been identified:</p> <ul style="list-style-type: none"> <li>• Eye</li> <li>• Kidney</li> </ul>		

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

- Liver and gall bladder
- Thyroid
- Pancreas
- Nervous system

RAC notes the 100-fold gap between dose levels in the rat studies (90-day, 1-year, 2-year), which creates considerable uncertainties in relation to STOT RE classification in cases where an effect is present at the higher dose but not at the lower dose. Interpolation, the generally recommended practice according to the Guidance on the application of the CLP criteria, would be difficult and rather speculative here and RAC would normally use it only in cases where the LOAEL is above but still reasonably close to the GV. RAC acknowledges that such large dose spacing is not in line with the OECD test guidelines, which advise against intervals greater than 10-fold.

**Eye**

Ocular opacity and keratitis were observed in the rat at doses below the GVs for classification; the incidences of keratitis in the oral studies are listed in the table below (no ocular effects were observed in the dermal study). No effects on the eye were observed in the mouse studies up to high dose levels ( $\approx$  1100 mg/kg bw/d in a 90-day study,  $\approx$  700 mg/kg bw/d in an 18-month study). In the dog, there was only one incidence of keratitis and ocular opacity at 670 mg/kg bw/d in a 90-day study, which is above the GV for classification.

<b>Incidence of keratitis in the rat oral repeated dose studies</b>				
<b>Type of study; Reference</b>	<b>Dose (mg/kg bw/d) m/f</b>	<b>Incidence of keratitis</b>		<b>GV for Cat. 2 / Cat. 1 (mg/kg bw/d)</b>
		<b>males</b>	<b>females</b>	
28-day, dietary Anonymous, 2013g	46/47	4/6	6/6	300 / 30
	4.5/5.0	2/6	0/6	
	controls	0/6	0/6	
90-day, dietary Anonymous, 2013h	133/159	7/10	10/10	100 / 10
	1.3/1.6	0/10	0/10	
	controls	0/10	0/10	
90-day, dietary ISK, study no. AN-2850	37/43	3/5	3/5	100 / 10
	3.6/4.2	0/5	0/5	
	controls	0/5	0/5	
2-year, dietary Anonymous, 2015f	84/108	51/51	51/51	12.5 / 1.25
	0.77/1.0	4/51	1/51	
	controls	4/51	0/51	

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Two-generation, dietary  Anonymous, 2015e	55/59: P	21/24	23/24	≈ 70 / 7
	55/59: F1	24/24	24/24	
	2.7/3.0: P	1/24	0/24	
	2.7/3.0: F1	1/24	0/24	
	controls: P	0/24	0/24	
	controls: F1	0/24	0/24	

A high incidence of keratitis below or around the GVs for classification in Category 2 was observed in several studies; two of them (the 28-day study and the 2-generation study) reported ocular effects even below the GVs for Category 1. However, the incidence below the GVs for Category 1 was relatively low and rats are generally more sensitive than humans to the ocular effects from exposure to HPPD inhibitors (see the carcinogenicity section). Therefore, RAC agrees with the DS that classification in Category 2 for effects on the eyes is appropriate.

**Kidney**

Increased deposition of hyaline droplets in proximal tubular cells was observed in male rats below the GVs for classification in 28-day and 90-day studies. In addition, a range of kidney abnormalities were reported in the 2-generation study, especially in the animals exposed to the test substance *in utero* and as juveniles. Kidney effects in the oral rat studies are summarised in the table below (no kidney effects were seen in the dermal study). Kidney effects were reported also in the dog and mouse studies, but occurred only at doses above the GVs for classification in these species (e.g., glomerulonephritis in female mice at 732 mg/kg bw/d in an 18-month study).

Kidney effects in the rat oral repeated dose studies		
Type of study; Reference	Effects on the kidneys	GV for Cat. 2 / Cat. 1 (mg/kg bw/d)
28-day, dietary Anonymous, 2013g	46/47 mg/kg bw/d m/f: increased deposition of hyaline droplets in proximal tubular cells (m 3/6 vs 0/6; f not examined) 4.5/5.0 mg/kg bw/d m/f: hyaline droplet deposition (m 1/6 vs 0/6; f not examined)	300 / 30
90-day, dietary Anonymous, 2013h	133/159 mg/kg bw/d m/f: ↑ kidney weight (m relative by 10%), hyaline droplet deposition (m 2/10 vs 0/10) 1.3/1.6 mg/kg bw/d m/f: hyaline droplet deposition (m 2/10 vs 0/10) 0.32/0.38 mg/kg bw/d m/f: no kidney effects	100 / 10
90-day, dietary ISK, study no. AN-2850	37/43 mg/kg bw/d: hyaline droplet deposition (incidence not reported) and increased positive response to α2u-globulin antibody in males 3.6/4.2 mg/kg bw/d: hyaline droplet deposition (incidence	100 / 10

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

	not reported) and increased positive response to α2u-globulin antibody in males	
1-year, dietary Anonymous, 2015i	97/126 mg/kg bw/d m/f: ↑ kidney weight (m relative by 17%), basophilic change of the renal tubule (m 8/21 vs 2/21) 0.92/1.2 mg/kg bw/d m/f: no kidney effects	25 / 2.5
2-year, dietary Anonymous, 2015f	84/108 mg/kg bw/d m/f: ↑ kidney weight (m relative by 23%) 0.77/1.0 mg/kg bw/d m/f: no kidney effects	12.5 / 1.25
Two-generation, dietary Anonymous, 2015e	55/59 mg/kg bw/d m/f – P generation: ↑ kidney weight (m relative by 13%) 55/59 mg/kg bw/d m/f – F1 generation: ↑ kidney weight (m/f relative by 17%/7%), basophilic change of renal tubule (m 10/24 vs 3/24; f 4/24 vs 0/24), calcification (m 7/24 vs 0/24; f 8/24 vs 3/24), cortical cysts (m 6/24 vs 0/24), hyaline droplet deposition (m 5/24 vs 2/24), nephropathy (m 11/24 vs 0/24; f 4/24 vs 0/24), dilatation of renal pelvis (f 5/24 vs 0/24) ≤ 2.7/3.0 mg/kg bw/d m/f: no kidney effects (very slight, statistically non-significant increase in the incidence of dilated renal pelvis in F1)	≈ 70 / 7

Association of hyaline droplets with α2u-globulin has been demonstrated using immunohistochemical staining in one of the 90-day studies (ISK, study no. AN-2850). Alpha2u-globulin nephropathy is a mechanism specific to male rats. Therefore, RAC does not consider the increased incidence of hyaline droplet deposition in male rats to support classification.

However, the relationship to α2u-globulin nephropathy of the kidney effects observed in the F1 and F2 generations of the 2-generation study is unclear and consequently, human relevance cannot be excluded. These findings are discussed in the reproductive toxicity section as they occur due to or are aggravated by *in utero* and early postnatal exposure. They are not considered for a STOT RE classification and are used to support classification for developmental toxicity instead.

**Liver and gall bladder**

Increased liver weight without associated histopathological findings was observed below or around the GVs for Category 2 in two rat studies (28-day oral, 90-day). This effect is not considered sufficiently adverse to warrant classification. No liver effects were observed below the GVs for classification in the mouse and dog studies.

A significantly increased incidence of gall bladder calculi was observed in the 18-month mouse study from ≈ 7 mg/kg bw/d (70 ppm), the lowest dose tested, without any other findings in the gall bladder or the liver at the low dose. Liver hypertrophy was observed from 700 ppm. Although the increased incidence of gall bladder calculi is likely to be a treatment-related effect, it is not considered sufficiently adverse to warrant classification.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

<b>Incidence of gall bladder calculi in the 18-month mouse study</b>				
<b>Dose (ppm)</b>	<b>0</b>	<b>70</b>	<b>700</b>	<b>7000</b>
Dose (mg/kg bw/d) (m/f)	0	7.4/7.3	79/73	793/732
No. of animals examined (m/f)	52/52	52/52	51/52	52/52
Incidence of gall bladder calculi – males	6	14*	18**	16*
Incidence of gall bladder calculi – females	4	11*	17**	20**

\* p ≤ 0.05; \*\* p ≤ 0.01 (Fisher's exact test)

### **Thyroid**

Thyroid effects in the rat oral repeated dose studies with tolpyralate are summarised in the table below. A relatively high incidence of follicular cell hypertrophy was observed especially in males in the 28-day and 90-day studies; the effects were far less prominent in the long-term studies. No effects on the thyroid were observed at doses below or around the GV's in the mouse and dog studies or in the rat dermal study.

<b>Effects on the thyroid in the rat oral repeated dose studies</b>		
<b>Type of study; Reference</b>	<b>Effects on the thyroid</b>	<b>GV for Cat. 2 / Cat. 1 (mg/kg bw/d)</b>
28-day, dietary Anonymous, 2013g	46/47 mg/kg bw/d m/f: follicular cell hypertrophy (m 6/6 vs 0/6) 4.5/5.0 mg/kg bw/d m/f: follicular cell hypertrophy (m 2/6 vs 0/6)	300 / 30
90-day, dietary Anonymous, 2013h	133/159 mg/kg bw/d m/f: follicular cell hypertrophy (m 9/10 vs 0/10; f 4/10 vs 0/10) 1.3/1.6 mg/kg bw/d m/f: no thyroid effects	100 / 10
1-year, dietary Anonymous, 2015i	97/126 mg/kg bw/d m/f: follicular cell hypertrophy (m 3/21 vs 0/21; f 2/21 vs 0/21) 0.92/1.2 mg/kg bw/d m/f: no thyroid effects	25 / 2.5
2-year, dietary Anonymous, 2015f	84/108 mg/kg bw/d m/f: colloid degeneration (f 16/51 vs 0/51) 0.77/1.0 mg/kg bw/d m/f: no thyroid effects	12.5 / 1.25
Two-generation, dietary Anonymous, 2015e	55/59 mg/kg bw/d m/f: no thyroid effects	≈ 70 / 7

Additionally, the DAR summarised a mechanistic study investigating the effects on the thyroid in the rat. Tolpyralate was administered in the diet at 0 or 20000 ppm (1930 mg/kg bw/d) to 6 male rats per group for 14 days. Serum TSH was significantly

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

increased by 16% relative to control animals, with an associated but non-significant decrease in circulating T4 (by 18%). Total liver cytochrome P450 content was significantly increased, as was UDPGT activity towards both 4-nitrophenol and 4-hydroxybiphenyl (by  $\approx$  60%). This indicates that the thyroid effects might be due to UDPGT induction. However, alternative modes of actions have not been investigated.

The follicular cell hypertrophy is considered a treatment-related effect and although it is an effect of an adaptive rather than adverse nature, it may be associated with reduced T4 levels, which is an adverse effect. However, the T4 reduction was less than 20% at a dose as high as 1930 mg/kg bw/d in a 2-week study, and the long-term studies show that the hypertrophy did not follow Haber's rule. In fact, hypertrophy diminished with increasing exposure duration and the lack of clear increase in thyroid hyperplasia or neoplasia in the 2-year study indicates that it was indeed weak and transient. Therefore, RAC agrees with the DS that classification for effects on the thyroid is not warranted.

**Pancreas**

Effects on the pancreas in the rat repeated dose studies with tolpyralate are summarised in the table below. No effects on the pancreas were observed in the mouse and dog studies.

<b>Effects on the pancreas in rat repeated dose studies</b>		
<b>Type of study; Reference</b>	<b>Effects on the pancreas</b>	<b>GV for Cat. 2 / Cat. 1 (mg/kg bw/d)</b>
28-day, dietary Anonymous, 2013g	447/496 mg/kg bw/d m/f: single acinar cell necrosis (m 3/6 vs 0/6) 46/47 mg/kg bw/d m/f: no pancreatic effects	300 / 30
90-day, dietary Anonymous, 2013h	133/159 mg/kg bw/d m/f: single acinar cell necrosis (m 3/10 vs 1/10; f 1/10 vs 0/10) 1.3/1.6 mg/kg bw/d m/f: no pancreatic effects	100 / 10
1-year, dietary Anonymous, 2015i	97/126 mg/kg bw/d m/f: acinar cell fibrosis (m 11/21 vs 2/21), acinar cell necrosis (m 7/21 vs 1/21) 0.92/1.2 mg/kg bw/d m/f: acinar cell fibrosis (m 7/21 vs 2/21)	25 / 2.5
2-year, dietary Anonymous, 2015f	84/108 mg/kg bw/d m/f: acinar cell fibrosis (m 46/51 vs 14/51; f 23/51 vs 10/51), fat infiltration (m 26/51 vs 3/51) 0.77/1.0 mg/kg bw/d m/f: no pancreatic effects	12.5 / 1.25
Two-generation, dietary Anonymous, 2015e	55/59 mg/kg bw/d m/f: no pancreatic effects	$\approx$ 70 / 7
28-day, dermal Anonymous, 2013l	1000 mg/kg bw/d: acinar cell apoptosis and inflammatory cell infiltration (m 3/10 vs 1/10; f 1/6 vs 0/10)	600 / 60

An increased incidence of single cell acinar cell necrosis and of acinar cell fibrosis was

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

reported in several studies. Although this is considered a treatment-related adverse effect, the incidence was increased mainly at doses above the GVs for classification and where the increase occurred marginally above the GVs, the incidence was relatively low. The only dose level with pancreatic effects below the GVs is 20 ppm (approx. 1 mg/kg bw/d) in the 1-year rat study; however, this increase was not statistically significant and was not replicated at the same dose level in the 2-year study. Taking a weight of evidence approach, classification for effects on the pancreas is not justified.

**Nervous system**

Increased incidence of vacuolation of the cerebellum was observed at 2000 ppm (approx. 100 mg/kg bw/d) in the 1-year and 2-year studies in the rat. Additionally, increased incidence of sciatic nerve degeneration was observed in female rats of the 2-year study at this dose. No such effect was observed at 2000 ppm in a 90-day rat study. As the effects appeared at doses above the GV for classification, classification for effects on the nervous system is not warranted.

**Conclusion**

RAC agrees with the DS on classification in Category 2 based on the eye effects (keratitis, opacity) in the rat.

As to the kidney effects, the hyaline droplet deposition in male rats treated with tolpyralate has been shown to be associated with accumulation of  $\alpha_2$ u-globulin and is not considered relevant to humans. The kidney findings in F1 and F2 generations of the 2-generation study are used to support classification for developmental toxicity.

Thus, RAC concludes that tolpyralate should be classified as **STOT RE 2; H373 (eye)**.

**10.13 Aspiration hazard**

Not relevant for solid materials.

**11 EVALUATION OF ENVIRONMENTAL HAZARDS**

**11.1 Rapid degradability of organic substances**


**Table 43: Summary of relevant information on rapid degradability**

Method	Results	Remarks	Reference
Aquatic hydrolysis OECD Guideline 111, GLP	Tolpyralate hydrolysis is pH dependent. At 10 °C DT50 for tolpyralate determined as 1050 d (pH 4), 231 d (pH 7) and 2.31 d (pH 9)  One degradant identified, MT-2153 this reached max. levels at study end of 1.1, 7.8 and 86.3 % AR at pH 4.0, 7.0,	Valid	Unsworth, R. 2013 (section B.8.2.1.1 in the DAR)

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Method	Results	Remarks	Reference
	and 9.0 at 10 °C. No further evidence of degradation was observed in a degradant dosed hydrolysis study, see below.		
Aquatic hydrolysis (MT-2153) OECD Guideline 111, GLP	The degradation product MT-2153 was stable at pH4.0, 7.0, and 9.0 at 50 °C. Indicated DT50 at 25 °C are at >365d. As MT-2153 is stable to hydrolysis at 50°C, normalising figures to 12°C (as proposed by ECHA) would not alter the conclusion, and so this correction has not been undertaken.	Valid	Hori, K. 2014b (section B.8.2.1.1 in the DAR)
Ready biodegradation OECD Guideline 301F, GLP	9% biodegradation after 25 days. Tolpyralate not classed as readily biodegradable.	Valid	Hammesfahr, U. 2013 (section B.2.2.1 in the DAR)

Proposed degradation pathway of tolpyralate under hydrolytic conditions:



### 11.1.1 Ready biodegradability

A ready biodegradability study was conducted to GLP, according to OECD test guideline 301F and there were no significant deviations that would affect the validity of the study. The test material was non-radiolabelled tolpyralate, lot number 20111222-1 (97.27% purity).



## ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Aliquots of washed activated sludge from a domestic waste water treatment plant equivalent to 3.5 g dry material per litre were mixed with test water. This suspension was aerated overnight and used for the test. Test water was prepared according to the description in the guideline OECD 301A; the pH was 7.6. Test flasks were prepared in duplicate for tolpyralate and the inoculum control, and single flasks were prepared for the procedure control (sodium benzoate), abiotic control (HgCl<sub>2</sub>) and toxicity control (tolpyralate + sodium benzoate).

Tolpyralate was incubated with activated sewage sludge under aerobic conditions and the oxygen uptake of the microorganisms determined. Sodium benzoate was tested under the same conditions in order to give a reference value. Each flask had a volume of 500 mL and was incubated in the dark at 22 ± 1°C with continuous stirring.

For tolpyralate, biodegradation reached a maximum of 9% of ThOD after 25 days. The extent of biodegradation of the reference substance (sodium benzoate) reached 85% of ThOD after 14 days and 94% after 28 days. The activated sludge and procedure used demonstrated the ready biodegradability of the reference substance, therefore was acceptable to test the ready biodegradability of tolpyralate. The extent of biodegradation of the reference substance and tolpyralate together in the toxicity control was 44% and 41% of ThOD within 14 days and 50% and 46% after 28 days of incubation. As degradation is >25% based on ThOD within 14 days, it can be concluded that tolpyralate is not inhibitory to microorganisms in activated sludge. There was no oxygen demand in the abiotic control at any time during the experiment. Substances are considered to be readily biodegradable in this test if the extent of degradation reaches 60% of the theoretical value within 10 days of achieving 10% degradation.

Tolpyralate is not classed as readily biodegradable.


Hammesfahr, (2013)

### 11.1.2 BOD<sub>5</sub>/COD

Not available.

### 11.1.3 Hydrolysis

The hydrolysis of tolpyralate in buffers at pH 4.0, 7.0, and 9.0 and at 10, 25, and 50°C. The study was conducted to GLP and according to OECD test guideline 111 and there were no significant deviations that would affect the validity of the study. The test material was tolpyralate, radiolabelled in two different positions as shown below with a radiochemical purity ≥97%:



# position of [14C-Ph] radiolabel \* position of [14C-Pz] radiolabel

The hydrolysis of tolpyralate in sterile buffer solutions is pH and temperature dependent, and follows first order reaction kinetics. Tolpyralate hydrolyses more rapidly under conditions of higher pH and under increasing temperature. DT50 values determined for each pH and temperature tested are detailed below:

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

**Table 44**

Test pH	Temperature (°C)	DT <sub>50</sub> (days)
pH 4.0	10	1050
	25	332
	50	25.9
pH 7.0	10	231
	25	31.4
	50	1.88
pH 9.0	10	2.31
	25	0.355
	50	0.033

The only hydrolysis product measured at greater than 5% of the applied radioactivity was MT-2153. MT-2153 reached maximum concentrations of 53.9, 88.9, and 101.4 %AR at pH 4.0, 7.0, and 9.0 respectively at 50°C and maximum levels of 1.1, 7.8 and 86.3 % AR at pH 4.0, 7.0, and 9.0 at 10 °C. The ratio of stereoisomers (1:1) was unchanged during hydrolysis, indicating that the rate of hydrolysis of the two stereoisomers was the same.

Unsworth, (2013a)

**11.1.4 Other convincing scientific evidence**

**Table 45. Summary of other relevant information on rapid degradation**

Method	Results	Remarks	Reference
Aquatic photolysis OECD Guideline 316, GLP	DT <sub>50</sub> of tolpyralate of 2.86 days in purified water (pH 6-7, 25 °C) DT <sub>50</sub> of tolpyralate of 4.41 days in natural water pH 6-7, 25 °C)	Valid	Unsworth, R. 2014 (section B.8.2.1.1 in the DAR)
Aerobic water/sediment simulation OECD Guideline 308, GLP	DT <sub>50</sub> of tolpyralate of 1.39 and 1.88 days at pH 7.4 and pH 5.7 respectively (whole system). MT-2153 reached a max. of 82 % and 79.9 % in the whole system and 19.8 % and 32.7 % in sediment. DT <sub>50</sub> of MT-2153 of 206 and 176 days (whole system).	Valid	Kane, T. 2014 (section B.8.2.2.3 in the DAR)
Anaerobic water/sediment simulation OECD Guideline 308, GLP	DT <sub>50</sub> of tolpyralate of 1.47 and 2.72 days at pH 7.3 and pH 5.4 respectively (whole system). MT-2153 reached a max. of 89.3 % and 93 % in the whole system and 23.6 % and 18.8 % in sediment. DT <sub>50</sub> of MT-2153 of 388 and 394 days at pH 7.4 and pH 5.7 respectively (whole system).	Valid	Crowe, A. (2015) (section B.8.2.2.3 in the DAR)

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Method	Results	Remarks	Reference
Aerobic mineralization OECD Guideline 309, GLP	DT <sub>50</sub> of tolpyralate of 2.43 days in surface water at an initial concentration of 10 µg/mL and 1.77 days at an initial concentration of 100 µg/mL	Valid	Van den Bosch, M.M.H. 2014 (section B.8.2.2.2 in the DAR)

**11.1.4.1 Field investigations and monitoring data (if relevant for C&L)**

Not available.

**11.1.4.2 Inherent and enhanced ready biodegradability tests**

Not available.

**11.1.4.3 Water, water-sediment and soil degradation data (including simulation studies)**

Aerobic mineralisation in surface water

The rate of degradation and mineralisation of tolpyralate in surface water under aerobic conditions was conducted to GLP and according to OECD test guideline 309, there were no significant deviations that would affect the validity of the study. The test material was tolpyralate, radiolabelled in both the phenyl and pyrazole ring positions and with a minimum radiochemical purity of 99.2%. The surface water for this test was collected from Schoonrewoerdse Weil in the Netherlands to a depth of 1 metre and had the following characteristics:

**Table 46:**

Parameter	Value
pH (at sampling)	8.3
Temperature (at sampling)	5.8°C
Oxygen (at sampling)	11.5 mg/L (93%)
Total organic carbon	11.0 mg/L
Dissolved organic carbon	9.5 mg/L
Total nitrogen as N	3.7 mg/L
Nitrate	4.1 mg/L
Nitrite	<1.6 mg/L
Ammonium	<0.7 mg/L
Total hardness	151 mg/L as CaCO <sub>3</sub>
Phosphate/orthophosphates	<0.3 mg/L
Total phosphorus as P	<0.1 mg/L

In microbially active surface water, at 20 °C, tolpyralate degraded rapidly to less than 2% of applied activity after 14 days incubation. The DT<sub>50</sub> values for tolpyralate were 2.06 days at an initial concentration of 10 µg/mL and 2.02 days at an initial concentration of 100 µg/mL. The degradant MT-2153 was formed and increased to greater than 90% AR at 7 days and there was no clear evidence of decline at the end of the study after 62 days. The maximum amount of CO<sub>2</sub> formed was 3.8% AR.

Van den Bosch (2014)

Aerobic water-sediment study

The route and rate of degradation of tolpyralate in two aquatic sediment systems under aerobic

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

conditions was determined. The study was conducted to GLP according to OECD test guideline 308 and there were no significant deviations that would affect the validity of the study. The test material was tolpyralate, radiolabelled in both the phenyl and pyrazole ring positions and had a minimum radiochemical purity of 99.5%.

The two aquatic sediments were ‘Calwich Abbey Lake’ and ‘Swiss Lake’, collected from Staffordshire and Derbyshire, UK respectively. The characterisation of sediment and water from ‘Calwich Abbey Lake’ and ‘Swiss Lake’ are detailed below:

**Table 47:**

Parameter	Calwich Abbey Lake	Swiss Lake
<b>Water</b>		
Total organic carbon (mg/L)	2.9	8.8
Total nitrogen (mg/L)	3.1	0.9
Total phosphorus (mg/L)	<0.1	<0.1
Total suspended solids (mg/L)	20	16
Hardness as CaCO <sub>3</sub> (mg/L)	245	26.5
<b>Sediment</b>		
Particle Size Distribution:		
0.063 mm - 2.00 mm (%)	26	91
0.002 mm - 0.063 mm (%)	61	6
<0.002 mm (%)	13	3
Texture Class	Sandy Silt Loam	Sand
pH (1:5 w/v) in water	8.0	6.3
pH (1:5 w/v) in 0.01 M CaCl <sub>2</sub>	7.4	5.7
Organic carbon (%)	5.0	0.8
Total nitrogen (%)	0.48	0.07
Total phosphorus (mg/kg)	965	139
Calcium carbonate (%)	44.6	<0.1
Cation exchange capacity (meq/100 g)	22.6	4.2

Both systems remained microbiologically active throughout the study. During the incubation period oxygen levels in the water were indicative of an aerobic, oxidising water phase and a reducing sediment phase. The temperature of the incubation chamber remained within the range 20 ± 2°C throughout. Total recoveries of applied radioactivity (AR) were in the range 90.8 - 103.9%.

The resulting data for tolpyralate and MT-2153 has been fitted according to FOCUS kinetics guidance and it was concluded that tolpyralate declined rapidly in the Calwich Abbey Lake and Swiss Lake aerobic aquatic sediment systems (DT<sub>50</sub> values summarised in the table below). There was little tolpyralate in the sediment at any time (<0.1% AR). The degradant MT-2153 was formed and was present in both water and sediment, reaching a maximum 82.0% and 79.9% AR in the whole systems. Amounts of MT-2153 in the sediment increased throughout the study, reaching a maximum of 19.8%

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

AR and 32.7% AR in the Calwich Abbey Lake and Swiss Lake sediments respectively at the end of the study.

Two other degradants (labelled Met A and Met B) and a polar fraction were also reported but were always less than 5% AR in the whole systems. The amount of bound residue in the sediment increased throughout the study and reached a maximum of 29.6% AR in the Calwich Abbey Lake system and 41.9% AR in the Swiss Lake system. Radioactivity recovered from soxhlet extraction of the bound residue was mostly MT-2153 (8.9 to 13.4% AR), with small amounts of tolpyralate, Met A, Met B and some polar components (all  $\leq$  0.5% AR).

**Table 48: Summary of endpoints (persistence and modelling) for tolpyralate and MT-2153 in the aerobic water / sediment systems**

Tolpyralate				MT-2153			
System	Kinetic fitting	DT <sub>50</sub> (days)	DT <sub>90</sub> (days)	System	Kinetic fitting	DT <sub>50</sub> (days)	DT <sub>90</sub> (days)
<b>Whole system (degradation)</b>							
Calwich Abbey	SFO	1.39	4.61	Calwich Abbey	SFO	206	683
Swiss Lake	SFO	1.88	6.24	Swiss Lake	SFO	176	585
<b>Geomean</b>		1.62	5.36	<b>Geomean</b>		190	632

Kane, (2014)

Anaerobic water-sediment study

A study to determine the route and rate of degradation of tolpyralate in two aquatic sediment systems under anaerobic conditions was conducted. The study was conducted to GLP and according to OECD test guideline 308 and there were no significant deviations that would affect the validity of the study.. The test material was tolpyralate, radiolabelled in both the phenyl and pyrazole ring positions and had a minimum radiochemical purity of 99.5%.The rate of degradation of tolpyralate was similar to the aerobic study, while that for MT-2153 was generally longer. A summary of endpoints is presented below.

**Table 49: Summary of endpoints (persistence and modelling) for tolpyralate and MT-2153 in the anaerobic water / sediment systems**


Tolpyralate				MT-2153			
System	Kinetic fitting	DT <sub>50</sub> (days)	DT <sub>90</sub> (days)	System	Kinetic fitting	DT <sub>50</sub> (days)	DT <sub>90</sub> (days)
<b>Whole system (degradation)</b>							
Calwich Abbey	SFO	1.47	4.89	Calwich Abbey	SFO	338	1120
Swiss Lake	SFO	2.72	9.02	Swiss Lake	SFO	394	1310
<b>Geomean</b>		2.00	6.64	<b>Geomean</b>		365	1211

#### 11.1.4.4 Photochemical degradation

A photodegradation study with tolpyralate was conducted to GLP and according to OECD test guideline 316, there were no significant deviations that would affect the validity of the study. Degradation DT<sub>50</sub> values and the quantum yield were determined in natural and purified water at 25 °C with pH ranging from 5.7 – 6.72.

The data indicated that tolpyralate degrades rapidly via photolysis with DT<sub>50</sub> values of 4.41 days in natural water and 2.86 days in purified water. The degradant MT-2153 was formed but at equal or lower amounts than in dark controls, suggesting that it was formed by hydrolysis, not photolysis. There were several photodegradation products, and there was strong evidence for the identification of EVC-005 and EVC-006 (both made up of two diastereoisomers). There was some evidence for the presence of a further set of four isomers structurally similar to EVC-005 and EVC-006, but these components were not positively identified and were all most likely below 10% of applied radioactivity.

Proposed pathway for photodegradation of tolpyralate in water:



Photolysis is of uncertain relevance as a route of degradation in typical European aquatic environments and, given the available data, there is insufficient information in this case to evaluate photodegradation in terms of mineralisation or transformation to non-classifiable substances. Therefore, aquatic photolysis is not considered further in relation to meeting the criteria for rapid degradation.

Unsworth (2014)

#### 11.1.5 Overall summary on environmental hazard

Tolpyralate is a stereoisomer compound made up of R:S isomers at a 50:50 racemic mix. The two isomers can be considered equally biologically active with regard to herbicidal activity in addition in vivo mammalian toxicity testing indicates it is stable to chiral conversion. The ratio of stereoisomers

## ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

(1:1) was unchanged during hydrolysis, indicating that the rate of hydrolysis of the two stereoisomers is the same in the aquatic environment.

The aquatic hydrolysis study indicates that there is no ultimate degradation i.e. >70% within 28d as a DT50 of 231 d is indicated at pH 7 for tolpyralate in purified water. Hydrolysis is to the degradant MT-2153 which in turn is hydrolytically stable (DT50 >365 d at all environmental relevant pH and temperature). Tolpyralate was subject to aqueous photolysis with a DT50 of <5d in both purified and natural systems but the relevance of this as a route of degradation in typical European aquatic environments is uncertain.

A ready biodegradation study with tolpyralate indicated 9% degradation after 25 days, therefore tolpyralate is not classified as readily biodegradable.

Regarding the CLP criteria for rapid degradation, consideration has been made of other scientific evidence that may demonstrate degradation of tolpyralate in the aquatic environment to a level <70% within 28d.

The aerobic mineralisation and water sediment studies (aerobic and anaerobic) indicate that tolpyralate underwent rapid primary degradation in natural waters with DT50 values at <4.41 days. In all studies degradation was to the major degradant MT-2153 which in the aerobic and anaerobic water /sediment studies had estimated whole system DT50 values of >176 days.

The classification of the primary degradant MT-2153 is discussed at section 11.5 below and it is indicated to have significant acute and chronic toxic effects to aquatic plants and will therefore be classified as hazardous to the aquatic environment. It is concluded therefore, that although there is rapid primary degradation of the active substance, tolpyralate it does not meet the CLH criteria as rapidly degradable because ultimate biodegradation of the substance, i.e. full mineralisation, is not achieved and it cannot be demonstrated that the degradation products do not fulfil the criteria as hazardous to the aquatic environment.

### **11.2 Environmental transformation of metals or inorganic metals compounds**

Not relevant.

#### **11.2.1 Summary of data/information on environmental transformation**

Not relevant.

### **11.3 Environmental fate and other relevant information**

#### Adsorption/desorption in soil

A GLP compliant adsorption/desorption study was conducted with tolpyralate in four contrasting soils according to OECD guideline 106. The soil physicochemical properties are detailed below.

**Table 50: Soil physicochemical properties.**

**ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE**

Soil	HDRA Biogarden	Cuckney	Fladbury	Uttoxeter Quarry
Particle size distribution <sup>a</sup> :				
Sand (%)	68	92	52	16
Silt (%)	16	4	15	41
Clay (%)	16	4	33	43
Texture class	Sandy loam	Sand	Sandy clay loam	Clay
pH in water	7.6	6.9	6.7	5.2
pH in 0.01 M CaCl <sub>2</sub>	6.8	6.4	6.1	4.9
Organic carbon (%)	5.0	0.5	3.1	4.2
Cation exchange capacity (meq/100g)	23.3	4.0	24.6	26.1

<sup>a</sup> USDA classification system except Uttoxeter Quarry, which is UK-ADAS system

An equilibration time of two hours was selected for both adsorption and desorption phases for tolpyralate due to its rapid degradation to MT-2153. Freundlich adsorption coefficients for tolpyralate were in the range 0.456 - 1.80 mL/g and adsorption coefficients corrected for organic carbon content (KFOC,ads) were in the range 14.9 - 91.2 mL/g, indicating the compound has the potential to be mobile in soil.

Two GLP compliant adsorption/desorption studies were conducted with MT-2153 in six contrasting soils in accordance with the OECD 106 guideline (Klaumann, S, 2015 and Sadgrove, L.2016). The soil physicochemical properties are detailed below:

**Table 51: Soil physicochemical properties.**

Soil	Calke	Cuckney	Fladbury	HDRA Biodynamic Garden	Uttoxeter Quarry	EVO-2	MCL-B
Particle size distribution:							
Sand (%)	69.6	93.6	50.5	65.4	14.3	17	12
Silt (%)	15.4	1.4	28.2	18.7	45.4	51	48
Clay (%)	15.0	5.1	21.4	16.0	40.4	32	40
Texture class	Sandy loam	Sand	Loam	Sandy loam	Silty clay	Silty clay loam	Silty clay
pH in 0.01 M CaCl <sub>2</sub>	4.80	6.17	5.65	6.21	4.92	7.4	6.8
Organic carbon (%)	2.1	0.37	2.8	3.7	3.8	0.8	3.0
Cation exchange capacity (meq/100g)	11.4	2.2	23.3	23.8	20.9	31.6	43.8

Freundlich adsorption coefficients for MT-2153 were in the range 0.35 – 5.64 mL/g and adsorption coefficients corrected for organic carbon content (KFOC,ads) were in the range 40.8 – 148.1 mL/g, indicating the compound has the potential to be mobile in soil.



## 11.4 Bioaccumulation

**Table 52: Summary of relevant information on aquatic bioaccumulation**

Method	Results	Remarks	Reference
Partition coefficient <i>n</i> -octanol/water	Results determined at 25±1 °C applying the HPLC method. pH 6.4: log K <sub>ow</sub> = 1.9	Valid	Furutami, E. 2014

### 11.4.1 Estimated bioaccumulation

#### 11.4.1.1 Bioaccumulation estimation

As tolpyralate has a log K<sub>ow</sub> of 1.9, it is considered to be below the CLP cut-off value of log K<sub>ow</sub> ≥ 4 intended to identify substances with a potential to bioaccumulate.

#### 11.4.1.2 Measured bioaccumulation data

No experimental aquatic study to determine the bioconcentration potential (BCF) of tolpyralate was submitted.

### 11.4.2 Summary and discussion of aquatic bioaccumulation

The log K<sub>ow</sub> value of 1.9 for tolpyralate is below the log K<sub>ow</sub> trigger value of ≥ 4 intended to identify substances with a potential to bioaccumulate under CLP. No experimental data are available, so the results of the bioaccumulation estimation will be used to classify tolpyralate. To conclude, tolpyralate does not meet CLP criteria as a bioaccumulative substance.

## 11.5 Aquatic hazard

A summary of the suitable aquatic toxicity studies for tolpyralate, as reviewed under EU Regulation 1107/2009, is presented in Table 53 below. The studies have been evaluated, considered reliable and deemed suitable for hazard classification purposes. All studies below conformed to GLP certification and were valid according to the criteria of the respective test guidelines (apart from the studies with *Anabaena flos-aquae* and *Crassostrea virginica* which failed some of the validity criteria, these did not highlight particular sensitivity to tolpyralate however). Additional information on the studies supporting tolpyralate has been presented in the subsections below.

Although valid and reliable studies are available on the formulated product “SL-573 100 OD” containing 103 g tolpyralate/L, studies using technical tolpyralate on the same species and endpoints are available. Therefore the studies using technical tolpyralate will take precedence over those of the formulated product, and consequently, studies using “SL-573 100 OD” have not been included in the hazard classification.

The degradants MMTA, MT-2153 and TAT-2049 were also tested in aquatic toxicity studies that were reviewed under EU Regulation 1107/2009. As MMTA and TAT-2049 are major degradants in soil studies only and were not sufficiently toxic to pass any of the hazard criteria, they are not considered any further for hazard classification. While MT-2153 exhibited high acute and chronic toxicity to aquatic plants with an E<sub>r</sub>C<sub>50</sub> of 0.0315 mg/L and a NOE<sub>r</sub>C of 0.0009 mg/L respectively, as MT-2153 reached maximum

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

concentrations of 53.9, 88.9, and 101.4 % AR at pH 4.0, 7.0, and 9.0 respectively at 50°C and maximum levels of 1.1, 7.8 and 86.3 % AR at pH 4.0, 7.0, and 9.0 at 10 °C, and a DT<sub>50</sub> at 25 °C of >365d, MT-2153 must be considered in the classification of tolpyralate. This is discussed further in Section 11.7.2.

**Table 53: Summary of relevant information on aquatic toxicity of technical tolpyralate**

Guideline	Species	Endpoint	Exposure		Results		Reference
			Design	Duration	Endpoint	Toxicity (mg a.s./L)	
OECD 203 (1992)	<i>Oncorhynchus mykiss</i>	Mortality	Semi-static	96h	LC <sub>50</sub>	>21 (mm)	Anonymous 2013m
OECD 203 (1992)	<i>Cyprinus caprio</i>	Mortality	Flow-through	96h	LC <sub>50</sub>	>19 (mm)	Anonymous 2013n
OECD 203 (1992)	<i>Pimephales promelas</i>	Mortality	Flow-through	96h	LC <sub>50</sub>	>19.7 (mm)	Anonymous 2014f
OECD 203 (1992)	<i>Cyprinodon variegatus</i>	Mortality	Semi-static	96h	LC <sub>50</sub>	>11.6 (mm)	Anonymous 2015h
OECD 210 (2013)	<i>Pimephales promelas</i>	Hatchability, average days to hatch, rate of developmental abnormality, survival rate, <b>body weight</b> , total length	Flow-through	28d	NOEC	0.30 (mm)	Anonymous 2014g
OECD 202 (2004)	<i>Daphnia magna</i>	Immobility	Static	48h	EC <sub>50</sub>	>19 (mm)	Yoshikawa, M. 2013
OPPTS 850.1035 (1996)	<i>Americamysis bahia</i>	Immobility	Semi-static	96h	EC <sub>50</sub>	0.66 (mm)	Brougher, D.S., Siddiqui, A.I., Gallagher, S.P. and Krueger, H.O. 2015b
OPPTS 850.1025 (1996)	<i>Crassostrea virginica</i>	Mortality, <b>shell deposition</b>	Flow-through	96h	EC <sub>50</sub>	6.8 (mm)	Brougher, D.S., Siddiqui, A.I., Gallagher, S.P. and Krueger, H.O. 2015c
OECD 211 (2012)	<i>Daphnia magna</i>	Immobility of parent, time to production of first brood, offspring survival, offspring immobilized, condition of parent, appearance of ephippium, body length of parent, dry weight of parent	Semi-static	21d	EC <sub>10</sub> & NOEC	≥ 8.94 (mm)	Yoshikawa, M. 2014b
OECD 201 (2011)	<i>Pseudokirchneriella subcapitata</i>	<b>Growth rate</b> , yield, biomass	Static	96h	96h E <sub>r</sub> C <sub>50</sub>	12.3 (mm) 1.4 (mm)	Yoshikawa, M. 2013b

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

					NOE <sub>rC</sub> 72h E <sub>rC</sub> <sub>10</sub>	4.44(mm)	
OECD 201 (2011)	<i>Anabaena flos-aquae</i>	<b>Growth rate</b> , yield, biomass	Static	96h	E <sub>rC</sub> <sub>50</sub> E <sub>rC</sub> <sub>10</sub>	>16.7 (mm) >16.7 (mm)	Arnie, J. R., Martin, K. H. and Porph, J. R. 2013a
OECD 201 (2011)	<i>Navicula pelliculosa</i>	<b>Growth rate</b> , yield, biomass	Static	96h	E <sub>rC</sub> <sub>50</sub> E <sub>rC</sub> <sub>10</sub>	>20.9 (mm) 14.8 (mm)	Arnie, J. R., Martin, K. H. and Porph, J. R. 2013b
OECD 201 (2011)	<i>Skeletonema costatum</i>	<b>Growth rate</b> , yield, biomass	Static	96h	E <sub>rC</sub> <sub>50</sub> E <sub>rC</sub> <sub>10</sub>	1.8 (mm) 0.15 (mm)	Arnie, J. R., Martin, K. H. and Porph, J. R. 2013c
OECD 221 (2006)	<i>Lemna gibba</i>	Growth frond number, growth dry weight, yield frond number, Yield dry weight	Semi-static	7d	E <sub>rC</sub> <sub>50</sub> E <sub>rC</sub> <sub>10</sub> NOE <sub>rC</sub>	0.0353 (nom) 0.00142 (nom) 0.00102 (nom)	Kuhl, R. and Wydra V. 2013
Proposed OECD test method for the rooted aquatic macrophyte, <i>Myriophyllum sp.</i> in a water-sediment system (2013)	<i>Myriophyllum aquaticum</i>	Growth rate total shoot length, yield total shoot length, growth rate wet weight, yield wet weight, growth rate dry weight, yield dry weight	Static	7d	E <sub>rC</sub> <sub>50</sub> NOE <sub>rC</sub> E <sub>rC</sub> <sub>10</sub>	>0.244 (mm) <0.000304* n.d.	Seeland-Fremer, A. and Wydra, V. 2014

**Bold words** indicate which type of data the endpoints were calculated from for where there multiple endpoints calculated in a study  
(mm) Endpoint based upon mean measured concentrations  
(nom) Endpoint based upon nominal concentrations  
n.d. Endpoint not determinable  
\* Uncertainty in test concentration

### 11.5.1 Acute (short-term) toxicity to fish

#### 11.5.1.1 Short-term toxicity to fish

Four acute toxicity to fish studies are available for tolpyralate, all following GLP and according to OECD 203 (1992). The toxicity endpoints are driven by the solubility limit of tolpyralate.

##### Anonymous, 2013m

The acute toxicity to juvenile rainbow trout was determined in an aerated, semi static, 96-hour test. The study encompassed 7 treatment groups, 5 dose rates of the test substance corresponding to mean measured

## ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

values of 21.0, 9.68, 4.47, 1.96 and 0.89 mg a.s./L, a control and N,N-dimethylformamide (DMF) solvent control (100 µL DMF/L) each containing 7 individuals. The samples of the test medium collected from freshly prepared (test start and day 2) and in aged (day 2 and test end) were analysed *via* HPLC-UV-method. Since some analysed values were below 80%, all reported endpoints were related to the mean measured concentrations. All the validity criteria were met, no mortalities occurred, and no sub-lethal effects were observed. Therefore, the 96-hour LC<sub>50</sub> of tolpyralate was >21.0 mg a.s./L based on mean measured concentrations.

### Anonymous, 2013n

A 96-hour limit test with common carp (*Cyprinus carpio*) was performed with a nominal tolpyralate concentration of 22 mg/L under semi-static conditions. Seven fish were exposed to the test material, with further groups of seven fish in control and vehicle control groups (0.10 mL DMF/L). All measured concentrations of tolpyralate throughout the test were within the range of 80 - 120% of the nominal concentration. No mortalities occurred and no sub-lethal effects were observed during the 96-hour period of the test and all the validity criteria were met. Therefore, the 48-hour and 96-hour LC<sub>50</sub> of tolpyralate is >19 mg a.s./L based on mean measured concentrations.

### Anonymous, 2014f

A 96-hour limit test with fathead minnow (*Pimephales promelas*) was carried out at a tolpyralate concentration of 22 mg/L under semi-static conditions. Seven fish were exposed to the test material, with further groups of seven fish in control and vehicle control groups (0.10 mL DMF/L). All measured concentrations of tolpyralate throughout the test were within the range of 80 - 120% of the nominal concentration. No mortalities occurred and no sub-lethal effects were observed during the 96-hour period of the test and all the validity criteria were met. Therefore, the 48-hour and 96-hour LC<sub>50</sub> of tolpyralate is >19.7 mg a.s./L based on mean measured concentrations.

### Anonymous, 2015h

Sheepshead minnows (*Cyprinodon variegatus*) were exposed to a single limit test of nominal concentration 26.5 mg a.s./L and a negative control (dilution water) for 96 hours under static-renewal conditions. Three replicate test chambers of ten fish were maintained in each treatment and control group. As analysis of the test concentration was outside the 80-120% range of the nominal, all results were based on the mean measured concentration after centrifugation. All the validity criteria were met, no mortalities occurred, and no sub-lethal effects were observed. Therefore, the 96-hour LC<sub>50</sub> of tolpyralate was ≥11.6 mg a.s./L based on mean measured centrifuged concentrations.

### **11.5.2 Acute (short-term) toxicity to aquatic invertebrates**

Three acute toxicity to aquatic invertebrate studies using tolpyralate are available for hazard classification, all GLP compliant.

#### Yoshikawa, M. 2013a

A 48-hour limit test with *Daphnia magna* was carried out at a tolpyralate concentration of 22 mg/L under static conditions. Twenty daphnids (four replicates of five organisms) were exposed to the test material, control and vehicle control (0.10 mL DMF/L). Measured concentrations of tolpyralate at test start and end were within the range of 80 - 120% of the nominal concentration and all the validity criteria were met. No immobility occurred and no sub-lethal effects were observed during the 48-hour period of the test at 22 a.s. mg/L. Therefore, the 24-hour and 48-hour EC<sub>50</sub> of tolpyralate is >19 mg a.s./L based on mean measured concentrations.

#### Brougher, D.S., Siddiqui, A.I., Gallagher, S.P. and Krueger, H.O. 2015b

## ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Saltwater mysids (*Americamysis bahia*) were exposed to five nominal test concentrations of 0.63, 1.3, 2.5, 5.0 and 10 mg a.s./L and a negative control (dilution water) for 96 hours under static-renewal conditions. Two replicate test chambers were maintained in each treatment and control group, with 10 mysids in each test chamber. All validity criteria were met. Test concentrations were measured in samples of test water collected from each treatment and control group at the beginning, prior to and after renewal and at 96 hours of the test. Measured concentrations of the un-centrifuged samples ranged from approximately 71.7 to 93.1% of nominal, and recovery decreased upon centrifugation. Consequently, the results were based upon mean measured centrifuged concentrations. The 96-hour LC<sub>50</sub> value was 0.66 mg a.s./L, with a 95% confidence interval of 0.41 to 8.4mg/L a.s./L. The confidence interval is large due to the flat dose response, therefore there is some uncertainty in the endpoint derived.

Brougher, D.S., Siddiqui, A.I., Gallagher, S.P. and Krueger, H.O. 2015c

Eastern oysters (*Crassostrea virginica*) were exposed to a geometric series of six test concentrations (nominal 0.19, 0.43, 0.94, 2.1, 4.5 and 10 mg a.s./L), a negative control (dilution water) and a solvent control (0.1 mL DMF/L) for 96 hours under flow-through conditions. One test chamber of 20 oysters was maintained in each treatment and control group. Test concentrations were measured in samples of test water collected from each treatment and control group at the beginning, the approximate mid-point and the end of the test. While measured concentrations of the samples ranged from approximately 88 to 101% of nominal, after centrifugation, mean measured recovery ranged from 68-91% of the nominal. Consequently, the results of the study were based on the mean measured concentrations for the centrifuged samples.

However, not all of the validity criteria were met as the criteria specifies that a minimum of 2 mm of shell growth should occur in the controls over the course of the test. Both the water control and the solvent control were below 2 mm (1.81 and 1.49 mm), with a pooled control value of 1.65 mm. Whilst this might reduce the sensitivity of the test to detect effects, a significant growth decrease was observed in the highest treatment solution and no clear dose-response was observed at lower concentrations. Consequently, the difference in control growth does not appear to have had any adverse impact on the study. Therefore this must be considered with the 96-hour EC<sub>50</sub> value for inhibition of shell deposition of 6.8 mg a.s./L (based upon mean measured concentrations, with a 95% confidence interval of 3.6 to 8.6 mg a.s./L).

### 11.5.3 Acute (short-term) toxicity to algae or other aquatic plants

Six studies testing toxicity to algae and aquatic plants have been evaluated for tolpyralate, all according to GLP certification. Four of these studies tested species of algae (OECD 201), one tested *Lemna* (OECD 221) and one study tested *Myriophyllum* (conducted prior to the OECD 239 guideline). Five of the studies are considered suitable for hazard classification. The endpoints derived from the algal study conducted with *Anabena flos-aquae* (Arnie *et al.* 2013) are not considered valid as two of the OECD 201 (2011) validity criteria were not met and there were issues regarding concentrations at test end for the two lowest test concentrations.

#### **Algae:**

Yoshikawa, M. 2013b

A 96-hour test with *Pseudokirchneriella subcapitata* was carried out at nominal tolpyralate concentrations of 0.94, 2.1, 4.5, 10 and 22 mg/L under static conditions. The initial cell density was  $0.5 \times 10^4$  cells/mL and there were four replicates at each concentration, with similarly constituted control and vehicle control (0.10 mL DMF/L) groups. All the validity criteria were met. As the measured concentrations ranged beyond  $\pm 20\%$  from nominal (range at test end was 49.9-65.3% of nominal and the overall geometric mean measured concentrations were in the range 66.5-76% of nominal), analysis of the results was based on geometric mean concentrations. The 96-hour E<sub>r</sub>C<sub>50</sub> was 12.3 mg a.s./L and the 96-hour NOE<sub>r</sub>C was 1.40 mg a.s./L based on mean measured concentrations. The E<sub>r</sub>C<sub>10</sub> was only calculated for 72 hours with a value of 4.44 mg a.s./L. Endpoints were based on statistical comparisons between treatment and solvent control data.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Arnie, J. R., Martin, K. H. and Porch, J. R. 2013a

The freshwater alga (cyanobacterium), *Anabaena flos-aquae*, was exposed to five test concentrations, a solvent control (0.1 mL DMF/L) and a negative control (culture medium) for 96 hours. Measured concentrations were determined from samples of test medium collected from each treatment and control group at 0, 72 and 96 hours of the test. Four replicate test chambers were maintained in each treatment and control group for the whole test, and an additional replicate was included in each control and treatment group to provide test solution for analytical sampling at 72 hours. At test initiation, an inoculum of the algal cells was added to each test chamber to achieve a nominal concentration of approximately 10,000 cells/mL.

Not all the validity criteria were met as the coefficient of variation of both the whole period and section-by-section were not met. Cell density data from tests conducted with this species are known to be highly variable, although sonification was performed. The results of the study are based on geometric mean, measured concentrations of 0.961, 1.61, 4.37, 8.36, 16.7 mg a.s./L, representing 58, 59, 66, 63 and 63% of the target nominal test concentrations. Therefore the 96-hour  $E_rC_{50}$  and  $E_rC_{10}$  value was determined to be >16.7 mg a.s./L for both endpoints based on statistical comparisons between treatment and medium control data. There is uncertainty regarding the geometric mean measured concentrations at the 2 lowest test concentrations, as the measured values were < LOQ on day 4 and a value of ½ the LOQ (0.50 mg a.s./L) was used to calculate the geometric mean. Given that two of the OECD validity criteria were not met and the issue regarding concentrations at test end for the two lowest test concentrations, the endpoints from this study are not considered reliable for hazard classification.

Arnie, J. R., Martin, K. H. and Porch, J. R. 2013b

The freshwater diatom, *Navicula pelliculosa*, was exposed to five test concentrations (geometric mean measured concentrations 0.737, 0.937, 2.25, 9.32, and 20.9 mg a.s./L), a solvent control (0.1 mL DMF/L) and a negative control (culture medium) for 96 hours. Samples of test medium collected from each treatment and control group at 0, 72 and 96 hours of the test to analyse tolpyralate concentration. Four replicate test chambers were maintained in each treatment and control group for the whole test, and an additional replicate was included in each control and treatment group to provide test solution for analytical sampling at 72 hours. At test initiation, an inoculum of the algal cells was added to each test chamber to achieve a nominal concentration of approximately 10,000 cells/mL. All of the validity criteria were met. The decline in measured concentrations at the end of the exposure period was outside  $\pm 20\%$  of the nominal (range at test end was <LOQ-70% of nominal and the overall geometric mean measured concentrations were in the range 28-79% of nominal). Consequently, the results of the study are based on geometric mean, measured concentrations. The 96-hour  $E_rC_{50}$  and  $E_rC_{10}$  values were determined to be >20.9 and 14.8 mg a.s./L respectively based on statistical comparisons between treatment and pooled control data. There is uncertainty in the geometric mean measured test concentrations for the lowest 3 test concentrations – as measured concentrations were < LOQ on days 3 and/or 4 (value of half LOQ was used when the measured concentration was < LOQ). The output from EFSA Peer Review Meeting 133 (2015) states that “the experts considered that this approach could be used when intermediate measurements (e.g. more than one intermediate point or other information) are available. This information may allow using the LOD or half of the LOQ, to calculate a geometric mean concentration”. The approach is considered acceptable for the 6.63 mg/l (nominal) test concentration as measured concentrations were obtained on day 3 and therefore it is known that concentrations declined below LOQ between days 3 and 4. However, it is not deemed appropriate for the lowest 2 concentrations. Nevertheless, since measured concentrations were obtained at all time points for the 2 highest concentrations, the  $E_rC_{50}$  endpoint is > than the highest concentration and the  $E_yC_{50}$  is between the 2 highest test concentrations – the  $EC_{50}$  endpoints from this study based on geometric mean measured concentrations are deemed reliable.

Arnie, J. R., Martin, K. H. and Porch, J. R. 2013c

## ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

A 96-hour study had the marine diatom, *Skeletonema costatum*, exposed to five test concentrations (mean measured concentrations 0.038, 0.092, 0.25, 0.61, 1.6 and 4.3 mg a.s./L), a solvent control (0.1 mL DMF/L) and a negative control (culture medium). Samples of test medium collected from each treatment and control group at 0, 72 and 96 hours of the test to analyse tolpyralate concentration. Four replicate test chambers were maintained in each treatment and control group for the whole test, and an additional replicate was included in each control and treatment group to provide test solution for analytical sampling at 72 hours. At test initiation, an inoculum of the algal cells was added to each test chamber to achieve a nominal concentration of approximately 10,000 cells/mL. All of the validity criteria were met. The decline in measured concentrations at the end of the exposure period was outside  $\pm 20\%$  of the nominal (range at test end was  $< \text{LOQ}$ -73.1% of nominal and the overall geometric mean measured concentrations were in the range of 71-86% of nominal). Consequently, the results of the study are based on geometric mean measured concentrations. The 96-hour  $E_rC_{50}$  and  $E_rC_{10}$  values were determined to be 1.8 and 0.15 mg a.s./L respectively based on statistical comparisons between treatment and pooled control data. It should be noted that there is some uncertainty in the mean concentration calculated for the lowest test concentration (0.038 mg/L) as an extrapolated value was used for day 4 as the measured concentration was  $< \text{LOQ}$ . The study report does not make it clear how the value was derived. However, as this is a measurement for a single time point at the lowest test concentration, whereas the  $E_rC_{50}$  endpoint relates to a much higher concentration, it is not considered to have a major impact upon the  $E_rC_{50}$  value derived from this study.

### **Aquatic plants:**

#### Kuhl, R. and Wydra V. 2013

Cultures of *Lemna gibba* were exposed to 6 dose rates of the test substance (nominal concentrations 100, 40.0, 16.0, 6.40, 2.56 and 1.02  $\mu\text{g}$  a.s./L), a solvent control (0.1 mL DMF/L) and a medium control for 7 days with four replicates per test concentration and control. At test start, 12 fronds were introduced in each replicate and incubated for 7 days under semi-static conditions. All the validity criteria were met. Test solutions were renewed on days 3 and 5. Analytical samples were taken from the freshly prepared solutions on days 0, 3, 5, and from the aged test media on days 3, 5 and 7. Over the test duration, the test substance was within  $\pm 20\%$  of the nominal at all times, and the *Lemna* were exposed to a mean of 99 % of nominal (measured concentrations were in the range 85-115% of nominal). Consequently, all the endpoints have been expressed as nominal concentrations. The 7-day  $E_rC_{50}$  and  $E_rC_{10}$  were calculated to be 0.0353 (dry weight) and 0.00142 mg a.s./L (frond number) respectively. The 7-day  $\text{NOE}_rC$  was 0.00102 mg a.s./L (dry weight and frond number).

#### Seeland-Fremer, A. and Wydra, V. 2014

It should be noted that this *Myriophyllum* study was conducted prior to the OECD 239 guideline. Nevertheless, the study meets the validity criteria outlined in the guideline apart from there is no reporting of whether or not sub-lethal effects occurred in control plants. However, the study was conducted over 7 days of exposure rather than the guideline duration of 14 days.

Plants of *Myriophyllum aquaticum* were exposed in a static water-sediment test to 5 dose rates of the test substance (geometric mean measured concentrations 244, 43.8, 8.36, 1.52 and 0.304  $\mu\text{g}$  test substance/L) and a control, with three replicates per test concentration and six replicates for the control. The sediment was prepared according to OECD 219. Each treatment group was spiked with a defined volume of the stock solution in order to obtain the desired test concentrations. Therefore these particular volumes were removed from the test water in each replicate before adding the stock solution. The overlying water was then mixed. After a pre-rooting phase of 3 days, 3 shoot tips per replicate were incubated for 7 days under static conditions. Over the test duration, the test substance declined outside  $\pm 20\%$  of the nominal, with an average recovery from the water phase of 66% at test initiation and 28% at test termination. Consequently, all the

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

endpoints have been expressed as geometric mean measured concentration. Therefore, the 7-day  $E_rC_{50}$  was calculated to be  $>0.244$  mg a.s./L (for growth rate based on shoot length, wet weight and dry weight). Due to  $> 10\%$  effects on growth rate (wet weight and shoot length) at the lowest test concentration it is not possible to derive a NOEC from this study. In addition, it has not been possible to derive an  $EC_{10}$ . It should be noted that there is uncertainty in the lowest test concentration ( $0.304 \mu\text{g}$  test substance/L), as measured concentrations were below the LOQ at test start and end. The study authors used the geometric mean recovery of 38% obtained from the next highest test concentration (nominal test concentration of  $4.0 \mu\text{g/L}$ ) for the statistical evaluation of the endpoints. This approach is not deemed appropriate and is considered likely to overestimate the amount of test substance as it is apparent that recovery at test end declined with lowering test concentration. However, this does not impact upon the  $EC_{50}$  endpoints as these are  $>0.244$  mg a.s./L (the highest concentration tested). In addition, it is noted that the guideline states that concentrations in sediment and sediment pore-water should be determined at test initiation and test termination, at least in the highest test concentration, unless the test substances are known to be stable in water ( $> 80\%$  of nominal). As tolpyralate does not appear to be stable in water – further monitoring should ideally have taken place.

**Table 54:  $EC_{10}$ , NOEC values and % inhibition for growth rate parameters**

Geometric mean measured concentration ( $\mu\text{g/L}$ )	Growth rate (total shoot length, 1/day) and percentage inhibition 7 days	Endpoint	Growth rate (based on wet weight, 1/day) and percentage inhibition 7 days	Endpoint	Growth rate (based on dry weight, 1/day) and percentage inhibition 7 days	Endpoint
Control	0.104		0.101		0.058	
0.304**	0.082 20.7%*	$E_rC_{10}$ n.d. NOE <sub>r</sub> C <0.304	0.089 12.1%*	$E_rC_{10}$ n.d. NOE <sub>r</sub> C <0.304	0.059 -2.6%	$E_rC_{10}$ n.d. NOE <sub>r</sub> C 0.304

\* mean value significantly different from the control

\*\* uncertainty in test concentration

n.d. = not determined

#### 11.5.4 Acute (short-term) toxicity to other aquatic organisms

No further relevant aquatic toxicity data are available.

### 11.6 Long-term aquatic hazard

#### 11.6.1 Chronic toxicity to fish

There is one suitable long-term toxicity to fish study for tolpyralate to be used for hazard classification. The fish early life stage test is GLP compliant and is according to OECD 210 (2013).

Anonymous, 2014g

An early-life stage study was conducted with fathead minnow (*Pimephales promelas*) at tolpyralate concentrations of 0.0300, 0.0949, 0.300, 0.949 and 3.00 mg/L under flow-through conditions. Eighty fish



## ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

embryos per test concentration (four replicates of 20 embryos per concentration) were exposed to the test material with the same number of embryos in similarly constituted control and vehicle control (0.10 mL DMF/L) groups. All measured concentrations of tolpyralate throughout the test were in the range  $\pm 20\%$  of the nominal concentration and all the validity criteria were met. There were no statistically significant differences between any of the exposure groups and the vehicle control with regard to hatchability, average days to hatch, rate of developmental abnormalities, survival rate after hatching, body weight and total body length. However, there were  $> 10\%$  effects (16.3-17.7%) on body weight at the two highest test concentrations. Therefore, the NOEC was considered to be 0.3 mg/L based on effects on body weight and mean measured concentrations. A reliable  $EC_{10}$  value could not be derived (the lower confidence limit was a negative value).

### 11.6.2 Chronic toxicity to aquatic invertebrates

There is one suitable long-term toxicity to aquatic invertebrate study for tolpyralate to be used for hazard classification. The *Daphnia magna* reproductive test is GLP compliant and conducted according to OECD 211 (2012).

Yoshikawa, M. 2014b

A 21-day reproduction study was conducted with *Daphnia magna* at tolpyralate concentrations of 0.625, 1.25, 2.50, 5.00 and 10.0 mg/L under semi-static conditions. Ten daphnids (as ten replicates) were tested per test concentration, with similarly constituted control and vehicle control (50  $\mu$ L DMF/L) groups. All measured concentrations of tolpyralate throughout the test were within  $\pm 20\%$  of nominal, and all the validity criteria were met. No test substance-related parental immobility occurred and no sub-lethal effects (parameters considered were size, swimming behaviour, abnormal appearance, sex distinction, time to production of first brood and presence of ephippium or aborted brood) were observed during the 21-day period of the test. Therefore the 21 day NOEC was  $> 8.94$  mg a.s./L based on mean measured concentrations.

Two acute aquatic invertebrate studies have been provided, one with *Daphnia magna* ( $EC_{50} > 19$  mg/l) and one with *Americamysis bahia* ( $EC_{50}$  0.66 mg/l). The data requirements (283-2013) state “*If acute toxicity tests have been conducted on two aquatic invertebrate species the acute endpoints shall be taken into account in order to determine the appropriate species to be tested in the chronic toxicity study*”. In addition, the EFSA 2013 aquatic guidance states that “*The PPR Panel proposes to select the more sensitive species in case the difference in acute toxicity is more than a factor of 10.*” *Americamysis bahia* is clearly the most sensitive aquatic invertebrate species tested in the acute studies ( $>$  factor of 10 difference). Therefore, this mysid species should have been tested in the chronic study, rather than *Daphnia magna* and as such this is considered by the RMS to be a data gap in the DAR.

### 11.6.3 Chronic toxicity to algae or other aquatic plants

See Section 11.5.3.

### 11.6.4 Chronic toxicity to other aquatic organisms

No further relevant aquatic toxicity data are available.

## 11.7 Comparison with the CLP criteria

The active substance, tolpyralate does not meet the criteria for ‘rapidly degradable’, as it remains  $> 70\%$  after 28 days. It does meet the primary criteria with a  $\frac{1}{2}$  life of  $< 16$  days. The major aquatic metabolite MT-2153 is persistent and is toxic to aquatic organisms. As a consequence, within the classification criteria,

## ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

tolpyralate is not considered ‘rapidly degradable’. Information presented in Annex II indicates the major aquatic degradant, MT-2153, has acute and chronic aquatic toxicity similar to, or slightly greater than parental toxicity (although the endpoints for algae and *Lemna* are slightly lower than parent, the differences are considered to be within the realms of inter-study variability). Therefore, this degradant, along with the active substance will be considered further for hazard classification.

MMTA and TAT-2049 are major degradants in soil studies only and were not sufficiently toxic to pass any of the hazard criteria; therefore they are not considered further for hazard classification.

Tolpyralate has a log  $K_{ow}$  value of 1.9, which is lower than the CLP cut-off Log  $K_{ow}$  value of  $\geq 4$ . Therefore, tolpyralate is not considered to have the potential to bioaccumulate.

Acute and chronic aquatic toxicity data on tolpyralate are available for fish, invertebrates, algae and aquatic plants. Aquatic plants are considered the most sensitive trophic group over both acute and chronic timescales which is not unexpected given the herbicidal activity of tolpyralate. Toxicity data is also available for the degradant MT-2153 (acute fish and invertebrates, algae and aquatic plants). Again, aquatic plants are the most sensitive group. Therefore, the classification proposals will focus on the toxicity to aquatic plants.

### 11.7.1 Acute aquatic hazard

Endpoints are available for tolpyralate and the degradant MT-2153 for the aquatic plants *Myriophyllum aquaticum* and *Lemna gibba*. The endpoints for *Myriophyllum aquaticum* are 7-day  $E_rC_{50}$   $>0.244$ mg tolpyralate/L and 14-day  $E_rC_{50}$  0.0611 mg MT-2153/L. The endpoints for *Lemna gibba* are 7-day  $E_rC_{50}$  0.0353 tolpyralate/L and a 7-day  $E_rC_{50}$  0.0315 mg MT-2153/L. The lowest overall acute endpoint is a 7-day mean measured  $E_rC_{50}$  of 0.0315 mg MT-2153/L for *Lemna gibba* (dry weight). This endpoint is  $> 0.01$  but  $\leq 0.1$  mg/L, therefore tolpyralate should be classified as Aquatic Acute category 1 with an acute M-factor of 10 based on the data for the major degradant MT-2153.

### 11.7.2 Long-term aquatic hazard (including bioaccumulation potential and degradation)

The lowest chronic endpoint is a 7-day mean measured  $NOE_rC$  of  $<0.000304$  mg tolpyralate/L for *Myriophyllum aquaticum*. No  $EC_{10}$  endpoints could be derived for this study. It should be noted that the study duration (7 days) was shorter than the recommended 14 days, there was no analytical monitoring of the sediment, and there is uncertainty in the lowest test concentration due to the manner in which the geometric mean measured concentration was derived (via extrapolation from a higher test concentration). In terms of the  $E_rC_{50}$  endpoints *Lemna gibba* appears to be more sensitive than *Myriophyllum aquaticum*, however it is less clear in terms of the  $NOE_rC$  values. The  $NOE_rC$  for *Lemna gibba* is 0.00102 mg a.s./L (dry weight and frond number), whereas the  $NOE_rC$  for *Myriophyllum* is  $<0.000304$  mg a.s./L. In addition, the results from the *Myriophyllum* study with the major aquatic degradant MT-2153 indicate a  $NOE_rC$  of  $< 0.000606$  mg a.s./L (again uncertainty in this the lowest test concentration as measured concentrations were  $< LOQ$  at test start and end), indicating that *Myriophyllum* is potentially more sensitive. An  $EC_{10}$  could not be derived for the most sensitive growth rate parameter (dry weight). As a consequence, there is no clear reliable endpoint that can be used for classification purposes for *Myriophyllum*.

In the absence of a reliable *Myriophyllum* endpoint (for either the active substance or degradant MT-2153) it is proposed to use the toxicity data derived from the studies with *Lemna gibba* (as an interim measure). As the degradant MT-2153 is not ‘rapidly degradable’ and appears to be marginally more toxic than the active substance to *Lemna gibba*, the chronic classification is based upon the 7 d  $NOE_rC$  of 0.0009 mg/l (based on dry weight) for MT-2153. This endpoint is between  $>0.0001$  to  $\leq 0.001$  mg/l and, since tolpyralate is not ‘rapidly degradable’, tolpyralate should be classified as Chronic 1 with a chronic M-factor of 100 based on the data for the major degradant MT-2153.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

It is acknowledged that there is an element of uncertainty in the chronic M-factor due to the absence of a reliable NOE<sub>r</sub>C or EC<sub>10</sub> endpoint for *Myriophyllum*. Should further reliable chronic data become available on this species or other sensitive aquatic plants (e.g. during the pesticide renewal process), then this classification should ideally be reconsidered. It is understood that a further study on *Myriophyllum* with the active substance will be provided during the current EU review of tolpyralate. Although, a further study with the degradant MT-2153 may also be useful.

## 11.8 CONCLUSION ON CLASSIFICATION AND LABELLING FOR ENVIRONMENTAL HAZARDS

**Aquatic Acute 1; H400: Very toxic to aquatic life**

**Acute M-factor = 10**

**Aquatic Chronic 1; H410: Very toxic to aquatic life with long lasting effects**

**Chronic M-factor = 100**

### RAC evaluation of aquatic hazards (acute and chronic)

#### Summary of the Dossier Submitter's proposal

The major aquatic metabolite of tolpyralate MT-2153 is persistent and toxic to aquatic organisms and is formed very fast and in significant amounts under normal environmental conditions. Although the DS considered that tolpyralate does not meet the criteria for 'rapidly degradable', the degradant MT-2153 together with the active substance was considered by the DS as relevant for hazard classification of tolpyralate. The DS proposed classification as:

Aquatic Acute 1, with an M factor of 10 based on the lowest 7 d E<sub>r</sub>C<sub>50</sub> value for the major degradant MT-2153 for aquatic plant (*Lemna gibba*) of 0.0315 mg/L.

Aquatic Chronic 1, with M factor of 100 based on the lowest 7 d NOE<sub>r</sub>C value for the major degradant MT-2153 for aquatic plant (*Lemna gibba*) of 0.0009 mg/L.

#### Degradation

The aquatic hydrolysis study indicates that there is no ultimate degradation i.e. >70% within 28 d, as at 10 °C DT<sub>50</sub> was 231 d at pH 7 for tolpyralate in purified water (respectively at pH 4 – 1050 d and at pH 9 - 2.31 d). However, tolpyralate hydrolyses more rapidly under conditions of higher pH and under increasing temperature. One hydrolysis product MT-2153 reached > 5 % of the applied radioactivity. At 25 °C degradant MT-2153 reached maximum concentrations of 6.6 % AR (pH 4), 47.6 % AR (pH 7), and 97 % AR (pH 9). At 10 °C MT-2153 reached maximum concentrations of 1.1, 7.8 and 86.3 % AR respectively at pH 4, 7, and 9 (Unsworth, 2013). As MT-2153 was stable at all pH values at 50 °C and no degradation of MT-2153 was seen, no further testing was conducted as the DT<sub>50</sub> value would be greater than one year at all environmentally relevant pH and temperature (Hori, K. 2014b).

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

In a ready biodegradation study (OECD TG 301F), biodegradation of tolpyralate observed after 25 days was 9% (Hammesfahr, 2013).

An aquatic photolysis study (OECD TG 316) indicated that tolpyralate degrades rapidly via photolysis with DT<sub>50</sub> values of 4.41 days in natural water and 2.86 days in purified water (6 – 7 pH, 25 °C) (Unsworth, 2014). The degradant MT-2153 was formed but at equal or lower amounts than in dark controls. That suggests that it was formed by hydrolysis, not photolysis. However, the DS considered that photolysis is of uncertain relevance and is not useful for classification purposes as the route of degradation is dependent on local conditions and the information is insufficient for classification purposes.

Aerobic mineralization in the surface water study (OECD TG 309) indicated that in microbially active surface water at 20 °C, tolpyralate degraded rapidly to less than 2% of applied activity after 14 days incubation (Van den Bosch, M.M.H. 2014). The DT<sub>50</sub> values for tolpyralate were 2.06 days at an initial concentration of 10 µg/mL and 2.02 days at an initial concentration of 100 µg/mL. The degradant MT-2153 reached >90 % AR at 7 days at both initial concentrations but there was no clear evidence of decline at the end of study after 62 days. The maximum amount of CO<sub>2</sub> formed was 3.8% AR.

An aerobic water/sediment simulation study (OECD TG 308) was conducted in two natural aquatic systems, Calwich Abbey Lake and Swiss Lake, UK. Whole system DT<sub>50</sub> values of tolpyralate were 1.39 and 1.88 days (geometric mean 1.62) for the two systems (Kane, T. 2014). Based on the results of the study, the DS considered that tolpyralate declined rapidly in both systems. Degradant MT-2153 in the whole system reached a maximum 82.0% and 79.9% AR. In the sediment, the amounts of MT-2153 reach a maximum 19.8 % and 32.7 % AR. DT<sub>50</sub> values of MT-2153 in the whole system was 206 and 176 days (geometric mean 190).

Based on an anaerobic water/sediment study (OECD TG 308), the rate of degradation of tolpyralate was similar to the aerobic study, while that for MT-2153 was generally longer (Crowe, 2015). Whole system DT<sub>50</sub> values of tolpyralate were 1.47 and 2.72 days (geometric mean 2), respectively, at pH 7.3 and 5. MT-2153 reached a max of 89.3 and 93 % in the whole system and 23.6 and 18.8 % in the sediment, respectively. DT<sub>50</sub> values of MT-2153 were 388 and 394 days (geometric mean 365) for the two systems, respectively, at pH 7.4 and 5.7.

Overall, the DS concluded that although there is rapid primary degradation of the active substance, tolpyralate does not meet the CLH criteria as rapidly degradable because ultimate biodegradation is not achieved to a level greater than or equal to 70% after 28 days and it cannot be demonstrated that the degradation products do not fulfil the criteria as hazardous to the aquatic environment. As MT-2153 indicated high acute and chronic toxicity and formed very fast and in significant amounts, MT-2153 was considered in the classification of tolpyralate by the DS.

#### **Aquatic Bioaccumulation**

Using the HPLC method, the determined log K<sub>ow</sub> of tolpyralate was 1.9 at 25 °C and pH 6.4 (Furutami, 2014). No experimental aquatic study to determine the bioconcentration potential (BCF) of tolpyralate was available.

Overall, the DS considered that tolpyralate does not meet the CLP criteria as a bioaccumulative substance as the log K<sub>ow</sub> value of 1.9 is below the log K<sub>ow</sub> trigger value of

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

≥4 and no experimental data (BCF) is available. It is therefore considered to have a low potential for bioaccumulation.

### **Aquatic Toxicity**

The ecotoxicological test results from available acute and chronic studies for all trophic levels of tolpyralate are summarised in the following table and sections. Whilst degradant MT-2153 demonstrates high aquatic toxicity to the aquatic plants and should be considered for classification of tolpyralate, the relevant tests results are provided as well. Accordingly, the new information (generated during Public Consultation) is included and discussed in further detail below.

Only the valid acute and chronic studies on tolpyralate and degradant MT-2153 which are relevant for hazard classification purposes are included in the following table and relevant endpoints from these studies are discussed in further detail below.

<b>Test organism / guideline, test method</b>	<b>Short-term result (endpoint)</b>	<b>Long-term result (endpoint)</b>	<b>Test material/ remarks</b>	<b>Reference</b>
<b>Fish</b>				
<i>Oncorhynchus mykiss</i> / OECD TG 203, GLP	96 h LC <sub>50</sub> > 21 mg/L (mm)		Tolpyralate	Anonymous, 2013m
<i>Cyprinus carpio</i> / OECD TG 203, GLP	96 h LC <sub>50</sub> > 19 mg/L (mm)		Tolpyralate	Anonymous, 2013n
<i>Pimephales promelas</i> / OECD TG 203, GLP	96 h LC <sub>50</sub> > 19.7 mg/L (mm)		Tolpyralate	Anonymous, 2014f
<i>Cyprinodon variegatus</i> / OECD TG 203, GLP	96 h LC <sub>50</sub> > 11.6 mg/L (mm)		Tolpyralate	Anonymous, 2015h
<i>Pimephales promelas</i> / OECD TG 210, GLP		28 d NOEC = 0.3 mg/L (mm)	Tolpyralate	Anonymous, 2014g
<i>Oncorhynchus mykiss</i> / OECD TG 203, GLP	96 h LC <sub>50</sub> > 100 mg/L (n)	96 h NOEC = 100 mg/L (n)	MT-2153	Anonymous, 2014f
<b>Aquatic invertebrates</b>				
<i>Daphnia magna</i> / OECD TG 202, GLP	48 h EC <sub>50</sub> > 19 mg/L (mm)		Tolpyralate	Yoshikawa, 2013
<i>Americamysis bahia</i> / OPPTS 850.1035, GLP	96 h EC <sub>50</sub> = 0.66 mg/L (mm)		Tolpyralate	Brougher <i>et al.</i> , 2015b
<i>Crassostrea virginica</i> / OPPTS 850.1025, GLP	96 h EC <sub>50</sub> = 6.8 mg/L (mm)		Tolpyralate	Brougher <i>et al.</i> , 2015c
<i>Daphnia magna</i> / OECD TG 211, GLP		21 d NOEC ≥ 8.94 mg/L (mm)	Tolpyralate	Yoshikawa, 2014b

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

<i>Daphnia magna</i> / OECD TG 202, GLP	96 h LC <sub>50</sub> > 100 mg/L (n)	96 h NOEC = 100 mg/L (n)	MT-2153	Handlos and Erk, 2014b
<b>Algae / aquatic plants</b>				
<i>Pseudokirchneriella subcapitata</i> / OECD TG 201, GLP	96 h E <sub>r</sub> C <sub>50</sub> = 12.3 mg/L (mm)	96 h NOE <sub>r</sub> C = 1.4 mg/L (mm) 96 h E <sub>r</sub> C <sub>10</sub> = 4.44 mg/L (mm)	Tolpyralate	Yoshikawa, 2013b
<i>Pseudokirchneriella subcapitata</i> / OECD TG 201, GLP	72 h E <sub>r</sub> C <sub>50</sub> = 8.88 mg/L (n)	72 h E <sub>r</sub> C <sub>10</sub> = 2.94 mg/L 72 h NOE <sub>r</sub> C = 1.0 mg/L	MT-2153	Handlos and Erk, 2014c
<i>Anabaena flos-aquae</i> / OECD TG 201, GLP	96 h E <sub>r</sub> C <sub>50</sub> > 16.7 mg/L (mm)	96 h E <sub>r</sub> C <sub>10</sub> > 16.7 mg/L (mm)	Tolpyralate	Arnie <i>et al.</i> , 2013a
<i>Navicula pelliculosa</i> / OECD TG 201, GLP	96 h E <sub>r</sub> C <sub>50</sub> > 20.9 mg/L (mm)	96 h E <sub>r</sub> C <sub>10</sub> = 14.8 mg/L (mm)	Tolpyralate	Arnie <i>et al.</i> , 2013b
<i>Skeletonema costatum</i> / OECD TG 201, GLP	96 h E <sub>r</sub> C <sub>50</sub> = 1.8 mg/L (mm)	96 h E <sub>r</sub> C <sub>10</sub> = 0.15 mg/L (mm)	Tolpyralate	Arnie <i>et al.</i> , 2013c
<i>Lemna gibba</i> / OECD TG 221, GLP	7 d E <sub>r</sub> C <sub>50</sub> = 0.0353 mg/L (n)	7 d E <sub>r</sub> C <sub>10</sub> = 0.00142 mg/L (n) 7 d NOE <sub>r</sub> C = 0.00102 mg/L (n)	Tolpyralate	Kuhl and Wydra, 2013
<i>Lemna gibba</i> / OECD TG 221, GLP	7 d E <sub>r</sub> C <sub>50</sub> = <b>0.0315</b> mg/L (mm)	7 d E <sub>r</sub> C <sub>10</sub> < 0.0009 mg/L (mm) 7 d NOE <sub>r</sub> C = <b>0.0009</b> mg/L (mm)	MT-2153	Hermes and Frank, 2015a
<i>Myriophyllum aquaticum</i> / OECD TG 239, GLP	7 d E <sub>r</sub> C <sub>50</sub> > 0.244 mg/L (mm)	7 d NOE <sub>r</sub> C < 0.000304 mg/L (mm)	Tolpyralate **	Seeland-Fremer and Wydra, 2014
<i>Myriophyllum spicatum</i> / OECD TG 239, GLP	14 d E <sub>r</sub> C <sub>50</sub> = 0.0611 mg/L (mm)	14 d NOE <sub>r</sub> C < 0.000606 mg/L (mm)	MT-2153 **	Hermes and Frank, 2015b

mm – mean measured

n – nominal

bold – lowest aquatic acute and chronic endpoints of tolpyralate and MT-2153 indicated by the DS

\*\* – DS indicated uncertainty in test concentration and/or pH

Acute and chronic aquatic toxicity data on tolpyralate and the degradant MT-2153 are available for fish, invertebrates, algae and aquatic plants. The DS considered aquatic plants as the most sensitive trophic group for both acute and chronic timescales. Therefore, the DS based the classification proposal on the toxicity to aquatic plants.

The DS considered that the lowest overall acute endpoint is a 7-day mean measured E<sub>r</sub>C<sub>50</sub> of 0.0315 mg/L of MT-2153 for *Lemna gibba* (dry weight). Furthermore, the lowest acute endpoint of tolpyralate (7 d E<sub>r</sub>C<sub>50</sub> of 0.0353 mg/L for *Lemna gibba*) was also in the same

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

classification range. In the same classification range was also the acute endpoint of MT-2153 for *Myriophyllum spicatum* (14-day E<sub>r</sub>C<sub>50</sub> of 0.0611 mg/L). Since the effects endpoint is above 0.01 but ≤ 0.1 mg/L, the DS proposed to classify tolpyralate as Aquatic Acute category 1 with an acute M-factor of 10 based on the data for the major degradant MT-2153.

In the absence of reliable *Myriophyllum* chronic toxicity endpoints (for either the active substance or degradant MT-2153), the DS proposed to use the chronic toxicity data derived from the studies with *Lemna gibba*. Since the degradant MT-2153 is not 'rapidly degradable' and slightly more toxic than the parent substance, the chronic classification was based on a 7-day NOEC of 0.0009 mg/L (dry weight) for MT-2153. This endpoint is between 0.0001 and 0.001 mg/L and, since tolpyralate is not 'rapidly degradable', tolpyralate should be classified as Chronic 1 with a chronic M-factor of 100, based on the data for the major degradant MT-2153.

Furthermore, the DS acknowledged that there is an uncertainty in the chronic M-factor due to the absence of a reliable NOE<sub>r</sub>C / EC<sub>10</sub> endpoint for *Myriophyllum*. The DS pointed out that if further reliable chronic data become available on *Myriophyllum* or other sensitive aquatic plant species, then the environmental classification should be reconsidered.

### Comments received during public consultation

These studies have been provided during and after the initial CLH public consultation (i.e. as part of the EFSA-led pesticide peer review programme). An additional targeted public consultation was launched on these new studies. The main results of the new studies are provided below.

Test organism / guideline, test method	Short-term result (endpoint)	Long-term result (endpoint)	Test material/ remarks	Reference
<b>Aquatic invertebrates</b>				
<i>Americamysis bahia</i> / OPPTS 850.1035, GLP		21 d NOEC = 0.022 mg/L (mm)	Tolpyralate	Amanda <i>et al.</i> , 2017
<i>Crassostrea virginica</i> / OPPTS 850.1025, GLP	96 h EC <sub>50</sub> = 8.7 mg/L (mm)	96 h NOEC = 3.1 mg/L (mm)	Tolpyralate	Brougher <i>et al.</i> , 2016
<b>Algae / aquatic plants</b>				
<i>Myriophyllum spicatum</i> / OECD TG 239, GLP	14 d E <sub>r</sub> C <sub>50</sub> = <b>0.0102</b> mg/L (mm)	14_d E <sub>r</sub> C <sub>10</sub> = <b>0.000129</b> mg/L (mm) 14 d NOE <sub>r</sub> C = <b>0.000603</b> mg/L (mm)	Tolpyralate **	Hermes and Emnet, 2018

mm – mean measured

n – nominal

bold – lowest aquatic acute and chronic endpoints indicated after PC

\*\* – DS indicated uncertainty in test concentration and/or pH

At the initial Public consultation, three MSCAs and one company submitted comments on the environmental part of the DS's proposal. One MSCA and Industry referred to a new *Myriophyllum spicatum* study (described above) with a duration of 14 days, performed

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

according to OECD TG 239 with tolpyralate. Nevertheless, the MSCA noted that effect endpoints from this new study ( $E_rC_{50}$  0.0102 mg/L and NOEC 0.00063 mg/L) wouldn't change the proposed classification and M-factors. Additionally, the same MSCA noted that a new chronic toxicity study with *Mysid* (*Americamysis bahia*) is available (also described above), which eliminates the data gap related to the chronic toxicity of invertebrates. In response, the DS noted that the new chronic *Mysid* study has been evaluated and a NOEC could be derived. However, as aquatic plants are clearly more sensitive than invertebrates, this study does not have any impact on the proposed classification.

Regarding the new *Myriophyllum spicatum* study, the DS indicated uncertainty in the lower test concentrations (i.e. due to recovery at the relevant test concentrations being < LOQ or < LOD in the aged media) and, therefore, indicated that the endpoint based on geometric mean measured concentrations may underestimate the toxicity of the test substance. Additionally, the DS pointed out the large difference in pH between the different test solutions. The DS noted that the pH in this study varied from well below to well above the recommended level by OECD over the renewal periods. Therefore, the DS does not deem the study as a reliable one to derive a NOEC although the study report states that all validity criteria were met. The DS noted that it is not possible to currently check two of the criteria, as the raw data do not appear to have been included within the study report. Overall, the DS concluded that as no reliable NOEC for *Myriophyllum* can be derived from this study, the chronic M-factor should be based on the data for *Lemna gibba* for the degradant MT-2153.

A second MSCA requested a better overview of the acute and chronic toxicity studies of the relevant degradant MT-2153 and remarked that, for long-term aquatic hazard classification and labelling purposes, it is recommended to use data for the substance itself (intrinsic toxicity). Hence, the MSCA referred to the chronic data of tolpyralate to aquatic plant *Myriophyllum aquaticum* ( $NOErC \leq 0.000304$  mg/L) as the lowest long term value. Furthermore, the MSCA noted that a further study with *Myriophyllum* with a duration of 14 days would be useful and preferable. In their response, the DS noted that further information can be provided regarding the aquatic studies with the degradant MT-2153, however the DS did not provide any detailed explanation on acute and chronic toxicity studies of the MT-2153.

Regarding the long-term aquatic hazard, the DS does not consider the new *Myriophyllum spicatum* study as reliable, hence the chronic M-factor will remain based on the data for *Lemna gibba* for the degradant MT-2153.

A third MSCA specified that they agree with the proposed classification and M-factors as the proposals are based on degradant data and not on the data of the parent substance itself. However, the MSCA indicated that if the classification would be based on toxicity data of the parent substance, the proposal would need to be revised. This MSCA also agreed that the chronic M-factor should be reconsidered if relevant further data become available. In their response, the DS noted that originally the chronic classification and M-factor were based on the parent substance (tolpyralate) data for *Lemna gibba*. However, the proposal was revised and was based on the degradant (MT-2153) aquatic toxicity data. In addition, the DS mentioned that new *Myriophyllum* studies with tolpyralate were provided, although it was not possible to obtain a reliable NOEC from this study.

At the targeted public consultation, three MSCAs submitted comments. All of them agreed with the classification as Aquatic Acute 1 (M = 10) and Aquatic Chronic 1 (M = 100).



ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Although one MSCA noted that the 14-day study with *Myriophyllum spicatum* includes the complicating factor of sediment and analytics at low concentrations and different pH was variable. However, they considered the study reliable and relevant for classification. Additionally, the MSCA suggested to use an  $E_rC_{10}$  value of 0.000129 mg/L for classification purposes, which is in same range as the  $NOE_rC$  value of 0.000603 mg/L. The other MSCA noted that the 14-day study with *Myriophyllum spicatum* fulfils the CLP requirements and that the endpoints can be considered as reliable for classification purposes.

### Additional key elements

Some additional information on the new studies with the substance (tolpyralate) submitted during/ after the initial public consultation PC can be found in this section:

96-hour shell deposition test with the Eastern Oyster (*Crassostrea virginica*) – not affecting the proposed classification as aquatic plants is the most sensitive group. No further action needed.

A flow-through life-cycle toxicity test with the saltwater Mysid (*Americamysis bahia*) – not affecting the proposed classification as aquatic plants is most sensitive group. However, this study eliminates data GAP of chronic toxicity of invertebrates as *Mysid* is clearly most sensitive aquatic invertebrate's species tested in acute and chronic tests. No further action needed.

Toxicity to the Aquatic Plant *Myriophyllum spicatum* in a Semi-Static Growth Inhibition Test with a Prior Rooting Phase – could affect the proposed classification as aquatic plants *Myriophyllum* are one of most sensitive species (the other is *Lemna*). The study is GLP compliant study based on OECD TG 239 ((study date 2018). Authors: Hanna Hermes, Philipp Emnet, PhD. Test item SL-573 TGAI (tolpyralate, purity 97.27 %)). The pH-values were measured in the test media of all test concentrations and the control at test start, at each test medium renewal and at test end.

	pH values	
pre-rooting phase	freshly prepared test media	aged test media
5.8-6.0	5.9-6.5	6.9-9.8

#### Results:

The 14-day  $E_rC_{50}$  was calculated to be 28.7, 43.9 and 10.2  $\mu\text{g}$  (0.0102 mg/L) test item/L for shoot length, fresh weight and dry weight, respectively.

The 14-day  $E_rC_{10}$  was calculated to be 0.458, 0.215 and 0.129  $\mu\text{g}$  (0.000129 mg/L) test item/L for shoot length, fresh weight and dry weight, respectively.

The 14-day  $NOE_rC$  and the  $LOE_rC$  for total shoot length, fresh weight and dry weight were determined to be 0.603 (0.000603 mg/L) and 4.34  $\mu\text{g}$  test item/L, respectively.

Although the study report states that all validity criteria are met, the DS indicated some issues with this study. The test design was semi-static with renewal of test solutions every 2-3 days. Despite this, test concentrations were not maintained at the three lowest concentrations tested. In the lowest test concentration – the majority of samples were < LOQ or < LOD in the aged media. In the second lowest concentration, half of the analytical samples were < LOQ or < LOD in the aged media. In the third lowest concentration, two

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

of the analytical samples were < LOD in the aged media. The study report has used half of the LOQ or the LOD (when concentrations were < LOQ or < LOD, respectively) to calculate geometric mean measured test concentrations. Therefore, there is uncertainty in the three lower concentrations – two of which are key concentrations for deriving a NOEC from this study.

The non-maintenance of test concentrations in the lower three test concentrations appears to be linked to pH. SI-573 appears to be more stable under acidic conditions. The pH in the control and lowest 3 concentrations drifted by > 3 pH units over some of the 2-3 day renewal periods. Although the pH was 5.9-6.5 in the fresh media, in the control aged media it drifted to a maximum of pH 9.5 and reached a maximum of pH 9.8 in the lowest test concentration. This large drift in pH was not seen in the 4 highest test concentrations (maximum pH was 7.4- 7.8 in the 4 highest test concentrations), and test concentrations were maintained much better. There is no explanation within the study report regarding the large difference in pH between the different test solutions. It is noted that the OECD guideline specifies that the pH of the test media (water phase) at test initiation should be between 7.5 and 8.0 for optimum plant growth. It appears that the pH in the study varied from well below to well above the recommended level over the renewal periods.

According to the study report, the pH increased by more than 1.5 units during the test at the test item concentrations of 0.603, 0.243 and 0.080 µg/L (3 lowest concentrations) and in the control. However, this could be explained due to growth and metabolism of the plants (biogenic decalcification). As the higher concentrations inhibit the plants' growth, pH increase did not occur. As well in terms of pH, it is acknowledged that the pH indeed varied more than what is recommended in OECD TG 239. However, in the guideline it is also mentioned that deviation of more than 1.5 units would not invalidate the test when it can be shown that the validity criteria are met. As the test report clearly mentions that the validity criteria have been met the pH increase did not compromise the reliability of the study. Also, according to the CLP guidance "where concentrations at the end of test are below the analytical detection limit, such concentrations shall be considered to be half that detection limit". In the study report, (table 19, last column) it is indicated that for geometric mean calculation, half of LOQ or LOD was used.

Overall RAC considers that the uncertainty identified by the DS has no critical impact on the study validity and does not eliminate the reliability of the study, as all validity criteria have been met and geometric mean calculations were performed according to the relevant guidance.

Therefore, RAC is of the opinion that the derived 14-day  $E_rC_{10}$  and  $NOE_rC$  of *Myriophyllum spicatum* with tolpyralate shall be considered as relevant and reliable for aquatic chronic classification purpose and to set M-factor(s).

### **Assessment and comparison with the classification criteria**

A ready biodegradation study with tolpyralate indicated 9% degradation after 25 days, indicating that tolpyralate is not readily biodegradable.

The hydrolysis study indicated that there is no ultimate degradation, with more rapid hydrolysis under conditions of higher pH and increasing temperature. The major aquatic metabolite MT-2153 (is persistent and toxic to aquatic organisms.. Additionally, tolpyralate degrades rapidly via photolysis (< 5 d in purified and natural water) and the major

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

degradant MT-2153 formed in equal or lower amounts than in dark controls, suggesting that it was formed by hydrolysis not photolysis. Moreover, photolysis is of uncertain relevance as a route of degradation.

The aerobic mineralisation study and water/sediment studies (aerobic and anaerobic) indicate that tolpyralate underwent rapid primary degradation in natural waters with DT<sub>50</sub> values at <3 days. In all studies, the major degradation product was MT-2153, which in the aerobic water/sediment study has in the whole system a geometric mean DT<sub>50</sub> value of 190 and in anaerobic water/sediment study – 365 days. The rate of degradation of tolpyralate was similar in both studies with DT<sub>50</sub> of 1.6 – 2 days (geomean). In the aerobic/water sediment study, MT-2153 in the whole system reached a maximum 82.0% and 79.9% AR. In the anaerobic water sediment study MT-2153 reached a max. of 89.3 and 93 %.

RAC agrees that tolpyralate does not meet the CLP criteria as rapidly degradable because ultimate biodegradation of the substance (i.e. full mineralisation) is not achieved and it cannot be demonstrated that the degradation products do not fulfil the criteria as hazardous to the aquatic environment. RAC also agrees that the major degradant MT-2153 should be considered for classification purposes of tolpyralate since MT-2153 is very toxic to aquatic environment and forms very fast in significant amounts under normal environmental conditions, as reported in the different biotic and abiotic degradation studies.

#### **Aquatic Bioaccumulation**

The determined log K<sub>ow</sub> of tolpyralate is 1.9 at 25 °C and pH 6.4 which is less than the CLP trigger of ≥ 4. Therefore, RAC agrees with the DS's conclusion that the substance is not bioaccumulative.

#### **Aquatic Toxicity**

There are reliable acute and chronic aquatic toxicity data for all trophic groups with tolpyralate, as well as with the degradant MT-2153. For both, the most acutely and chronically sensitive trophic group were aquatic plants *Lemna gibba* and *Myriophyllum*. The acute toxicity results of tolpyralate and degradant MT-2153 from two studies with *Lemna gibba* and two studies with *Myriophyllum spicatum* were slightly different, but still in the same range for aquatic acute classification purposes and M-factor derivation.

Regarding chronic toxicity, tolpyralate seems be more toxic to *Myriophyllum* than to *Lemna gibba*. However, the chronic toxicity of degradant MT-2153 to *Myriophyllum* and *Lemna gibba* was slightly different, albeit still in the same range for aquatic chronic classification purposes and M-factor derivation. The same was the case (slightly different but still in the same classification range as for the degradant MT-2153) for the tolpyralate results obtained with *Myriophyllum*.

Due to the degradant MT-2153 being formed in levels up to 90% in less than 16 days, RAC considers that MT-2153 should be considered for classification purposes of tolpyralate as it seems slightly more toxic at least to *Lemna gibba* than the parent substance. RAC notes that some key studies have uncertainties related to the concentration and/or pH, however, RAC is of opinion that these uncertainties are unlikely to compromise the reliability of all

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

studies overall. Nevertheless, if additional/more reliable chronic data of tolpyralate or the degradant MT-2153 become available in the future for the most acutely sensitive species, the chronic M-factor(s) may need to be revised.

Therefore, RAC agrees with the DS proposed classification as Aquatic Acute 1 (M-factor 10) and Aquatic Chronic 1 (M-factor 100), but base the classification on the toxicity results of *Myriophyllum spicatum*, from the new 14-day study, performed with tolpyralate. The lowest acute endpoint for aquatic acute classification purposes is 14 d  $E_rC_{50}$  for *Myriophyllum spicatum* of 0.0102 mg/L, based on mean measured concentration of tolpyralate. It should be noted that one more study with tolpyralate derived a 7 d  $E_rC_{50}$  for *Lemna gibba* of 0.0353 mg/L and two studies with the degradant MT-2153 derived a 7 d  $E_rC_{50}$  for *Lemna gibba* of 0.0315 mg/L and 14 d  $E_rC_{50}$  for *Myriophyllum spicatum* of 0.0611 mg/L that are all in the same classification range.

For aquatic chronic classification, despite the uncertainties RAC concluded to use the 14 d  $E_rC_{10}$  for *Myriophyllum spicatum* of 0.000129 mg/L, based on mean measured concentration of tolpyralate. However, the  $NOE_rC$  value from same study with tolpyralate derived a 14 d  $NOE_rC$  for *Myriophyllum spicatum* of 0.000603 mg/L, which is in the same classification range.

It should also be noted that as supplemental information, one more study with tolpyralate derived a 7 d  $NOE_rC$  for *Myriophyllum aquaticum* of 0.000304 mg/L and two studies with MT-2153 derived a 7 d  $NOE_rC$  for *Lemna gibba* of 0.0009 mg/L and a 14 d  $NOE_rC$  for *Myriophyllum spicatum* of 0.000606 mg/L, all of which are in the same classification range.

#### **Conclusion on classification**

Tolpyralate is considered as not rapidly degradable and does not fulfil the CLP criteria for bioaccumulation. Based on the available and reliable information, RAC is of the opinion that tolpyralate warrants classification as:

**Aquatic Acute 1** based on  $E_rC_{50} = 0.0102$  mg/L for *Myriophyllum spicatum*. As this acute toxicity value falls within the  $0.01 < L(E)C_{50} \leq 0.1$  mg/L range, the **acute M-factor is 10**.

**Aquatic Chronic 1** based on  $E_rC_{10} = 0.000129$  mg/L for *Myriophyllum spicatum*. As this chronic toxicity value falls within the  $0.0001 < NOEC \leq 0.001$  mg/L range, the **chronic M-factor is 100**.

## 12 EVALUATION OF ADDITIONAL HAZARDS

### 12.1 Hazardous to the ozone layer

Not applicable.

## 12.1 Hazardous to the ozone layer

### 12.1.1 Short summary and overall relevance of the provided information on ozone layer hazard

Not applicable. Based upon its molecular structure tolpyralate would not qualify as a controlled substance in the Annexes to the Montréal Protocol. Furthermore, it is not expected to enter in contact with stratospheric ozone molecules given its physico-chemical parameters.

### 12.1.2 Comparison with the CLP criteria

Not applicable. Based upon its molecular structure tolpyralate would not qualify as a controlled substance in the Annexes to the Montréal Protocol. Furthermore, it is not expected to enter in contact with stratospheric ozone molecules given its physico-chemical parameters.

## RAC evaluation of hazards to the ozone layer

### Summary of the Dossier Submitter's proposal

The DS noted that based on molecular structure of tolpyralate it wouldn't qualify as a controlled substance according to the Montreal Protocol. Additionally, it is not expected to enter into contact with stratospheric ozone molecules given its physico-chemical parameters.

### Comments received during public consultation

No comments.

### Assessment and comparison with the classification criteria

A substance shall be classified as hazardous to the ozone layer (Category 1) if the available evidence concerning its properties and its predicted or observed environmental fate and behaviour indicate that it may present a danger to the structure and/or the functioning of the stratospheric ozone layer. RAC assumes that it is unlikely that tolpyralate would be available in the stratosphere based on its chemical structure and other available information on its physico-chemical properties and considers that tolpyralate may not present a danger to the structure and/or the functioning of the stratospheric ozone layer.

Consequently, RAC agrees that tolpyralate is not expected to be hazardous to stratospheric ozone and does not require a classification according to the CLP regulation.

## 13 ADDITIONAL LABELLING

Not relevant.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

## 14 REFERENCES

This section contains the non-confidential references. The confidential references are included in separate Annex (Annex III)

### Human Health References:

Author	Year	Study
Ahmad S, Teckma JH and Lueder GT (2002)	2002	Corneal opacities associated with NTBC. American Journal of Ophthalmology. 134(2):266-8
Antonenko AM, Blagaia ST, Omelchuk MM, Korshun HP, Vavrinevych DS, Milohov IM and Pelo IB	2015	Mechanism of action of 4-hydroxyphenylpyruvate dioxygenase inhibitor herbicide on homoterm animals and humans. J of Pre-Clinical and Clinical Research, 9, 145-150.
Buist	1974	Disorders of tyrosine metabolism in heritable disorders of amino acid metabolism, (ed by. W. L.Nyhan), p. 160. J. Wiley & Sons, New York
Comb AL	2012	SL-573 PAI: Water solubility Huntingdon Life Sciences, Ltd. Laboratory no. JSM0339 Ishihara Sangyo Kaisha, Ltd. GLP, unpublished
Foster, J.R.	2015	[ <sup>14</sup> C]SL-573: Mouse, rat and human liver microsomal metabolism Huntingdon Life Sciences, Ltd. Laboratory no. JSM0729 Ishihara Sangyo Kaisha, Ltd. Non-GLP, unpublished
Furutani E	2014	Measurement of 1-octanol/water partition coefficient for SL-573 TGAI (HPLC method) Chemicals Evaluation and Research Institute Laboratory no. 84175 Ishihara Sangyo Kaisha, Ltd. GLP, unpublished
Goldsmith	1983	Tyrosinemia and related disorders. In: Stanbury JB., Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS (eds): The. Metabolic Basis of Inherited Disease, 5th ed. New York, McGraw-Hill, pp. 287-299.
Hall MG, Wilks MF, Provan WM, Eksborg S and Lumholtz B	2001	Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers. Br J Clin Pharmacol, 52, 169-177
Henderson MJ, Faraj BT, Ali FM and Rudman D	1981	Tyrosine transaminase activity in normal and cirrhotic liver. Digestive Diseases and Sciences, 26 (2), 124-128
Lewis, RW and Botham JW	2013	A review of the mode of toxicity and relevance to humans of the triketone herbicide 2-(4-methylsulfonyl-2-nitrobenzoyl)-1,3-cyclohexanedione. Crit.Rev.Toxicol. 43: 185–199

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Lock EA, Gaskin P, Ellis M, Provan WM and Smith LL	2006	Tyrosinemia produced by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1, 3-dione (NTBC) in experimental animals and its relationship to corneal injury. <i>Toxicology Appl. Pharmacol.</i> , 215, 9-16.
Matsumoto K	2012b	SL-573 TGAI: Gene mutation test in mouse lymphoma cells The Institute of Environmental Toxicology Laboratory no. IET 11-0119 Ishihara Sangyo Kaisha, Ltd. GLP, unpublished
Matsumoto K	2012a	SL-573 TGAI: Chromosome aberration test in cultured mammalian cells The Institute of Environmental Toxicology Laboratory no. IET 11-0116 Ishihara Sangyo Kaisha, Ltd. GLP, unpublished
Schauwvlieghe, PP, Jaeken J, Kestelyn P, & Claerhout I	2013	Confocal microscopy of corneal crystals in a patient with hereditary tyrosinemia type I, treated with NTBC. <i>Cornea</i> , 32, 91-94.
Turner B	2013a	SL-573 (PAI): Physico-chemical properties Huntingdon Life Sciences, Ltd. Laboratory no. JSM0320 Ishihara Sangyo Kaisha, Ltd. GLP, unpublished
Turner B	2013b	SL-573 (PAI): Thermal stability Huntingdon Life Sciences, Ltd. Laboratory no. JSM0323 Ishihara Sangyo Kaisha, Ltd. GLP, unpublished
Turner B	2013c	SL-573 (TGAI): Physico-chemical properties (EPA requirements) Huntingdon Life Sciences, Ltd. Laboratory no. JSM0326 Ishihara Sangyo Kaisha, Ltd. GLP, unpublished
Turner B	2013d	SL-573 (PAI): Vapour pressure and calculation of volatility (Henry's law constant) Huntingdon Life Sciences, Ltd. Laboratory no. JSM0321 Ishihara Sangyo Kaisha, Ltd. GLP, unpublished
Wada, K.	2012	SL-573 TGAI: Bacterial reverse mutation test The Institute of Environmental Toxicology Laboratory no. IET 11-0115 Ishihara Sangyo Kaisha, Ltd. GLP, unpublished
Wisse RPL, Wittebol-Post D, Visser G and van der Lelij A	2012	Corneal depositions in tyrosinaemia type 1 during treatment with Nitisinone. <i>BMJ Case Reports</i> ; doi:10.1136/bcr-2012-006301
Yokoyama H	2016	Species differences in tyrosine metabolism under inhibition of 4-HPPD activity by SL-573 TGAI in hepatocytes LSI Medience Corporation Laboratory no. B160036 Ishihara Sangyo Kaisha, Ltd. Non-GLP, unpublished

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

**Environment References:**

<b>DAR Section</b>	<b>Author</b>	<b>Date</b>	<b>Study title</b>
B.9.2.7.1/1	Arnie, J.R., Martin, K.H. and Porch, J.R.	2013a	SL-573 TGAI: A 96-hour toxicity test with the freshwater alga ( <i>Anabaena flos-aquae</i> ). Study no. 272P-108. GLP, unpublished.
B.9.2.7.1/3	Arnie, J.R., Martin, K.H. and Porch, J.R.	2013b	SL-573 TGAI: A 96-hour toxicity test with the freshwater diatom ( <i>Navicula pelliculosa</i> ). Study no. 272P-109. GLP, unpublished.
B.9.2.7.1/4	Arnie, J.R., Martin, K.H. and Porch, J.R.	2013c	SL-573 TGAI: A 96-hour toxicity test with the marine diatom ( <i>Skeletonema costatum</i> ). Study no. 272P-110. GLP, unpublished.
B.9.2.4.1/2	Brougher, D.S., Siddiqui, A.I., Gallagher, S.P. and Krueger, H.O.	2015b	SL-573 TGAI: A 96-hour static-renewal acute toxicity test with the saltwater mysid ( <i>Americamysis bahia</i> ). Study no. 272A-133C. GLP, unpublished.
B.9.2.4.1/3	Brougher, D.S., Siddiqui, A.I., Gallagher, S.P. and Krueger, H.O.	2015c	SL-573 TGAI: A 96-hour shell deposition test with the eastern oyster ( <i>Crassostrea virginica</i> ). no. 272A-132. GLP, unpublished.
B.8.2.2.3	Crowe, A.	2015	SL-573: Anaerobic aquatic metabolism Study number: JSM0409 GLP / Unpublished
B.8.2.2.1	Hammesfahr, U.	2013	Ready biodegradability of SL-573 TGAI in a manometric respirometry test. Study number 72805163 . GLP/Unpublished
B.9.2.4.2/1	Handlos, F. and Erk, T.	2014b	Acute toxicity of MT-2153 to <i>Daphnia magna</i> in a static 48-hour immobilisation limit test. Study no. 85651220. GLP, unpublished.
B.9.2.7.2/1	Handlos, F. and Erk, T.	2014c	Toxicity of MT-2153 to <i>Pseudokirchneriella subcapitata</i> in an algal growth inhibition test. Study no. 85651210. GLP, unpublished.
B.9.2.8.2/1	Hermes, H. and Frank, C.	2015a	Toxicity of MT-2153 to the aquatic plant <i>Lemna gibba</i> in a static growth inhibition test. Study no. 85651240. GLP, unpublished.
B.9.2.8.2/2	Hermes, H. and Frank, C.	2015b	Toxicity of MT-2153 to the aquatic plant <i>Myriophyllum spicatum</i> in a static growth inhibition test with a prior rooting phase. Study no. 85651215. GLP, unpublished.
B.8.2.1.1	Hori, K.	2014b	Hydrolysis test for MT-2153 (SL-573 metabolite). Study Number: 84072 GLP/Unpublished
B.8.2.2.3	Kane, T.	2014	SL-573: Aerobic aquatic metabolism Study Number: JSM0408 GLP / Unpublished
B.9.2.8.2/4	Kosak, L. and Emnet, P.	2016	TAT-2049: Toxicity to the aquatic plant <i>Lemna gibba</i> in a static growth inhibition test. Study no. 114161240. GLP, unpublished.
B.9.2.6/1	Kuhl, R. and Frank, C.	2015	Effects of MT-2153 on the development of <i>Chironomus riparius</i> in a sediment-water system - exposed via spiked sediment. Study no. 85652250. GLP, unpublished.
B.9.2.8.1/1	Kuhl, R. and	2013	Toxicity of SL-573 TGAI to the aquatic plant <i>Lemna gibba</i> in a semi-



ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

DAR Section	Author	Date	Study title
	Wydra, V.		static growth inhibition test. Study no. 72801240. GLP, unpublished.
B.9.2.7.2/2	Seeland-Fremer, A. and Mosch, W.	2014b	Toxicity of MMTA to <i>Pseudokirchneriella subcapitata</i> in an algal growth inhibition test. Study no. 93291210. GLP, unpublished.
B.9.2.8.2./3	Seeland-Fremer, A. and Mosch, W.	2014c	Toxicity of MMTA to the aquatic plant <i>Lemna gibba</i> in a static growth inhibition Test. Institut für Biologische Analytik und Consulting IBACON GmbH. Laboratory no. 93291240. Ishihara Sangyo Kaisha, Ltd. GLP, unpublished.
B.9.2.8.2.1/2	Seeland-Fremer, A. and Wydra, V.	2014	Toxicity of SL-573 TGAI to the aquatic plant <i>Myriophyllum aquaticum</i> in a static growth inhibition test with a prior rooting phase. Study no. 72809215. GLP, unpublished.
B.8.2.1.1	Unsworth, R.	2013	SL-573: Hydrolysis in water Study Number: JSM0399 GLP / Unpublished
B.8.2.1.1	Unsworth, R.	2014	SL-573: Photodegradation in water and determination of the quantum yield. Study Number. JSM0400 GLP/Unpublished
B.8.2.2.2	Van den Bosch, M.M.H.	2014	Aerobic mineralisation of SL-573 in surface water. Study Number: 504338 GLP/Unpublished
B.9.2.4.1/1	Yoshikawa, M.	2013a	A 48-hour acute immobilization study of SL-573 TGAI in <i>Daphnia magna</i> . Study no. 96015. GLP, unpublished.
B.9.2.4.2/2	Yoshikawa, M.	2014a	A 48-hour acute immobilization study of MMTA in <i>Daphnia magna</i> . Study no. 96787. GLP, unpublished.
B.9.2.5/1	Yoshikawa, M.	2014b	<i>Daphnia magna</i> reproduction study of SL-573 TGAI. Study no. 96530. GLP, unpublished.
B.9.2.7.1/1	Yoshikawa, M.	2013b	Algae growth inhibition study of SL-573 TGAI in <i>Pseudokirchneriella subcapitata</i> . Study no. 96014. GLP, unpublished.

### Additional references

Ellaway, *et al.* (2001) Outcome of tyrosinaemia type III. Journal of Inherited Metabolic Disease 24:824-832

Gissen, *et al.* (2003) Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC. Journal of Inherited Metabolic Disease 26:13-16

Najafi, *et al.* (2018) A case of tyrosinemia type III with status epilepticus and mental retardation. Advanced Biomedical Research 7:7

Szymanska, *et al.* (2015) Tyrosinemia type III in an asymptomatic girl. Molecular Genetics and Metabolism Reports 5:48-50

Hermes and Emnet, PhD, 2018 Toxicity to the Aquatic Plant *Myriophyllum spicatum* in a

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

Semi-Static Growth Inhibition Test with a Prior Rooting Phase.

Milligan *et al.* (2017) A Flow-Through Life-Cycle Toxicity Test with the Saltwater Mysid (*Americamysis bahia*)

Brougher *et al.* (2016) A 96-Hour Shell Deposition Test with the Eastern Oyster (*Crassostrea virginica*)

15 ANNEXES

**Annex I – Robust Study Summaries**

Not provided as part of this report.

**Annex II - Summary of the aquatic toxicity of degradants of Tolpyralate**

**Table 1 Summary of toxicity of Tolpyralate degradants to fish and invertebrates**

Test spp./substance	Study type & duration	L/EC50 mg/L	NOEC mg/L	Reference
<i>Oncorhynchus mykiss</i>				
MT-2153	static acute (96h)	> 100 (n)	100 (n)	Anonymous (2014f)
MMTA	static acute (96h)	> 100 (n)	100 (n)	Anonymous (2014g)
<i>Daphnia magna</i>				
MT-2153	static acute (48h)	>100 (n)	100 (n)	Handlos, F. and Erk, T. (2014b)
MMTA	static acute (48h)	>100 (n)	100 (n)	Yoshikawa, M., (2014a)

(n) = nominal

**Table 2 Summary of toxicity of Tolpyralate degradants to sediment dwellers, algae and plants**

Test spp./substance	Study type	Endpoint mg/L	References
<i>Chironomus riparius</i>			
MT-2153	Chronic sediment study (spiked sediment)	28d EC10 & 28d NOEC = $\geq$ 1000 mg/Kg (n)	Kuhl, R and Frank, C (2015)
<i>Pseudokirchneriella subcapitata</i>			

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-[1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

MT-2153	Static chronic	72h E <sub>r</sub> C <sub>50</sub> = 8.88 (n) 72 h E <sub>r</sub> C <sub>10</sub> = 2.94 72 h NOE <sub>r</sub> C = 1.0	Handlos, F. and Erk, T. (2014c)
MMTA	Static chronic	72h E <sub>r</sub> C <sub>50</sub> = > 32 (n) 72 h E <sub>r</sub> C <sub>10</sub> = 17.5 72 h NOE <sub>r</sub> C = 10	Seeland-Fremer, A & Mosch, W. (2014b)
<b><i>Lemna gibba</i> G3</b>			
MT-2153	Static chronic	7d E <sub>r</sub> C <sub>50</sub> = 0.0315 7d E <sub>r</sub> C <sub>10</sub> = <0.0009 7d NOE <sub>r</sub> C= 0.0009 Endpoints based on dry weight (mm)	Hermes, H. and Frank, C. (2015a)
MMTA	Static chronic	7d E <sub>r</sub> C <sub>50</sub> = > 100 (n) 7d NOE <sub>r</sub> C= > 100	Seeland-Fremer, A & Mosch, W. (2014c)
TAT-2049	Static chronic	7d E <sub>r</sub> C <sub>50</sub> = > 100 (n) 7d NOE <sub>r</sub> C= > 100	Kosak, L. & Emnet, P. (2016)
<b><i>Myriophyllum spicatum</i></b>			
MT-2153	Static chronic sediment study (spiked aqueous medium)	14d E <sub>r</sub> C <sub>50</sub> = 0.115 EC <sub>10</sub> = nd EC <sub>20</sub> = 0.00103 NOE <sub>r</sub> C = < 0.000606* Endpoints based on dry weight (mm)	Hermes, H. and Frank, C. (2015b)

(n) = nominal

(mm) = mean measured

nd = not determined (for dry weight the most sensitive growth parameter in this study)

\*uncertainty in test concentration

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON (RS)-1-{1-ETHYL-4-[4-MESYL-3-(2-METHOXYETHOXY)-O-TOLUOYL]PYRAZOL-5-YLOXY}ETHYL METHYL CARBONATE; TOLPYRALATE

**Annex III – Confidential references**

See separate document.